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ABSTRACT OF THE DISSERTATION 
 
Structural Mechanism of Orthopoxvirus Sabotage of MHCI Antigen Presentation 
by 
 William H. McCoy IV 
Doctor of Philosophy in Biology and Biomedical Sciences 
Immunology 
Washington University in St. Louis, 2013 
Associate Professor Daved H. Fremont, Chairperson 
 
Immunomodulatory proteins that subvert major histocompatibility complex class I (MHCI) 
antigen presentation can help viruses to evade cytotoxic T-lymphocyte (CTL) detection and 
clearance. Cowpox virus, like other orthopoxvirus family members, is a large DNA virus, whose 
genomic termini encode numerous immunomodulatory genes, including two ER-resident MHCI 
saboteurs (CPXV012 and CPXV203). CPXV012 inhibits peptide loading of MHCI within the 
peptide-loading complex (PLC), while CPXV203 inhibits surface expression of both murine and 
human MHCI through the use of a C-terminal ER-retention sequence (KTEL). An association 
(direct or indirect) between CPXV203 and MHCI was first demonstrated in pull-down 
experiments.  This doctoral work explores and dissects the molecular details of this interaction. 
 In order to elucidate the nature of CPXV203/MHCI association, biophysical studies were 
pursued using recombinant CPXV203 and MHCI. Binding studies demonstrated that CPXV203 
directly binds mature MHCI heterodimers, thus bridging MHCI to the KDEL receptor (KDELR) 
rescue pathway. Unlike other ER-resident immune evasion proteins, CPXV203 did not display 
	   xxiii	  
distinct allelic preferences, but instead proved to be an extremely promiscuous MHCI-binder 
(murine and primate, Ia and Ib). Similar to KDELR/KDEL binding, CPXV203/MHCI binding 
was found to be pH-dependent, insuring high-affinity association of KDELR/CPXV203/MHCI 
in the Golgi and rapid dissociation within the ER.  
 Molecular characterization of the pH-dependent nature of CPXV203/MHCI binding 
required knowledge of the interface contacts. X-ray crystallography was used to examine the 
CPXV203/MHCI complex at low pH revealing that CPXV203 interacts with MHCI by binding 
conserved surfaces required for tapasin association/function.  CPXV203 is an 11-stranded β-
sandwich consisting of two β-sheets stabilized by five disulfide bonds. CPXV203 topology is 
reminiscent of the poxvirus chemokine-binding family of proteins, though MHCI contacts 
largely originate from structural regions unique to CPXV203.  Structure-based mutations 
introduced into CPXV203 and MHCI validated the crystallographically-defined binding 
geometry and identified several binding and functional hotspots. These studies support that 
CPXV203 binds mature MHCI in the Golgi and releases it in the ER where it accumulates and is 
eventually degraded via non-viral mechanisms. These results suggest that CPXV203 could be 
used as a viral tool to probe natural ERAD pathways that dispose of properly folded proteins that 
accumulate in the ER. 
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Chapter 1 
 
Viral Immunevasion 
  
	   2	  
1.1 Adaptive immune response to intracellular invasion. 
The adaptive immune system is alerted to a variety of intracellular invasion events of either 
domestic (cancer) or foreign (viral & parasitic) origin through the action of major 
histocompatibility complex class I (MHCI) molecules on the cell surface.  MHCI present a 
sample of the intracellular milieu via the acquisition of a diverse array of peptides derived from 
intracellular proteins. Peptide-loaded MHCI (pMHCI) travel to the cell surface, where they are 
able to present their peptide cargo. MHCI that lose this cargo are rapidly degraded, thus limiting 
the presentation of peptides derived from extracellular sources to T cells. Cytotoxic T 
lymphocytes (CTLs) respond to MHCI bound to non-self peptides, as self-reactive CTLs 
(specific for either MHCI or pMHCI) are normally eliminated during negative selection in the 
thymus. CTLs are exquisitely sensitive to non-self pMHCI (≥1 pMHCI/cell)1, and so only a 
small number of non-self pMHCI are required to elicit a robust immune response. This 
surveillance strategy is critically dependent on MHCI assembly, as an MHCI molecule folds 
around its peptide cargo. 
 
1.2 Viral antigen presentation. 
MHCI is a heterotrimer comprised of a heavy chain (HC) with three domains (α1-3), a β2-
microglobulin (β2m) light chain, and a peptide (8-10 aa) typically derived from proteasomal 
degradation of cytosolic proteins (viral & host) (Fig. 1). The peptide cargo of MHCI is 
transported from the cytosol to the endoplasmic reticulum (ER) via the action of the transporter 
associated with antigen processing (TAP). Upon ER entry, peptide is loaded onto the HC/β2m 
heterodimer via the chaperone assembly known as the peptide loading complex (PLC) made up 
of TAP, tapasin (Tpn), ERp57, and calreticulin (CRT)2. Specifically, the peptide is bound within 
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the HC peptide-binding groove formed by parallel α-helices (α1/α2) supported by a β-sheet 
floor formed by both the α1 & α2 domains. The β-sheet floor & the α3 domain participate in 
heterodimer assembly with β2m. Stable, peptide-loaded MHCI dissociate from the PLC and 
travel to the cell surface where they may engage virus-specific cytotoxic T lymphocytes (CTLs) 
capable of exerting antiviral effector functions (cytotoxicity & cytokine secretion)3. For a more 
detailed review of MHCI assembly, I refer the reader to recent reviews by Raghavan et al. 
(2008)4 and Van Hateren et al. (2010)5. 
 
1.3 Viral disruption of antigen presentation.   
1.3.1 General viral sabotage of MHCI 
 Viruses attempt to thwart the immune system by compromising its ability to combat 
infection and by attempting to evade detection.  The latter approach, viral immune evasion6, 
utilizes proteins referred to as immunoevasins that can target antigen-presentation to CTLs or the 
detection of non-self by natural killer (NK) cells.  Molecules targeting antigen presentation use 
one of three methods to decrease cell surface MHCI: inhibition of MHCI-folding in the ER, 
targeting MHCI in the ER-Golgi for retention/destruction, or lysosomal degradation of MHCI 
after ER exit (Golgi-to-cell surface)7. See Table I for a summary of these immunevasins and 
Hansen & Bouvier (2009) for a recent review of viral sabotage of MHCI.  While these distinct 
strategies can effectively disrupt MHC class I presentation of viral peptides, they may also 
trigger NK cell-mediated cytolytic consequences (non-self killing), and so these same viruses 
often encode immunevasion strategies to avoid NK cell detection, such as the secretion of a high-
affinity soluble antagonist (OMCP) of activating NK receptor NKG2D by cowpox virus8. Each 
strategy of antigen presentation subterfuge has distinct outcomes due to the step in MHCI 
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expression that is targeted, and so these differences have proven extremely informative in studies 
investigating the steps of MHCI assembly and trafficking. 
 MHCI-folding inhibition. Though viruses have been shown to interfere with MHCI 
synthesis from transcription (HIV Tat9,10) to ER translocation (RhCMV Rh17811) to chaperone-
assisted folding, the vast majority of the identified immunevasins inhibit MHCI-folding within 
the ER, though the immunevasin itself may be a resident of the cytosol, ER, or even localized to 
the nucleus (Tat). As shown in Fig. 2, viruses employ three strategies in this pursuit: prevention 
of proteasomal generation of peptides (EBV EBNA1, HIV Tat, HCMV pp65), impair TAP 
transfer of peptides into the ER (HSV ICP47, HCMV US6, HV UL49.5), and inhibition of 
assembly/function of the MHCI-specific chaperone complex known as the PLC (AdV E3-19K, 
CPXV012, HCMV US3, MHV mK3).  The first two strategies limit peptide supply and thus 
target all classical MHCI, while PLC inhibition can be circumvented by MHCI alleles that are 
Tpn-independent, like H-2Kk12,13,14, HLA-B*270515, & HLA-B*440516. Perhaps it is not 
surprising that viruses do not interfere directly with general protein folding chaperones (calnexin, 
ERp57, CRT), as such a mechanism would likely decrease both cellular and viral fitness. Viral 
proteins that impede the folding of Tpn-dependent MHCI generally use a non-degradative 
mechanism, such as inhibition of Tpn function (US3)1718 or impairing Tpn/TAP association (E3-
19K)19. An exception to the non-destructive route is the targeting of PLC components to ER-
associated degradation (ERAD) via bystander ubiquitination by mK320, though it is believed that 
the primary function of mK3 is ERAD destruction of MHCI. 
 ER retention & ERAD. Instead of interfering with MHCI folding, some viral 
immunevasins operate within the ER to prevent cell surface expression of newly synthesized 
MHCI via ER retention (AdV E3-19K, CPXV203) or targeting MHCI to ERAD (HCMV US2, 
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US11; MHV mK3), as shown in Fig. 3. ER retention by E3-19K operates by using its lumenal 
domain to directly bind MHCI lumenal domains21, thereby tagging MHCI with its cytosolic ER 
localization signal2223. On the other hand, MHCI degradation within the ER requires the 
formation of a membrane pore involving either signal peptide peptidase (SPP) or Derlin1.  
HCMV US2 uses the SPP complex24, while Derlin1 complex (Derlin1, VIMP, p97/Np14/Ufd1) 
is employed by HCMV US1125 and γHV68 mK326.   Structural studies of US2 have shown that it 
uses an Ig-like fold to directly bind MHCI lumenal domains, and these studies predict that US3 
& US11 will adopt similar Ig-like folds27.  Unlike US2, the type III ER membrane protein mK3 
is a modulator of immune recognition (MIR), a family of E3 ubiquitin ligases that ubiquitinate 
immunoreceptors to target them for down-regulation via ERAD or lysosomal degradation. 
 Lysosomal degradation of MHCI. Viral proteins may also target MHCI for lysosomal 
degradation (EBV BILF1, HIV Nef, KSHV kK3 & kK5, MCMV gp48), as shown in Fig. 4.  The 
KSHV proteins kK3 & kK5 (aka MIR1 & MIR2) are members of the same family as mK3, but 
kK3 & kK5 target cell surface MHCI to endosomal/lysosomal compartments for degradation.  
Alternatively, HIV Nef uses the clathrin adaptor AP1 (adaptor protein 1) to redirect MHCI from 
the TGN to endocytic compartments before it is able to reach the cell surface28. MCMV gp48 
also targets newly synthesized MHCI to lysosomes, though it picks up its MHCI cargo within the 
ER and uses standard di-LEU sorting machinery for lysosomal degradation29. Finally, EBV 
BILF1 was recently described as the first viral G-protein coupled receptor (GPCR) to directly 
down-regulate MHCI and target it for lysosomal destruction, though the signaling function of 
BILF1 is not required for this activity30. Though post-ER MHCI degradation by viruses utilize a 
wide variety targeting strategies, they all lead to the lysosome just as MHCI degradation within 
the ER always leads to the proteasome. 
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1.3.2 Adenovirus (AdV) E3-19K 
Identification. Though viruses are known to disrupt antigen presentation at every stage 
from HC transcription to mature MHCI at the cell surface, viral immunevasins that interact with 
MHCI lumenal domains appear to function exclusively within the ER, as is the case for the first 
immunevasin reported to decrease MHCI cell-surface expression, AdV E3-19K31. AdV is a 
nonenveloped, icosahedral virus with a double-stranded, linear DNA genome that encodes a 
variety of immunomodulatory genes within early region 3 (E3) that have been the focus of 
scientific study for more than 30 years3233. Of these immunomodulatory genes, E3-19K was the 
first to be found associated (co-IP) with a cellular protein (MHCI34), and later this association 
was shown to be direct via both cross-linking & in vitro translation assays21.  
Mechanism. The immunevasion role of E3-19K was revealed by studies that 
demonstrated this viral protein specifically localized MHCI lacking mature glycosylations to a 
perinuclear compartment (ER or post-ER exocytic compartment) and reduced cell surface MHCI 
in both stable E3-19K cell lines31 and cells acutely infected with AdV35. Though these findings 
clearly supported an ER retention mechanism, they did not actually demonstrate an 
immunomodulatory benefit to the virus, later demonstrated using CTLs specific for H-2Kd36. 
Interestingly, these E3-19K/MHCI localization & CTL protection studies were essential to the 
use of E3-19K as a viral tool to probe CTL recognition of vaccinia virus (VACV) antigens in the 
seminal paper demonstrating that MHCI assembles with peptide antigens in the ER 37. The 
immunomodulatory role of E3-19K was later expanded to include PLC inhibition through TAP 
binding that excluded both Tpn & HC association19, thereby expanding the pool of retained 
MHCI from those that are directly bound by E3-19K to all Tpn-dependent alleles. E3-19K 
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modulates the host immune system by sequestering cellular targets (MHCI/TAP) so that they are 
unavailable to perform their usual antigen presentation function, and though little is known of the 
latter interaction, a great deal of research has been done to characterize the E3-19K/MHCI 
interface.  
 Protein/protein interface. Following the initial studies that demonstrated a direct 
association between E3-19K & MHCI, a variety of strategies (E3-19K truncations, chimeric 
MHCI, MAbs, mutagenesis) were pursued to characterize the binding interface. E3-19K domain 
mutants first localized the MHCI binding interface to the ER lumenal domain, while ER 
localization was shown to require TM and/or cytosolic E3-19K sequence22. Chimeric MHCI (H-
2Kd/Kk) localized the E3-19K binding surface to the α1/α2 domain, and these same studies 
demonstrated the E3-19K/MHCI association did not require glycosylation or intermolecular 
disulfide bonds38. Immunoprecipitation studies utilizing MAbs with defined MHCI epitopes later 
showed that E3-19K does not bind on top of the peptide-binding platform like a TCR39, but 
instead it appeared to associate with the N-terminal end of the α1 helix and the C-terminal end of 
the α2 helix40. Recombinant expression (baculovirus system) of the E3-19K lumenal domain 
allowed for the first biophysical evaluation of immunevasin/MHCI binding affinity (AUC), 
which showed that E3-19K/MHCI associated as a 1:1 complex with 50 nM affinity for pMHCI 
and >10 µM affinity for peptide-free MHCI41.  Additional binding studies (SPR) of an MHCI 
panel (E3-19K susceptible & null molecules) confirmed the previously measured affinity and 
identified the region around MHCI residue 56 (confirmed through mutagenesis, G56R) as the 
likely E3-19K binding surface42. Please	  see	  Table	  II	  for	  a	  complete	  list	  of	  susceptible	  alleles	  identified	  from	  the	  literature.	  	  Recently, E3-19K was shown to also down-regulate major 
histocompatibility complex class I chain-related proteins A and B (MICA and MICB)43, and 
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these studies were followed by site-directed mutagenesis of E3-19K (monitored by E3-19K 
MAbs that differentiate folded from unfolded E3-19K) that suggest E3-19K uses distinct 
surfaces to bind MICA/B & classical MHCI44,45,46.  Though a great deal has been learned about 
the association of E3-19K & MHCI, the lack of E3-19K structural information continues to 
cloud the interpretation of these results, and so our understanding of the first immune evasion 
protein identified to target MHCI remains quite incomplete after nearly 30 years of study. 
 
1.3.3 Human cytomegalovirus (HCMV) US2 
Identification. HCMV was initially identified to interfere with MHCI synthesis in a study 
of the HCMV MHCI-like protein UL18, which was suggested to decrease MHCI through β2m 
sequestration 47. A follow up UL18-KO virus study clearly demonstrated that UL18 was not 
responsible for this phenomenon 48, and ensuing studies demonstrated that HCMV infection 
reduced cell surface MHCI through a mechanism that specifically accelerated HC degradation 
rather inhibiting HC synthesis 49.  Further, this degradative mechanism was not protein-intrinsic 
49, but rather it involved an energy-dependent, nonlysosomal proteolytic pathway50. A bank of 
HCMV deletion mutants was later used to demonstrate that at least two genes within the 7 kb 
unique short (US) region can produce this phenotype, one of which was identified as US1151. 
Soon thereafter, US2 was shown to both associate with and degrade HC, and its mechanism 
(ERAD) was described for the first time 52. 
Mechanism. The US2 mechanism of HC degradation was initially described as an 
apparent reversal of nascent polypeptide translocation (dislocation) by the Sec61 complex 
followed by glycan removal and proteasomal degradation 52. Later work revealed that dislocation 
required the cytoplasmic tails of both MHCI and US2, while the ER lumenal domains were 
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sufficient for US2/MHCI association53. The HC cytoplasmic tail requirement was later refined in 
a study demonstrating that the cytosolic tail beyond 4 residues of MHCI was not required for 
US2-mediated degradation 54.  Interestingly, US2 was also shown to degrade components of 
MHCII presentation, HLA-DRα and HLA-DMα5556, and an MHC Ib molecule, HFE 57, by the 
same degradation mechanism. Detailed mechanistic studies clearly showed that US2 dislocates 
folded HC that is then targeted for proteasomal degradation via ubiquitination of HC residues 
present on either the cytosolic tail or ER lumenal domains 58. The US2 dislocation machinery 
was found to include signal peptide peptidase (SPP)24 instead of Derlin-1 (used by US11 & 
mK3) 59, and recent work has identified TRAM1 as a cellular cofactor that enhances (not 
required) for dislocation by both US2 & US11 60. Finally, US2 function has been shown to be 
enhanced via the co-expression of another HCMV immune evasion protein (US3) that delays 
MHCI trafficking through Tpn-inhibition, thus creating a “target-rich environment” for US261. 
Though the details of dislocation remain to be elucidated, the general scheme of US2-mediated 
HC degradation has been well studied, including the direct association between US2/MHCI 
lumenal domains. 
Protein/protein interface. Though US2/MHCI was shown to associate via co-IP 
experiments when it was originally identified 52, it was unknown whether this association was 
direct or specific for particular MHCI alleles. Later work identified US2 preferences for first 
murine (susceptible: Dd>Db>Kd>Ld; null: Kb)62 and later human (susceptible: HLA-A, most 
HLA-B, HLA-G; nulls: HLA-B7, -Cw3, -E)54 HC alleles.	  Please	  see	  Table	  II	  for	  a	  complete	  list	  of	  susceptible	  alleles	  identified	  from	  the	  literature.	  It should be noted that the murine HC 
study used FL versions of all alleles except for H-2Kb, which was a “tailless” version (no 
length/sequence reported). Fortunately; the latter human study reproduced this finding with FL 
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H-2Kb. Using recombinant forms of US2 & MHCI lumenal domains, direct binding was 
demonstrated using biophysical (SEC, NATIVE gel-shift) 63 and structural studies (US2/HLA-
A2) 27. This interaction was clearly shown to be peptide-independent (5 distinct HLA-A2/peptide 
complexes) & high affinity, though weak/null binding alleles (HLA-B27, HLA-DMα, HLA-
DRα) are still degraded by US2 (see Table II). The complex structure revealed the US2 lumenal 
domain is an Ig-like fold that functionally binds the α2-α3 hinge region of MHCI (site 1), while 
a second crystallographically-observed interaction surface (site 2, α2 helix) was shown to have 
no functional relevance 276465. Evaluation of sites 1 &2 utilized twenty HC mutants (16 single, 2 
double, 1 triple), yet only one mutant (R181E) allowed MHCI to escape degradation.  Though 
US2 was crystallized with fully assembled MHCI, studies in β2m-deficient cell lines have shown 
that US2 is able to degrade unassembled HC, thus suggesting this immune evasion protein 
actually targets an early stage of MHCI assembly66. As such, the status of the US2/MHCI 
interface in viral-directed ERAD requires further investigation to delineate the mechanistic 
details, just as the dislocation mechanism itself requires further study.  
 
1.3.4 Summary  
Though AdV E3-19K & HCMV US2 have been extensively studied, many questions remain 
both for these specific immune evasion mechanisms and for general viral sabotage of antigen 
presentation within the ER. For example, both of these unrelated viral proteins exhibit sensitivity 
to polymorphism at similar PLC-distal MHCI surfaces, yet it is not yet known whether all viral 
proteins that target MHCI lumenal domains share a similar binding profile. The study of 
additional viral proteins that interfere with MHCI via ER lumenal interactions should not only 
reveal whether the E3-19K/US2 approach is a common binding mode, but, hopefully, such work 
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will continue to expand our understanding of normal antigen presentation through the 
development of viral tools that interfere with specific steps in MHCI assembly. 
 
1.4 Poxvirus disruption of antigen presentation. 
Poxviridae are a family of brick-shaped, envelope viruses that replicate in the cytosol and (as a 
family) may infect both vertebrate and invertebrate hosts67.  These viruses have very large 
genomes (130-300 kb) composed of linear dsDNA capped by inverted terminal repeats & hairpin 
termini. Replication/assembly genes (~90 conserved ORFs) are located centrally, while genes 
with host restriction and immunomodulatory roles are generally located peripherally (Fig. 5a,b). 
Poxviruses are able to modify the mammalian immune response using a variety of strategies 
(viromimicry, virotransduction, virostealth)68 that can target both intracellular and extracellular 
host immune responses. CPXV immunomodulatory genes discussed in this thesis are 
summarized in Fig. 5c.  While many examples of the first two strategies have been described, 
poxviruses appear to encode far fewer proteins charged with the goal of virostealth, which either 
inhibits NK cell recognition (OMCP)8 or viral antigen presentation on MHCI. 
 
1.4.1 Myxoma virus MV-LAP/M153R 
Poxvirus sabotage of antigen presentation was first demonstrated for two leporipoxviruses 
(MYXV & malignant RFV), which were observed to specifically down-regulate primate MHCI 
(not transferrin receptor; CD71) in primate (BGMK) cells69. This study also revealed that a 
related leporipoxvirus, rabbit (shope) fibroma virus (RFV/SFV: Kasza), and the orthopoxvirus 
vaccinia (VACV) do not down-regulate MHCI. Ensuing studies identified a lysosomal 
degradation mechanism was employed to degrade cell surface MHCI in a manner dependent on 
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the HC intracellular tail70. Work by Guerin et al. (2002) identified MV-LAP (M153R) as the 
MYXV protein responsible for MHCI down-regulation and clearly demonstrated the 
immunevasion function of this protein (in vitro & in vivo) through a comparison of MYXV 
(MV-LAP) to MYXV (ΔMV-LAP)71. MV-LAP was originally selected for study due to its 
similarities to a variety of described MIRs (kK3, kK5, mK3) and the presence of similar proteins 
in a number of other poxviruses (Capripoxvirus, LSDV 010 [31% identity]; Leporipoxvirus, 
RFV S153R [69% identity]; Suipoxvirus, SWPX C7L [26% identity]; Yatapoxvirus, YLDV 5L 
[27% identity]). Importantly for this work, a similar protein does not exist in any form within 
orthopoxviruses. A later study confirmed that MV-LAP is a membrane-bound ubiquitin ligase 
that targets both MHCI & CD4 to lysosomes through ubiquitination of lysines in their 
cytoplasmic tails72. Interestingly, a viral co-factor present in MYXV but not in a heavily 
attenuated vaccinia strain (MVA) is required for MV-LAP to be fully effective73. MV-LAP, like 
the HV MIRs, appears to have arisen via from the modification of a captured host gene 
(MARCH I-IX), some of which have been identified to down-regulate various immunoreceptors 
(recently reviewed by Ishido 2009)74. As the earlier study comparing MYXV to SFV clearly 
showed the latter did not decrease cell surface MHCI, the various related poxvirus MIRs may 
target other membrane proteins for degradation, leaving MYXV MV-LAP as the only poxvirus 
protein known to disrupt antigen presentation sabotage prior to the work of Byun et al. (2007)75.  
 
1.4.2 Cowpox & Monkeypox 
Until recently, orthopoxviruses were not believed to target the antigen presentation system, as 
they do not contain a protein similar to MV-LAP. Work by the Früh & Yokoyama labs revealed 
that an orthopoxvirus, cowpox virus (CPXV), expresses two unrelated immune evasion proteins, 
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CPXV012 and CPXV203, that use complementary mechanisms to block antigen presentation in 
both human and mouse cells75,76,77. CPXV012 appears to be a severely truncated C-type lection 
domain that has evolved to associate with the PLC and impair peptide loading of MHCI76. By 
contrast, CPXV203 is a member of the T4 poxvirus protein family that sequesters mature MHCI 
proteins within the ER by a mechanism dependent upon its C-terminal KTEL sequence75, a motif 
known to bind the KDEL receptor (KDELR)78 that functions in Golgi retrieval of several soluble 
ER resident proteins79. Initially, a MPXV protein related to CPXV203, MPX184 (64% identity), 
was suggested to also down-regulate MHCI75, though later work by a competing group has 
disputed this suggestion80.  In vivo infection studies demonstrated that mutant viruses lacking 
both CPXV012 and CPXV203 showed attenuated virulence in a manner dependent upon CTLs76.  
As versions of these proteins that down-regulate MHCI appear only appear to exist in the 
orthopoxviruses cowpox and monkeypox, it has been suggested that they arose quite recently due 
to the evolution of the potent NK cell antagonist OMCP (CPXV018) (Fig. 6)8. The location of 
these virostealth genes is indicated within the CPXV-BR genome in Fig. 5b. This two-pronged 
strategy of limiting peptide supply and retrieving assembled MHCI proteins effectively blocks 
the presentation of cowpox antigens at the cell surface, while secretion of OMCP reduces (or 
eliminates) the negative impact of a loss of self. 
 
1.4.3 CPXV012 
 Identification. In the original identification of CPXV203-mediated MHCI down-
regulation, infection of murine MC57G cells by CPXVΔCPXV203 virus75 revealed sustained 
MHCI down-regulation, thereby indicating that an additional poxviral mechanism(s) existed to 
down-regulate MHCI. This observation led two groups to independently identify CPXV012 
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(deletion virus screen 76 and targeted TM protein gene expression77 studies) as the only other 
cowpox virus gene able to down-regulate MHCI. CPXV012 was shown to be a short, type II 
transmembrane protein (69 aa) using in vitro translation assays with microsomes (± proteinase 
K)77. These studies also revealed that CPXV012 appears to be a truncated version of another 
orthopoxvirus protein (CPXV-GER-91 D10L) that is similar (47% identity, 137/160 aa) to 
RCMV RCTL (rat CMV C-type lectin ligand), which was shown to be a ligand for the inhibitory 
NK cell receptor NKR-P181. In addition to CPXV012 & D10L, two other versions of this gene 
exist (CPXV-GRI D10L & ECTV 0070), but only CPXV012 was able to down-regulate 
MHCI7776. Interestingly, a high-affinity NK cell antagonist OMCP is present in both CPXV and 
MPXV8, which may have provided sufficient NK cell interference to allow CPXV012 to evolve 
another virostealth function i.e. MHCI sabotage. As the CPXV012/D10L group of proteins 
shares high identity (>70%) in the cytosolic & TM regions, the short, unique ER lumenal domain 
is believed to orchestrate MHCI down-regulation activity. 
 Mechanism. Virostealth by CPXV012 appears to be a result of this protein’s ability to 
delay MHCI exit from the PLC, though the root cause of this delay is somewhat contentious 
(Fig. 6). Both groups that identified CPXV012 showed that this protein is ER-localized, impairs 
TAP-dependent transport of cytosolic peptides, destabilizes MHCI (thermolabile & peptide-
receptive), and increases HC degradation7677. While these findings led one group to conclude that 
CPXV012 operates solely as a TAP inhibitor77, the other group suggested that peptide-transport 
inhibition was not sufficient to account for the degree of MHCI down-regulation, and so they 
suggested CPXV012 likely has an additional mechanism to delay MHCI release from the PLC76.  
 Protein/protein interface. Though co-IP experiments clearly demonstrated that 
CPXV012 associates with PLC components (TAP, Tpn, CRT) and HC76, the exact details of this 
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association remain to be elucidated. Of note, CPXV012 appears to greatly prolong PLC/MHCI 
association, and so the additional mechanism mentioned above may in fact be a type of 
conformational lock that prevents MHCI release independent of its peptide-loading state. 
Regardless, the CPXV012/PLC/MHCI association clearly shows that CPXV012 targets an 
immature MHCI assembly state, which thereby restricts the MHCI that may be targeted by this 
immune evasion to those that require the PLC for assembly.   
 
1.4.4 CPXV203 
 Identification. CPXV203 was initially identified through a comparative genomics 
approach followed by the evaluation of potential ORFs for the ability to down-regulate H-2Kd in 
the murine BaF/3 cell line75.  This work was initiated by the authors due to their observation that 
CPXV could down-regulate MHCI, while VACV-WR and ECTV were unable to do so.  Twenty-
one genes were selected as potentially CPXV-unique immune evasion proteins (<80% identical 
or absent in VACV-WR/ECTV), one of which was CPXV203. Retroviral transduction of 
CPXV203 revealed that it could down-regulate MHCI in both murine (C1498: H-2Db, -Kb) and 
human (Jurkat82,83: HLA-A3, -A9, -B7, -B35; HEK293T84:	  HLA-A3, -B7, -Cw7) cell lines. 
 Mechanism. Initial mechanistic studies of CPXV203 suggested a non-degradative 
mechanism is used to retain peptide-loaded MHCI in the ER via the viral protein's C-terminal ER 
retention sequence (KTEL)(Fig. 6)75. KDELR retrieval of ER chaperones is reviewed in Fig. 7. 
Unlike many other ER resident immune evasion proteins (US2, US11, mk3), the amount of 
MHCI actually increased in cells transduced with CPXV203 relative to controls. Retained MHCI 
was recognized by conformational MAbs specific for peptide-loaded MHCI, and the addition of 
allele-specific peptides was unable to relieve MHCI retention, suggesting that retention of MHCI 
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is not due to a problem with peptide loading (US3, US6, E3-19K).  ER or early Golgi 
localization of MHCI by CPXV203 was further supported by the early status of MHCI 
glycosylation (EndoH-sensitive) and confocal microscopy clearly showed co-localization of HA-
tagged CPXV203 with an ER marker (calnexin) but not a Golgi marker (Giantin). Deletion of the 
C-terminal KTEL of CPXV203 demonstrated the essential nature of this sequence to both 
CPXV203 localization and MHCI retention, but these initial studies did not distinguish whether 
the localization itself or the process of KDELR retrieval was necessary to MHCI-retention 
mechanism. Of note, the act of CPXV203 retrieval did not appear to decrease steady-state levels 
of ERp5775 or CRT75, suggesting that this viral protein does not simply act as “dominant-
negative” of KDELR retrieval. Finally, physical association after PLC-release was indicated by 
co-IP (CPXV203-HA/HC/β2m but not TAP). Though direct binding of CPXV203/MHCI & 
retrieval by KDELR could account for MHCI down-regulation, it is also possible that a host 
protein (e.g. Tpn, CRT, ERp57, BiP) could bridge CPXV203 to MHCI, thus additional studies of 
the interface were necessary to complement the initial mechanistic studies. 
 Protein/protein interface. The initial work on CPXV203 demonstrated a clear 
association of this viral molecule with MHCI via pull-down, but the nature (direct/indirect, 
MHCI assembly status) of this association was not revealed by these studies.  While direct 
binding of CPXV203/MHCI & retrieval by KDELR could account for MHCI down-regulation, it 
is also possible that a host protein (e.g. Tpn, CRT, ERp57, BiP) may bridge CPXV203 to MHCI, 
thus explaining the ability of CPXV203 to down-regulate all MHCI ligands that have been 
tested. The study of viral sabotage of antigen presentation has often provided significant insight 
into physiologic pathways of relevance to antigen presentation7, thus suggesting that studies 
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probing the details of CPXV203-mediated MHCI retrieval will likely provide further insight into 
the mammalian immune system. 
 
1.4.5 MPX184 
While T4 poxvirus protein family members are found in numerous poxvirus genera, the only 
members described to down-regulate MHCI are CPXV203 and a similar T4 protein (MPX184, 
64% identical) found in MPXV75. MPX184-mediated down-regulation of MHCI has been 
disputed by another group that suggests MPXV encodes an immune evasion protein(s) that helps 
to evade antiviral T cell responses without affecting cell surface MHCI80.  Regardless, MPX184 
is present in the Congo basin MPXV strain Zaire, and this strain is far more virulent than the 
West African strain COP-58 that contains a non-functional truncated version of MPX184. This 
suggests that whatever function MPX184 encodes may increase MPXV virulence, and so further 
investigation into this T4 family member is warranted. 
 
1.4.6 M-T4 
Myxoma virus (MYXV) encodes two identical T4 proteins (m004L and M-T4) in its genomic 
termini that appear to have an anti-apoptotic effect on infected cells85. ER localization was found 
to be independent of this protein’s C-terminal KDEL variant, RDEL86. This T4 protein was the 
original family member identified87; it contains the 10 conserved T4 family cysteines and 2 novel 
cysteines; and it is 26% identical to CPXV203. 
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1.5 Summary 
Work by Byun et al. (2007) revealed that CPXV203 does not inhibit peptide-loading (like E3-
19K) or directly target ERAD (like US2), but instead CPXV203 operates by localizing mature 
MHCI (post-PLC) to the ER via as yet unidentified lumenal interactions75.  Though direct 
binding of CPXV203/MHCI & retrieval by KDELR could account for MHCI down-regulation, it 
is also possible that a host protein (e.g. Tpn, CRT, ERp57, BiP) may bridge CPXV203 to MHCI, 
thus explaining the ability of CPXV203 to down-regulate all MHCI that have been evaluated (H-
2Db,k,H-2Kb,d,k, & HLA-A3,-A9,-B7,-B35)75. Alternatively, two PLC components, CRT and 
ERp57, utilize KDEL domains to remain in the ER, thus creating the potential for disrupted PLC 
function due to KDELR competition. The study of viral sabotage of antigen presentation has 
often provided significant insight into physiologic pathways of relevance to antigen 
presentation7, suggesting that studies probing the details of CPXV203-mediated MHCI retrieval 
will likely provide further insight into adaptive immunity.  
 
As knowledge of this interaction(s) seemed likely to provide insight into not only 
immune evasion but also normal cellular processes, I sought to define the basis of how 
CPXV203 associates with MHCI and limits their surface expression. In the following chapters, I 
report biophysical & crystallographic studies that investigated the nature of CPXV203/MHCI 
association. Biosensor studies revealed that CPXV203/MHCI binding is pH regulated (µM <---> 
nM) to promote Golgi retrieval of MHCI by the KDELR.  This pH dependent mechanism 
predicted histidine interfacial residues that were later observed in my structure of 
CPXV203/MHCI. CPXV203 was observed to bind conserved sites (Tpn, CD8, NKRs) spread 
across three MHCI domains (α2, α3, β2m), an epitope that should only exist in mature MHCI. 
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Cellular assays by our collaborators confirmed CPXV203 solely targets assembled MHCI after it 
has dissociated from the PLC. Mutagenesis confirmed the functional relevance of the interface 
and identified critical contacts within the α3 interface, where CPXV203 histidines (H75 & H80) 
interact with Tpn contacts (D227 & E229). The evolution of CPXV203/MHCI pH dependent 
binding suggests a substantial survival advantage to the virus, which may be due to coordinated 
antigen presentation sabotage with CPXV012. 
 
Figure 
1. MHCI folding and cell surface expression. Nascent HC is translocated into the ER where it 
initially folds & associates with general ER chaperones (CNX, CRT, ERp57) prior incorporation 
of β2m and then entry into the PLC. This MHCI-specific chaperone complex then promotes 
assembly of the HC:β2m heterodimer with a peptide derived (primarily) from proteasomal 
degradation of intracellular proteins. Stable MHCI heterotrimers are then released from the PLC 
to travel to the cell surface. 
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Figure 2. MHCI folding inhibition by viral immunevasins. (a) Examples of how viruses can 
decrease peptide supply via either direct (EBV EBNA1) or indirect (transcriptional, HIV Tat) 
inhibition of the proteasome. (b) Viruses may prevent cytoplasm-ER peptide transport by TAP 
through direct blocking of cytoplasmic interactions (HSV ICP47) or conformational locks that 
either arrest transport (BHV-1/PRV UL49.5) or prevent ATP hydrolysis (HCMV US6).  Equine 
HV UL49.5 has also been shown to target TAP for proteasomal degradation, thus further 
reducing peptide available for MHCI folding. (c) Inhibition of the peptide-loading complex 
(PLC) by viral proteins has been observed via either interference with Tpn function (HCMV 
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US3) or Tpn/TAP association (AdV E3-19K).  In addition, MHV68 mK3 can affect both peptide 
transport (b) and PLC function (c) through by-stander ubiquitination of PLC components. 
 
 
 
 
 
Figure 3. Targeting MHCI for degradation in ER through ERAD. (a) HCMV US2 (Ig-like fold) 
directly binds MHCI lumenal domains and then uses a dislocation complex that includes signal-
peptide peptidase (SPP) to transport MHCI across the ER membrane. (b) Dislocation by the 
Derlin1 complex is utilized by both HCMV US11 (Ig-like fold) and MHV68 mK3 (MIR family 
member), though US11 appears to target MHCI directly while mK3 binds TAP in order to 
localize to the PLC and then target MHCI for ubiquitin-dependent degradation. 
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Figure 4. Targeting MHCI for lysosomal degradation. (a) KSHV proteins kK3 and kK5 are MIR 
family members that target cell surface MHCI to endosomes/lysosomes.  kK5 also down-
regulates a variety of other cell-surface molecules (CD31, CD166, IFNGR, ICAM1, CD86, 
CD144, MICA, MICB, CLEC2B). (b) EBV BILF1 is a G-protein coupled receptor that has 
shown to direct cell surface MHCI to lysosomes for degradation independent of its constitutive 
signaling function. (c) MHCI may also be targeted for lysosomal degradation prior to reaching 
the cell surface, as is the case for MCMV gp48 and HIV Nef, the latter of which utilizes AP1 to 
direct MHCI to the lysosome.  
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References: Adv E3-19K (susceptible31,36,37,41–43,88,89, null37,38), HCMV US2 (susceptible27,53–
55,57,62,90, null27,54,62,64,90,91), CPXV012 (susceptible76,77, nullNONE), CPXV203 (susceptible75, 
nullNONE). 
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Figure 
5. Poxvirus genome organization & immunevasion strategies. (a) General poxvirus genome 
organization is shown to highlight conservation of the core domain (~90 ORFs) responsible for 
replication & general virus morphology, while the ends of the genome are far more variable and 
encode various genes that have host restriction & immunomodulatory roles. (b) The CPXV-BR 
genome is shown to highlight the position of immune evasion genes (magenta) discussed in this 
dissertation.  Genes that down-regulate MHCI have been bolded. Note that both CPXV203 and 
OMCP (CPXV018) are more central than many other labeled immune evasion proteins. (c) 
CPXV-BR immune evasion genes from b have been grouped by function 
(viromimicry/virostealth), gene/domain, and targeted ligand  (TNF, CK, NKG2D, PLC, MHCI). 
Ligand assignments were based on experimental evidence for the indicated protein or protein 
family members with high sequence identity (various Crm molecules). 
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Figure 6. CPXV virostealth mechanisms. OMCP (CPXV018), a secreted MHCI-like protein 
that inhibits NK cell activation by acting as a high-affinity antagonist of the activating NK 
receptor NKG2D. CPXV012, a truncated C-type lectin-like domain that down-regulates MHCI 
by inhibiting peptide transport & peptide-loading through association with the PLC components. 
CPXV203, a T4 family member originally described to down-regulate MHCI in a KDELR-
dependent manner.  
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Figure 7. KDELR rescue of ER chaperones. The KDELR selectively binds soluble proteins with 
a C-terminal KDEL (or similar variant78) with high affinity (nanomolar) in the low pH 
environment found in the ERGIC-Golgi92. KDELR/KDEL binding initiates transport to the ER 
via a COPI mechanism93.  Upon return the higher pH of the ER, the KDELR/KDEL complex 
rapidly dissociates due an extremely low affinity (undetectable) 92.  Calreticulin (CRT) is shown 
as an example chaperone retrieved by the KDELR. Listed organelle pH values have been 
reported previously94,95,96,97.  
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Protein expression & purification 
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2.1 Introduction 
Rigorous structural & biochemical investigation required the production of large quantities (mg) 
of pure, recombinant protein for analysis. Both eukaryotic and bacterial expression systems were 
utilized to produce viral proteins in their native form as well as various mutated/truncated 
constructs deemed necessary during the project.  MHCI molecules were refolded by following or 
adapting previously published protocols. Finally, a limited number of ER chaperones and control 
proteins were produced in E. coli using established methods. 
 
2.2 T4 poxvirus protein expression & purification from mammalian cells.  
Transient gene expression in mammalian cells was chosen for initial expression of T4 poxvirus 
protein family members due to the high number of expected disulfides (≥5), the ability to rapidly 
evaluate gene expression (≤5 days from cloning to WB evaluation of test expression), and the 
highly reproducible expression inherent in a stable transfection stock (frozen DNA) versus the 
quickly decreasing yields obtained from baculovirus stocks stored at 4o C over time. 
 Mammalian expression constructs. All mammalian constructs are listed and described 
extensively in Table I. The ORFs of CPXV203 (aa 1-205, MVI-LHV) & MPX184 (aa 1-201, 
MSI-LHA) were initially amplified from poxvirus genomic DNA (CPXV: Brighton Red, 
MPXV: Zaire-1979) kindly provided by R.M. Buller, and then cloned into the mammalian 
expression vector pHLsec (AgeI-KpnI) in-frame between a strong, upstream secretion signal 
sequence (NP_990738.1, chicken PTPRS [-28 aa, R-27G],) and the downstream 6His tag 
(GTKHHHHHH) 1.  The poxvirus endogenous signal-peptide and the C-terminal KTEL of each 
gene were removed prior to transfer to create CPXV203ΔKTEL & MPX184ΔKTEL. The 
pHLsec expression construct is shown in Fig. 1a. After initial expression studies, poxvirus ORFs 
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were transferred into the A1.2 GFP (EcoRI-XhoI cut & drop) to monitor expression/function via 
IRES-GFP. Later, a variety of CPXV203 pHLsec & A1.2 GFP constructs (endogenous signal 
peptide, HA-tagged, BirA-tagged, etc.) were created using standard mutagenesis techniques 
(Phusion, QuikChange, SOE).  Myxoma virus (MYXV: Lausanne) M-T4, the first T4 family 
member identified2, was synthesized from oligonucleotides designed using DNAWorks3 and 
then cloned into pHLsec & A1.2 GFP to create tagged & untagged constructs. M-T4 A1.2 GFP 
(Lausanne) was later site-specifically mutated (R216C) to create M-T4 (6918 strain), which has 
an even number of cysteine residues (unlike Lausanne M-T4) and so is expected to form 6 
disulfides.  
 Initial viral ORF evaluation (DNA sequencing & test expression). Following initial 
cloning of viral ORFs into pHLsec (1-2 days), miniprep DNA was prepared for parallel 
evaluation of primary sequence (DNA sequencing: PNACL or GENEWIZ) and protein 
expression (small scale test expression). Each sequencing reaction required ~400 ng DNA (~2 µl 
miniprep) & 3.2 pmol of primer (pHLsec ForSeq & RevSeq). Please see DNA sequencing 
service websites for additional details4,5. Protein expression was evaluated in 6 well plates using 
similar protocols based on published transfection protocols1) for HEK293T (adherent) & 
HEK293F (suspension) cells. HEK293T protocol: cells were grown to ~90% confluency in 2 ml 
DMEM growth media per well, media was exchanged (optional 1X PBS wash) for 1 ml of 
DMEM expression media immediately prior to transfection, transfection reaction was assembled 
(add in order & mix between each step: 12.3 µl miniprep DNA  5.2 µl EtOH [sterilize DNA] 
 1 ml DMEM  3.7 µl PEI [1 mg/ml (pH 7.0), 1.5:1 PEI:DNA ratio]) and then allowed to 
incubate at RT for 10 min, transfection material was slowly added drop-wise to cells, and then 
the plate was gently oscillated (<1 min) to mix media with transfection reaction. HEK293F 
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protocol changes: 106 HEK293F (suspension) cells in 1 ml of HEK293F media were aliquoted 
into each well, transfection reaction was assembled as above using GIBCO FreeStyle 293 media. 
Transfection efficiency was monitored using a GFP pcDNA3.1 control well or by including 
0.1% GFP pcDNA3.1 (2.5 ng/well) in the transfection reaction. Cells were grown at 37o C with 
5% CO2 (no shaking). After 3 days, protein expression in each well was evaluated by α6His WB 
(Bethyl Rabbit pAb α6His, GE Healthcare ECL Plus) of a cell pellet sample (lysed cells in 250 
µl 1X SDS LB, loaded 5 µl/lane) and a soluble, secreted sample (0.2 µm-filtered supernatant to 
remove cells & large aggregates, loaded 24 µl supernatant/lane).  Comparison of secreted 
material to previous purifications allowed for an approximation of the yield (µg to mg) from a 
large-scale prep.  Total time from PCR amplification to WB results ≤ 5 days. All reagents were 
used at 1x concentration and are listed in Buffers. 
 Large-scale transient gene expression (TGE). T4 poxvirus proteins were expressed via 
large-scale transient transfection of either HEK293T or HEK293F cells by adapting a published 
protocol to the particular cell line and the available tissue culture materials 1. For adherent 
HEK293T cells, three T175 flasks were grown to >90% confluency in growth media (see above) 
prior to being washed with PBS (30 ml/flask), trypsinized (5 ml/flask, 5-10 min), and then 
resuspended in 500 ml of expression media (see above); the transfection reaction was assembled 
(add in order & mix between each step: 0.5 mg Gigaprep DNA  EtOH to 30%  5 ml DMEM 
 0.75 mg PEI) in a 15 conical tube and incubated at RT for ≥10 min; cells & transfection 
reaction were mixed (inverted 6-8 times) and then poured into a Corning HYPERFlask or ten 
T175 flask (50 ml/flask). After 24 hr, cells should appear to be 80-90% confluent and GFP (if 
present) should be visible in the bottom HYPERFlask layer. Cell survival was consistently much 
higher with HYPERFlask (CELLBIND surface) as compared to standard T175 flasks, though no 
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survival difference was observed if cells were grown in flasks to 80-90% confluency prior to 
transfection so that no trypsinization is required prior to transfection. HEK293F (suspension) 
protocol changes: three 1 L flasks with 150 ml cells (5 x 105 cells/ml) were grown O/N to 1 x 106 
cells/ml (optional step to insure cells are healthy), transfection reaction (0.15 mg DNA  EtOH 
to 10%  5 ml FreeStyle media  0.225 mg PEI  10 min @ RT  mix with cells by 
swirling for 30 s), cell growth conditions (shaking, 37o C, 5% CO2).  After 3 & 6 & 9 days of 
growth, the media for either cell line was collected and replaced with fresh media.  Conditioned 
media was stabilized as follows: addition of anti-microbial & protease inhibitors and NiNTA 
buffer (see Buffers); centrifugation to remove aggregate & cell debris (>20,000 x g, 4o C, 10 
min); and finally 0.2 µm filtration (1L bottle-top filter with 2-3 glass fiber pre-filters). Stabilized 
media was stored at 4o C until purification.  
 Preparation of stable cell lines expressing T4 poxvirus proteins. Polyclonal stable cell 
lines (initially CPXV203 & MPX184) were prepared by adapting previously published protocols 
that outlined transfection of a chosen expression cell line (HEK293F) with the A1.2 GFP vector 
containing your GOI followed by multiple rounds of cell-sorting for GFP(+) cells678.  In brief, 
each construct was transfected (50 µg DNA) into a T175 flask with HEK293F cells at 80-90% 
confluency, cells were allowed to recover/grow for 1.5 days prior to selection (optional) with 
puromycin (1.6 µg/ml, 3 days), cells were split as appropriate until ≥5 x 107 cells were available 
for sorting (FACSDiva, 100 µm tip, top 1%), sorted population was expanded (105  ≥107) and 
then resorted (3-4 total sorts). Cell stocks were frozen (5 x 107 cells/ml in 90% FBS + 10% 
DMSO) at each step in cell line production. Cells were maintained in DMEM growth media, 
sorted in sorting buffer, and collected in post-sort growth media.  Cells were then allowed to 
grow in post-sort media for 1 day to recover from the sorting procedure.  Cell lines were also 
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created without puromycin selection for CPXV203 (MEE-DIQ) and one other viral proteins 
(VOX2-Fc, please see Chris Nelson), which reduced the lag time between transfection & sorting 
by ~5 days without compromising the selection process7.  All poxvirus stable cell lines were 
verified to secrete recombinant protein by WB and then stored in liquid N2. CPXV203 & 
CPXV203 (MEE-DIQ) cell lines were later scaled up for large-scale protein production. All 
reagents were used at 1x concentration and are listed in Buffers. 
 Purification strategies. Purification consisted of using an Amicon stirred cell 
concentrator (YM10, 76 mm, 80-100 ml/hr) to concentrate sample ≥50X (required for DMEM 
preps, optional for FreeStyle preps), IMAC purification (4o C; Ni-NTA SuperFlow bench top or 
HisTrap Bio-Rad Profinia), and then SEC on an ÄKTA FPLC run in HSB. Concentrating the 
conditioned media to a volume equal to 4-5X the volume of the IMAC column greatly increased 
recombinant protein recovery. HiLoad 16/60 Superdex 75 pg was required to separate T4 
proteins from BSA in DMEM preps. FPLC fractions were evaluated via SDS PAGE (±BME) 
and then selected fractions were concentrated (Amicon Ultra or Vivaspin sample concentrators). 
This purification strategy is summarized in Fig. 1b. Preps routinely yielded 0.5-1.0 mg/L and 
expressed protein had the N-terminus & MW predicted from 1o sequence (see results for 
additional details). Please see company literature (Millipore, Qiagen, GE Healthcare, Bio-Rad) 
or the QIAexpressionist9 for additional purification details. All reagents were used at 1x 
concentration and are listed in Buffers. 
 Results: CPXV203 & MPX184 are secreted from HEK293 cells. TGE of CPXV203 & 
MPX184 in HEK293T cells routinely resulted in purified yields of 1.0 mg/L and ~0.4 mg/L, 
respectively. The difference in TGE yield between these two T4 proteins was not identified, 
though it may be related to difficulties encountered during creation of the MPX184 stable line 
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(see below). TGE yield for both proteins increased ≥3X when suspension HEK293F cells were 
used. Also, CPXV203 constructs expressed more protein as an adherent, polyclonal stable (2-3 
mg/L) than observed for large-scale TGE, while MPX184 expression was not evaluated due to 
low recombinant protein expression (see below). CPXV203 & MPX184 eluted as 
monodispersed, symmetric peaks from SEC, and this purification step removed FBS 
contaminants to leave >95% pure (SDS PAGE) poxvirus protein (Fig. 1c,d). Electrospray 
ionization mass spectrometry (ESI-MS) & N-terminal sequencing confirmed the signal-peptide 
cleavage position predicted by SignalP3.0 (see Table I)10. ESI-MS & PNGase confirm that 
neither of these proteins is glycosylated. 
 MPX184 expression may be limited by cellular toxicity. During the creation of an 
MPX184 stable cell line, two observations were made that suggested this poxvirus protein 
reduces cell viability.  First, MPX184 expression greatly increased the sensitivity of transfected 
cells to puromycin selection (24 hr post-Puro: MPX184, >90% dead; CPXV203, <10% dead).  
This trend continued throughout the antibiotic selection process. Second, the final MPX184 
polyclonal cell line produced 10-fold less protein (monitored by GFP fluorescence) than the 
CPXV203 cell line, though these lines were sorted in an identical fashion. Though these 
observations do not identify an MPX184 mechanism that affects cell viability, I believe they 
suggest such a mechanism may be present, perhaps related to the unidentified anti-apoptotic 
pathway manipulated by MYXV M-T4.  
 Secreted M-T4 (Lausanne) appears to be unstable. Small-scale test expression (TGE) of 
MYXV M-T4 (Lausanne) suggested this protein was secreted from HEK293F cells at a similar 
level to MPX184 (Fig. 2a), but a large-scale expression resulted in little usable protein following 
SEC (Fig. 2b,c). The unstable behavior of this protein is believed to be due to an unpaired 
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cysteine (C160) that is predicted to be solvent-exposed based on the crystal structure of 
CPXV203 (this work). The M-T4 (R216C) construct (equivalent to strain 6918) was cloned, but 
time was not available during this dissertation work to pursue expression studies.  
 Incomplete work. Due to time constraints, two mammalian T4 projects were left 
unfinished.  First, constructs were created to produce soluble, site-specifically biotinylated 
OVA257-264: H-2Kb:hβ2m via TGE in HEK293 cells in order to evaluate the effect (if any) of 
glycosylation on CPXV203 association.  This expression strategy would have utilized a 
transfection of H-2Kb (MVP-LTL)-BirA and sOVA pHLsec constructs, as transfection of tagless 
H-2Kb alone did not produce sufficient protein for purification (see control in Fig. 6a). Further, 
other plasmids could be co-transfected to in vivo biotinylate (sBirA) MHCI or deliberately retain 
it intracellularly with immature glycosylation (CPXV203FL). As little MHCI-biotin is required 
for biosensor analysis (<50 µg), small-scale expressions should be sufficient for these 
experiments. 
The second unfinished mammalian project sought to evaluate the requirement of KDELR 
cycling in MHCI retention.  Specifically, CPXV203 & a control protein (WNV DIII) were fused 
to a Golgi-targeting construct, TM of SARS Orf7a linked to cytoplasmic GFP11. These 
constructs should remain in the Golgi even if the ER-Golgi pH gradient was eliminated by 
ammonium chloride treatment12. These constructs are available as sequenced Gigapreps, so they 
are ready to be evaluated functionally (flow-cytometry) and to confirm Golgi localization 
independent of the ER-Golgi pH gradient (confocal). 
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2.3 T4 poxvirus protein expression & purification from E. coli 
 E. coli expression. All T4 poxvirus constructs are listed and described in Table II. Each 
T4 ORF was initially amplified from previously discussed mammalian expression constructs, 
and then ligated into a modified version of the pET28a vector (Stratagene) that contains a 
cleavable C-terminal tag (Thr-BirA-6His; GSLVPRGSLNDIFEAQKIEWHERLEHHHHHH).  
Various modified T4 constructs (tagless, truncations, mutations, fusions) were created using 
standard mutagenesis techniques (Phusion, QuikChange, SOE). Bacterial expression constructs 
were transformed into BL21-CodonPlus (DE3)-RIL competent cells (Stratagene) using a 
standard heat-shock protocol and expression of both native and selenomethionine-labeled protein 
was carried out via autoinduction, as reviewed by Studier (2005)13. Selenomethionine 
incorporation was verified to by >90% by ESI-MS for multiple constructs (data not shown). T4 
proteins were expressed as insoluble inclusion bodies (IB), except for a limited number of 
peptide constructs fused to PpL (single domain of protein L). Multi-domain CPXV203 fusion 
proteins will be discussed in later crystallography sections. All reagents were used at 1x 
concentration and are listed in Buffers. 
Inclusion body (IB) purification. A bacterial cell pellet from 1 L of culture was initially 
resuspended in 100 ml solution buffer via sonication (30 s, maximum power) followed by 
vigorous stirring for 1 hr (RT or 4o C). Cell lysis was initiated by the addition of lysozyme to 0.3 
mg/ml, DNase I to 60 µg/ml, MgCl2 to 12 mM, and 100 ml of lysis buffer. Stirring was 
continued for 1 hr, sonication was repeated to complete lysis, and then EDTA was added to 12.5 
mM.  Centrifugation (15 min, >10,000 x g, RT) was used to pellet the IB. If centrifugation 
produced a gelatinous mass (unlysed cells) rather than a compact pellet (IB), sonication was 
repeated (≥60 s, maximum power) and then the sample was again centrifuged. IB was washed 
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with wash buffer with Triton (2-3 times), wash buffer without Trion (1-2 times), and finally 
wash buffer without Triton supplemented with either 1 M NaCl or 0.5 M GndCl, as needed. All 
wash steps used two stages of sonication (50 ml buffer, 15-20 s, maximum power; add 200 ml 
buffer 15-20 s, maximum power) to dissolve the IB in wash buffer prior to collection of the IB 
pellet via centrifugation. Purified IB was solubilized by O/N shaking in solubilization buffer (10 
ml/L cell culture), insoluble material was removed via high-speed centrifugation (20 min, 
>16,000 x g, RT), and then IB was stored at -80o C. IB purity was confirmed by SDS PAGE. All 
reagents were used at 1x concentration and are listed in Buffers. 
 T4 Refolding protocol#1. All constructs were refolded using an adaptation of the rapid 
dilution method (arginine refolding under, oxidative conditions, 4° C)14. Briefly, refolding buffer 
#1 was assembled and then set to stir at max speed w/o frothing (4o C). Then 1-2 ml IB diluted in 
20 ml of injection buffer was 0.2 µm filtered into a capped syringe (closed 2-way stopcock & a 
25-gauge needle). The syringe assembly was placed above the refolding, opened, injection (i.e. 
dripping) was confirmed, and then the needle was inserted into the refolding buffer so that IB 
was injected immediately above the stir bar. The refolding was then incubated at 4o C O/N. 
Purification of refolded material entailed 0.2 µm filtration of the refolding (Nalgene bottletop 
filter, Supor machV PES membrane), Amicon stirred-cell concentration (YM10, 350 ml  ≤10 
ml), and SEC (HiLoad 16/60 Superdex 75 pg or 200 pg). Post-SEC purity of each T4 protein 
depended on the amount & quality of IB used in each refolding. T4 protein that required further 
purification (polishing step) underwent either IEX (GE Healthcare MonoS, 0-50%, 60 CV) or 
HIC (GE Healthcare Phenyl HP, 0-100%, 30 CV). All reagents were used at 1x concentration 
and are listed in Buffers. 
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 T4 Refolding protocol#2. This strategy modifies the previously described protocol by 
initially capturing the T4 protein from the refolding via IEX and then ending with SEC to buffer-
exchange (BE) the protein into HSB. Refolding protocol #1 is followed (except for the use of 
refolding buffer #2) until the Amicon concentration step. Then the refolding is diluted 10-fold 
into T4-RP#2A buffer, 0.2 µm filtered, pumped  (50-100 ml/min) over a Sartobind S15 IEX 
membrane (Sartorius) to capture T4 protein. Finally, the protein is bulk eluted in 10 ml of T4-
RP#2B buffer and BE via SEC.   This refolding protocol was developed to reduce initial prep 
time (350 ml refolding: Amicon, 3-6 hr; Sartobind, <1 hr) and to remove the IEX “polishing” 
step. When necessary, HIC was used to further purify this material. All reagents were used at 1x 
concentration and are listed in Buffers 
 Soluble E. coli expression. Soluble E. coli expression was used to prepare CPXV203 
peptides (PpL-fusions), control proteins (PpL variants), and two ER chaperones (mCRT & 
mERp57). All of these constructs are listed in Table III. These protocols were adapted from a 
various literature sources (PpL15, chaperones16). In brief, proteins were expressed in 
autoinduction media (chaperones, 25o C; PpL; 37o C), cells were collected by centrifugation, 
resuspended (stir plate, ≥1 hr) in appropriate lysis buffer, lysed by sonication (12 cycles: 5 s on, 
60 s off), insoluble material was removed by centrifugation (32,000 x g, 20 min) & 0.2 µm 
filtration, and finally recombinant protein was purified by Ni-NTA (GE Healthcare HisTrap, 
Bio-Rad Profinia) & then SEC (HiLoad 16/60 Superdex 200 pg). All steps were performed at 4o 
C unless otherwise noted. SEC buffer was supplemented with 2 mM CaCl2 for mCRT. Tagless 
versions of chaperones were produced via thrombin digestion, Ni-NTA purification (capture of 
FL & tag), and finally SEC of Ni-NTA FT (tagless chaperone). Alternative PpL protocol: 
following (or in place of) sonication, sample may be incubated at 70-80o C (1 hr, occasional 
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mixing) to aid cell lysis & purification (precipitates out most other proteins). All reagents were 
used at 1x concentration and are listed in Buffers. 
  Results: T4 proteins refold with varied efficiency. Refolding strategies for T4 proteins 
(Fig. 3a) successfully produced milligram quantities of both CPXV203 and MPX184. Refolding 
efficiency varied both with the amount/quality of the IB used in a refolding (Fig. 3b) and with 
the particular construct. CPXV203 constructs refolded with relatively high efficiency and the 
recombinant material was extremely stable, while MPX184 constructs refolded with lower 
efficiency and were susceptible to significant aggregation and proteolysis. Exhaustive attempts to 
minimize these MPX184 problems were unsuccessful. M-T4 refolding was attempted a number 
of times without success, likely due to the presence of an exposed cysteine (see above).  
Following SEC purification, IEX or HIC purification was used to polish both CPXV203 & 
MPX184 material (Fig. 3c,d). Use of refolding protocol #2 normally negated the necessity of a 
polishing step following SEC purification. CPXV203 was also refolded in a variety of modified 
refolding buffers: - EDTA; -EDTA, +2 mM CaCl2; +50-500 µM ZnCl2. Of these buffers, only 
addition of Zn changed the refolding efficiency, though not in a productive manner. All 
CPXV203 mutants purified in a manner identical to wt CPXV203. CPXV203 mutants did not 
exhibit decreased stability during purification or in later biophysical analyses, except for three 
CPXV203 β5-β6 loop mutants at pHGolgi 6.0 (F76A; G77A; H75A, H80A). The first two mutants 
produced very, slight precipitation in low pH BLI buffer, while the latter only demonstrated 
instability in low pH MBS-EP+. As such, biophysical analyses of these three mutants at low pH 
in these buffers are preliminary at this point in time. 
 Successful refolding of CPXV203 fusion proteins. CPXV203 fusion proteins were 
designed to attempt to increase crystallization success of CPXV203/MHCI complex (OVA-
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CPXV203, hβ2m-CPXV203) or CPXV203 alone (FadA-CPXV203). The first two fusions were 
created to promote CPXV203/MHCI complex assembly, while the latter sought to fuse a 
crystallization chaperone to CPXV203. Both OVA- and FadA-CPXV203 fusions refolded & 
purified readily (data not shown), while the hβ2m-CPXV203 construct did not refold efficiently 
and was not able to be purified.  OVA-CPXV203 was able to promote MHCI refolding and 
could be used to exchange a low-affinity peptide (YEA9) bound to H-2Kb (data not shown), 
while FadA-CPXV203 was found to be functional via low pH NATIVE gel-shift with MHCI 
(data not shown). Please see crystallography section for additional details on these constructs. 
 Soluble expression of ER chaperones and PpL-peptide fusions. ER chaperones (mCRT 
& ERp57) were produced for biosensor & SEC studies. These chaperones purified as expected 
from E. coli lysates (Fig. 4a). CPXV203 peptides (26 & 31 aa) were produced as soluble PpL 
(single domain protein L) fusions for use in biosensor experiments. Peptides were designed using 
the CPXV203 crystal structure (see later sections). Expression varied significantly for these two 
peptides (7 mg/L and 2 mg/L, respectively), though more than enough material was available for 
biosensor analysis (Fig. 4b). PpL was produced (≥10 mg/L cell culture) as a control for both 
expression & biosensor experiments. A pentamerized version of PpL was also cloned & 
produced in these studies.  
 
2.4 Minimal soluble domain of CPXV203 and MPX184 
Since flexible regions of a protein may interfere with crystallization, strategies were pursued to 
define the minimal soluble domain of T4 proteins.  Initially, a mass spectrometry technique was 
used to define boundaries for both proteins, while later work refined the boundaries for 
CPXV203 using a series of PCR truncations evaluated by mammalian expression.  
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2.4.1 Limited proteolysis/mass spectrometry (LPMS) 
Separate limited proteolysis reactions of CPXV203 & MPX184 with carboxypeptidase A & Y, 
chymotrypsin, and trypsin were prepared and then analyzed by mass spectrometry (Keck 
Facility, Yale) to define new construct boundaries 17. Carboxypeptidase preparations produced 
uninterpretable spectra, while chymotrypsin & trypsin preparations both produced spectra that 
defined new T4 construct boundaries. The general procedure is shown in Fig. 5a, while the 
minimal CPXV203 domain defined by this technique is shown in Fig. 5b. 
 
2.4.2 Mammalian expression screen of PCR truncations 
A series of N- and C-terminal truncations (every 3-4 residues, 11 constructs/terminus) were 
introduced into CPXV203 A1.2 GFP using Phusion mutagenesis. See Table I for a complete list 
of truncations and their boundaries. Small-scale test expressions were conducted as described 
above. Since secretion of recombinant material in mammalian cells must pass through multiple 
folding checkpoints, the presence of soluble 6His(+) material on day 3 post-transfection was 
interpreted as a truncation that did not adversely affect protein folding/stability. Only fourteen 
constructs were completed, as initial expression data negated the necessity of the remaining 8 
constructs. 
 Results: Minimal soluble domains of CPXV203 & MPX184. While chymotrypsin 
LPMS analysis suggested similar domain boundaries for CPXV203 and MPX184, trypsin LPMS 
analysis removed more flexible sequence (~2.3 kDa total) and identified identical boundaries 
(RCE-FDR) for CPXV203 (5-190) & MPX184 (5-186) (Fig. 5b). Screening of fourteen 
CPXV203 PCR truncation mutants refined this minimal soluble domain to KIG-DIQ or residues 
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17-174 (Fig. 6a,b), thereby reducing the MW of the minimal soluble domain by an additional 3.6 
kDa. In total, these analyses removed 2.3 kDa from the N-terminus and 3.6 kDa from the C-
terminus for a total of 5.9 kDa (~23% of the MW of the original construct). 
 Truncation does not prevent T4 protein refolding. Both the LPMS-designed T4 
constructs and the minimal soluble domain defined by PCR truncation were able to be refolded 
using refolding protocol #1 (Fig. 7a). Of the LPMS-constructs, only CPXV203 (5-190) was 
stable enough to be further purified (IEX/HIC) for biophysical and structural studies. CPXV203 
(17-174) was of sufficient purity following SEC to use in crystallographic trials. Later structural 
studies (see Chapter 6) allowed for the design of two more severe CPXV203 truncations (6-153 
and 13-153) that sought to eliminate all flexible loops/termini from CPXV203.  Both of these 
constructs could be refolded and purified for biophysical & structural analysis (Fig. 7b). 
 
2.5 MHCI expression & purification from E. coli. 
 E. coli expression and IB purification. All β2m/peptide constructs are listed in Table 
III, while all HC constructs are listed in Table IV. Bacterial stocks of OVA:H-2Kb single-chain 
trimer (SCT) Y84C, H-2Kd, and mβ2m were available at the inception of this project, while all 
other MHCI constructs required cloning, including H-2Kb. The former H-2Kb pET21a construct 
produced very little IB/L, thus requiring multiple L of culture for a single 350 ml MHCI 
refolding. The pET28a construct created in this dissertation work produces sufficient IB from 1 
L for 5-7 standard refoldings. DNA manipulation, E. coli transformation, protein expression, 
selenomethionine incorporation, and IB purification techniques have been previously described 
for T4 proteins. Non-MHCI ORFs were amplified from available DNA stocks or synthesized as 
necessary. 
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 MHCI refolding protocol #1. Recombinant MHCI were refolded from bacterial IB in a 
manner similar to that of T4 refolding protocol #1. The MHCI-specific changes for a standard 
350 ml refolding are as follows: refolding sequence – β2m (IB from 1/5 L culture diluted to 8 ml 
with injection buffer) were initially refolded over the course of 3-4 hr, peptide was then added to 
10 µM, protease inhibitor cocktail concentration was then increased from 0.03x to ≥0.06x, and 
then HC (IB from 1/10 L culture diluted to 12 ml with injection buffer) was refolded over 4-6 hr; 
Amicon concentration used a YM30; and SEC was always performed on a HiLoad 16/60 
Superdex 75 pg. This protocol attempts to produce a peptide:β2m:HC ratio of 10:2:1. Less 
peptide may be used (5 µM), though refolding efficiency will decrease. Following SEC, MHCI 
was further purified by either IEX (GE Healthcare MonoQ, 0-30%, 30 CV) or HIC (GE 
Healthcare Phenyl HP, 25-100%, 30 CV). Refolding buffer may be reused up to twice, though 
yield/purity will decrease with each use. All reagents were used at 1x concentration and are listed 
in Buffers. 
MHCI refolding protocol #2.  Similar to the T4 refolding protocol #2, this strategy 
modifies the previously described MHCI refolding protocol by initially capturing MHCI from 
the refolding via IEX and then ending with SEC to BE the protein into HSB. MHCI refolding 
protocol #1 is followed (except for the use of refolding buffer #2) until the Amicon concentration 
step. Then the refolding is diluted 30-fold into MHCI-RP#2A buffer, (if necessary) adjusted to 
pH 9.0 with 10 N NaOH, 0.2 µm filtered, pumped  (50-100 ml/min) over a Sartobind Q15 IEX 
membrane (Sartorius) to capture MHCI. Finally, the protein is bulk eluted in MHCI-RP#2B 
buffer and BE via SEC. This refolding protocol was developed to reduce the required prep time 
for refolding multiple MHCI in parallel for biosensor experiments (350 ml refolding: Amicon, 3-
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4 hr; Sartobind, <2 hr) and to remove the IEX “polishing” step. Occasionally, HIC was used to 
further purify this material. All reagents were used at 1x concentration and are listed in Buffers 
Peptides. Peptides for in vitro MHCI refolding were synthesized by Fmoc chemistry and 
then subjected to reverse-phase HPLC for purification (S. Horvath, Allen lab).  Peptides were 
chosen based on available MHCI crystal structures or personal suggestions by A. Stout (NIH 
Tetramer Core Facility). Peptides were resuspended at >1 mM in ddH2O, DMSO, or 6M GndCl, 
as dictated by peptide solubility. The peptides used in this study are as follows: H-2Kb (OVA257-
264, SIINFEKL18; YEA9, SRDHSRTPM1920; SEV9, FAPGNYPAL2120), H-2Kd (TYQRTRALV, 
Flu NP147–155)22, H-2Kk (SV40560–568, SEFLLEKRI)23, H-2Dd (Env-modified PA9, 
IGPGRAFYA)24, H-2Dk (Middle T-antigen389-397, RRLGRTLLL), H-2Dq (Her2395-404, 
PDSLRDLSVF), H-2Ld (p29,YPNVNIHNF)25, Ceat-B*12 (nef20-28, LLRARGETY), Mamu-
A*01 (Tat28–35, TTPESANL)26, Patr-B*0802 (Polyprotein1527-1536, AGCAWYELTP), H-2Q9-H-
2Db (Minor capsid protein VP324-32, HALNVVHDW), H-2Kb-HLA-A*0201 (OVA257-264, 
SIINFEKL)18, HLA-A*0201-H-2Kb (Insulin2-10, ALWMRLLPL). OVA257-264 was also 
synthesized with an internal biotinylated lysine for biosensor analysis. 
 Results: Standard MHCI refolding. H-2Kb (aa 0-280, mGPH-PST, mGPH-LRW)/H-2Kd 
(aa 0-283, mGPH-VSN) constructs were produced in house, while H-2Dd, H-2Dk, H-2Dq, H-2Kk, 
H-2Ld, Mamu-A*01, Patr-B*0802, H-2Q9-H-2Db, H-2Kb-HLA-A*0201, HLA-A*0201-H-2Kb 
were produced by the NIH Tetramer Core Facility. H-2Db biotinylated monomer (LCMV Gp33, 
KAVYNFATC) was purchased from Beckman Coulter. All MHCI include human β2m (hβ2m, 
aa 0-99, mIQR-RDM) unless otherwise noted. Typical SEC purification of a variety of MHCI 
refoldings are shown in Fig. 7a, which also demonstrates how MHCI refolding protocol #2 
removes aggregate, excess β2m, and Arg/GSH/GSSG. MHCI refolding using protocol #1 
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required additional purification via either IEX (Fig. 7b) or HIC (Fig. 7c). All MHCI mutants 
(HC & β2m) purified in a manner identical to that observed for wt MHCI. Mutants did not 
exhibit decreased stability at any point during purification or later biophysical analysis.  
 Refolding & purification of hβ2m fusion proteins. Human β2m was fused to a number 
of moieties during this work for the purposes of purification (N-terminal eXact tag, Bio-Rad), 
construct assembly (N-terminal OVA257-264), and biosensor capture (C-terminal Thr-BirA-6His). 
These hβ2m fusion constructs refolded and purified without problem. Example purifications of 
eXact-hβ2m and hβ2m-BirA are shown in Fig. 9a, and an example of eXact tag purification 
releasing hβ2m with an authentic N-terminus is shown in Fig. 9b. MHCI produced from IB 
retains an N-terminal methionine on β2m (often observed in MHCI crystal structures), and so the 
material in Fig. 9b was prepared for biosensor experiments designed to address the effect of this 
methionine on CPXV203/MHCI association. 
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Figure 1. Large-scale TGE of T4 poxvirus proteins in HEK293T cells. (a) General outline of the 
pHLsec vector. Constructs that utilized the vector signal peptide were inserted using AgeI-KpnI, 
constructs with an endogenous signal peptide were inserted EcoRI-KpnI, and tagless constructs 
were inserted EcoRI/AgeI-XhoI. All mammalian constructs were initially tested in pHLsec prior 
to transferring to A1.2 GFP as an EcoRI-XhoI insert.  (b) General strategy for mammalian 
expression of T4 poxvirus proteins. (c) Example SEC elution profiles for T4 poxvirus proteins 
produced from adherent HEK293T cells.  Both proteins eluted as single, monodispersed peaks. 
The estimated MW (CPXV203: 26 kDa, MPX184 21 kDa) suggested these proteins are 
monomeric. Clear separation of recombinant material (~25 kDa) from contaminants (BSA, 66 
kDa) was achieved by using a HiLoad 16/60 Superdex 75 pg. (d) SDS PAGE analysis (+BME) 
shows that this strategy produces proteins that are >95% pure.  Colored bars (c,d) indicate 
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fractions examined on this gel. Disulfide-linked multimers were not observed on gels run without 
BME. 
 
 
Figure 2. Large-scale TGE expression of MPX184 & M-T4 in HEK293F cells. (a) Expression of 
these T4 proteins in HEK293F cells was monitored by α6His WB of both cell pellets and filtered 
supernatants. WB confirmed both proteins are secreted at similar levels into the supernatant. Cell 
pellet samples partially precipitated before entering the gel, which likely explains the weak 
6His(+) bands in the pellet lanes. (b) SEC elution profiles (S200) demonstrate the expected 
single, monodispersed peak profile for MPX184, while M-T4 had a much smaller peak at the 
appropriate size for monomer. The estimated MW for both proteins was ~20 kDa. (c) SDS 
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PAGE analysis (+BME) confirmed MPX184 is >95% pure, while M-T4 purity is closer to 60%. 
Colored bars (b,c) indicate fractions consolidated and then examined on this gel. Evaluation of 
the aggregate peak confirmed neither T4 protein elutes earlier as a multimer. Disulfide-linked 
multimers were not observed on gels run without BME. 
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Figure 3. Refolding of T4 poxvirus proteins. (a) General strategy for the two refolding protocols 
used to produce T4 poxvirus proteins. (b) SEC profiles for a variety of refolded CPXV203 preps 
(wt & two mutants) are shown.  All of these CPXV203 constructs were tagless.  The two mutant 
profiles provide examples of the range of refolding efficiency observed for CPXV203 constructs. 
Similar profiles were routinely obtained for wt constructs, thereby supporting the suggestion that 
refolding efficiency was tied to IB amount/purity.  Comparison of the wt and H196Y,H204Y 
profiles provides an estimate of the purification provided by the Sartobind S15 membrane in 
refolding protocol #2. (c) MonoS purification of CPXV203 following SEC. (d) HIC purification 
of CPXV203 following SEC. Gel analysis (SDS PAGE & NATIVE) confirmed the purity of the 
dominant peak for both c & d. 
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Figure 4. Soluble expression of proteins in E. coli. (a,b) SEC traces are shown for representative 
preps of each protein. The MWSEC of each recombinant protein (*) estimated from gel-filtration 
standards is shown with the MWCalc calculated from 1o sequence listed in parentheses. All 
proteins were confirmed to be the correct MW by SDS PAGE analysis. (a) SEC (HiLoad 16/60 
Superdex 200 pg) purification of mERp57 (200 ml culture) and tagless mCRT  (4.8 L culture). 
Tagless mCRT was prepared as described above except that SEC was only performed as a final 
purification step. **Degraded mERp57 (confirmed by SDS PAGE). (b) Comparison of SEC 
(HiLoad 16/60 Superdex 75 pg) purifications of various PpL proteins purified from 
autoinduction volumes of either 500 ml (PpL) or 400 ml (fusions). Proteins in this analysis have 
similar ε280 values: PpL, 9970; PpL-CPXV203(151-181,C153S,C168S), 14440; and PpL-
CPXV203(184-209), 12950. The PpL preps compared the two purification strategies (same day, 
same starting material), which revealed that the 70o incubation step increased yield by nearly 
50%. SDS PAGE analysis of the 22 kDa hump/peak in the PpL fusion profiles suggests a small 
degree of proteolytic degradation occurred during protein expression. 
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Figure 5. LPMS assessment of poxvirus domain boundaries. (a) General outline of the 
experiment is shown.  The recombinant poxvirus proteins were bacterially refolded ΔKTEL 
versions of CPXV203 and MPX184.  Four mass spec samples (native and three protease rxns) 
were evaluated for each poxvirus protein. (b) Spectra were analyzed and nearly identical domain 
boundaries were identified for both poxvirus proteins corresponding to expected protease sites 
for trypsin and chymotrypsin.  Unfortunately, the carboxypeptidase samples did not provide 
interpretable spectra. As the trypsin cleavage sites are conserved in these two poxvirus proteins 
and trypsinization created the greatest degree of truncation, these boundaries were used for new 
poxvirus constructs, CPXV203(5-190) and MPX184(5-186). These truncations removed ~2.3 
kDa from each construct.  
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Figure 6. PCR truncation to identify minimal CPXV203 soluble domain. (a) A test expression of 
each PCR truncation construct was evaluated on day 3 by α6His WB to evaluate mammalian 
secretion of protein. Truncations are listed by their CPXV203 domain boundaries (see Table I). 
Six truncations were identified that did not secrete protein and one truncation (MVI-CGA) 
appeared to severely limit secretion. The protein ladder (SeeBlue Plus2, Invitrogen) was marked 
on the x-ray film following WB development. (b) Truncation secretion data is shown graphically 
to demonstrate the identification of a minimal soluble domain that is 3.6 kDa smaller than the 
LPMS construct. The LPMS, dMEE-DIQ, and wt CPXV203 constructs were all shown to be 
soluble in refolding/mammalian expression systems in separate experiments.  
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Figure 7. Refolding T4 truncation constructs. All proteins were purified on the same type of 
SEC column, though not necessarily the same column (accounts for slight elution profile 
discrepancies). MWSEC (MWCalc) is shown for each protein peak (*) along with its construct 
boundaries and how it was designed. (a) Example purifications are shown for the T4 truncation 
constructs developed through either LPMS or PCR truncation studies. All three constructs elute 
at MWSEC larger than MWCalc for a monomer, but this behavior was also observed for FL 
proteins.  Further, light scattering of FL CPXV203 (1-205, MVI-LHV) and CPXV203 (5-190, 
mRCE-FDR) indicates these constructs are monomers.  (b) Later structural work (see Chapter 
6) identified a minimal globular domain of CPXV203 that might be used in additional 
biophysical & structural studies. Purifications of two variants of this domain are shown (6-153 & 
13-152) with the LPMS CPXV203 construct from a shown for comparison. Interestingly, 
MWSEC ≈ MWCalc for both of these constructs, suggesting that the removal of the all extraneous 
loops and termini did result in a compact, globular protein that elutes as predicted by gel-
filtration standards. All proteins were confirmed by SDS PAGE analysis. 
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Figure 8. Refolding & purification of MHCI. (a) Comparison of various MHCI refoldings. 
MWSEC (MWCalc) is shown for each protein peak. Comparison of the refolding protocols #1 & #2 
for H-2Kb demonstrates the purification provided by the Sartobind Q membrane. (b) MonoQ 
purification of OVA:H-2Kb(GPH-PST):hβ2m following SEC. The IEX artifacts in this profile 
are non-proteinaceous spikes in both absorbance and conductivity. (c) HIC purification of 
OVA:H-2Kb(GPH-LRW):hβ2m from six standard 350 ml refoldings. The HIC column was 
loaded prior to beginning this method. Gel analysis (SDS PAGE & NATIVE) confirmed the 
purity of the dominant peak for both b & c.  
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Figure 9. Refolding of hβ2m variants. (a) SEC profiles for two hβ2m variants are shown. 
MWSEC (MWCalc) is shown for each protein. Both the N-terminal eXact tag (8.5 kDa, prodomain 
of the subtilisin protease) and the C-terminal Thr-BirA-6His tags elute with a larger MWSEC than 
expected based on MWCalc due to the flexible nature and likely extended conformation of the 
tags.    (b) The gel insert shows the eXact purification of eXact-hβ2m that produces refolded 
hβ2m with an authentic N-terminus following elution in the presence of fluoride or other small 
anions. The N-terminus the eluted β2m was confirmed by N-terminal sequencing. 
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Chapter 3 
 
Biosensor analysis of CPXV203/MHCI binding 
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3.1 Introduction  
Biosensor analysis was chosen to probe CPXV203/MHCI binding because this type of assay 
could be used to determine both the requirements and nature of this association using 
recombinant proteins easily amendable to perturbation (alleles, truncation, site-directed 
mutagenesis).  In regards to binding requirements, I sought to investigate whether these 
molecules are sufficient for association (direct vs. indirect binding), whether CPXV203 displays 
MHCI allele preferences, and whether this association was sensitive to a variety of 
environmental factors found in the ER/Golgi.  As to the nature of this interaction, biosensor 
studies measure binding in real-time, thus allowing for both equilibrium and kinetic analyses.  
My studies employed two distinct biosensor technologies (SPR & BLI) due to the inherent 
advantages unique to each system that I will discuss in the following sections. 
   
3.2 Surface-plasmon resonance (SPR) 
  
3.2.1 SPR background 
Surface plasmon resonance (SPR) technology measures macromolecule binding events in real-
time by immobilizing the ligand on a gold-plated surface and then flowing analyte over that 
surface.  When analyte binds ligand, the mass on the surface of the chip increases, and this is 
observed as an increase in response signal (RUs). Response signal is actually a measure of the 
local refractive index (RI) change near surface, which makes this technology both extremely 
sensitive to binding events and a variety of experimental artifacts (nonspecific RI changes).  
Nonspecific RI changes are often due to sample-system buffer differences, including 
unavoidable differences that arise due to the use of high (µM-mM) protein concentrations. 
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Proper SPR technique and experimental design can greatly limit or in many cases eliminate the 
problems associated with non-specific RI changes. I refer the reader to a recent SPR review for a 
more in depth description of this technology and its various applications 1.  
 
3.2.2 SPR experimental setup 
Surface plasmon resonance (SPR) experiments were run on a Biacore T100 (GE Healthcare) in 
either standard HBS-EP+ (pH 7.4) or low pH MBS-EP+ (pH 6.0). MHCI chips were generated 
by activating Biacore CM5 chips (0.2 M EDC/50 mM NHS, 5 µl/min, 7 min), coupling 
0.1 mg/ml neutravidin (20 mM Na citrate (pH 4.5), 5 µl/min, 7 min), saturating available sites 
(1 M ethanolamine-HCl (pH 8.0), 5 µl/min, 7 min), washing away non-covalently bound protein 
(0.1% SDS, 5 µl/min, 1 min), and then capturing site-specifically biotinylated MHCI ligand 
(equilibrium: <1000 RUs, kinetics: <500 RUs). Flow cell 1 (F1) (neutravidin) was used as the 
control flow cell, as non-specific binding to neutravidin was observed to be equivalent to 
neutravidin-captured control proteins (scTCR, WNV DIII, various MAbs). Experiments were 
performed at 20 µl/min and 25 oC. Proper SPR experimental technique was followed in all 
assays2. Reversing ligand-analyte orientation produced kinetic & equilibrium constants within 2-
fold. Also, mammalian & bacterial T4 proteins bound equivalently and increasing the HEPES 
concentration from 10 mM to 25 mM did not affect ether binding constant. 
 
3.3 Biolayer interferometry (BLI)  
 
3.3.1 BLI background 
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Biolayer-interferometry (BLI)3 was used as a separate biophysical approach to evaluate 
CPXV203/MHCI association.  BLI measures the optical thickness of a biosensor via the 
interference pattern of white light reflected from two surfaces: an internal reference layer & an 
immobilized protein layer. Any change in the thickness of the protein layer causes a shift in the 
interference pattern that can be measured in real-time.  Unlike SPR, this technology is far less 
sensitive to buffer differences, including high protein concentration.  Further, the dip-and-read 
format used by the ForteBio Octet system greatly reduces the problem of mass-transport 
limitation in biosensor assays that often limit SPR assays. 
 
3.3.2 BLI experimental setup 
BLI affinity/kinetic experiments were run using a similar approach to the above SPR assays: 
HBS-EP+/MBS-EP+ supplemented with 0.05% (v/v) TWEEN & 1% BSA, immobilized MHCI 
on streptavidin sensors, soluble CPXV203. These assays confirmed the previously observed SPR 
equilibrium binding constants (within 2-fold). General CPXV203/MHCI pH dependence was 
evaluated by monitoring the increase in BLI signal (CPXV203 binding) as pH decreased (7.6-
6.0) for seven immobilized MHCI proteins (H-2Dk, H-2Kb, H-2Kk, H-2Ld, TL, Mamu-A*01, & 
Patr-B*0802).  [CPXV203] was held constant, while pH was varied via the NaH2PO4/ Na2HPO4 
ratio in PBS-EP+. This assay was also used to evaluate CPXV203 C-terminal truncation (aa 5-
190) and C-terminal histidine mutations (H196, H204) on CPXV203/MHCI pH regulation.   
 
Results for sections 3.2 and 3.3: 
 CPXV203 directly binds MHCI. Since previous studies by the Yokoyama lab had 
demonstrated CPXV203 associates with MHCI, biosensor assays using recombinant proteins 
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were pursued to investigate the nature of this interaction. Initially, direct binding was shown for 
CPXV203/H-2Kb:β2m (KD,Kin = 480 nM) using standard surface-plasmon resonance (SPR) 
conditions (25o C, pHER 7.4) and fit to a 1:1 Langmuir model (Fig. 1a). The expansion of these 
studies to additional MHCI molecules revealed that CPXV203 exhibits similar affinity (KD,Kin = 
480-11,000 nM) for all murine Ia alleles (D, K, L), a murine Ib allele (TL), and a primate allele 
(Ceat-B*12) (Table I). Equilibrium & kinetic analyses produced similar dissociation constants 
with differences likely due to a more complex binding mechanism (see below). Direct 
CPXV203/MHCI association fit well with the previously published data that CPXV203 down-
regulates murine H-2D & -2K alleles, though the affinities were weaker than those previously 
reported for ER retention by E3-19K (11-50 nM)45. 
 CPXV203/MHCI association is pH-regulated. The affinity difference between 
CPXV203 & E3-19K led to evaluation of a variety of buffer conditions that might more closely 
reproduce ER/Golgi conditions (divalent cations: Ca2+, Mg2+, Zn2+; ATP; pH 6-8). Of these 
changes, only low pH augmented CPXV203/MHCI affinity with a decrease to pHGolgi 6.0 
increasing CPXV203/MHCI affinity ~50-fold (KD,Kin = 10 nM, Fig. 1b) through both an 
increased on-rate (ka) and a decreased off-rate (kd). In fact, low pH CPXV203/MHCI affinity 
(KD,Kin) for all tested murine & primate MHCI (Table I) was very similar to the high affinity 
described for HCMV US2:HLA-A2 (pHER 7.4)6, AdV E3-19K (pHER 7.4)45, and the nanomolar 
affinity reported for KDELR/KDEL (pH 5.0)7. This pH enhancement was confirmed using a 
separate biophysical technique, biolayer interferometry (BLI), where the equilibrium response of 
CPXV203/MHCI was monitored as a function of pH (7.6-6.0) (Fig. 1c). Low pH equilibrium 
analysis was suggestive of a more complex binding mechanism (Fig. 2), and so biophysical 
studies were pursued to evaluate binding stoichiometry & protein conformation as a function of 
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pH. Light scattering experiments using a high-affinity MHCI mutant demonstrated 1:1 
stoichiometry for CPXV203/MHCI from pH 6.5-8.5 (Chapter 4, Fig. 2), while circular 
dichroism studies revealed that the conformation of these proteins (alone or in complex) did not 
change as a function of pH (data not shown). As the source of complex binding has yet to be 
identified, all of our data was conservatively fit using the simple 1:1 Langmuir model used in our 
pHER studies. These biophysical studies demonstrated that CPXV203 directly binds diverse 
MHCI ligands and that CPXV203/MHCI association is pH-regulated to favor association in the 
Golgi rather than the ER. 
 C-terminal CPXV203 residues increased complex association at low pH. Prior to 
successful structural investigation of CPXV203/MHCI association, the truncated CPXV203 
construct (5-190) was evaluated for binding to MHCI using both SPR & BLI assays.  This 
construct displayed similar affinity for MHCI at pHER but reduced affinity at pHGolgi for two 
MHCI mutants (N127K; K131D) that bind wt CPXV203 with normal affinity (Table II). Kinetic 
evaluation revealed that this difference in affinity is due to increased on-rate, suggesting that 
electrostatics may account for this component of CPXV203/MHCI pH regulation.  This 
increased on-rate was observed for one additional MHCI mutant (M228T) that exhibits wt low 
pH binding affinity. This truncation work led to the identification of two C-terminal CPXV203 
histidines (H196,H204) as potential sources for this binding regulation. BLI evaluation revealed 
that simultaneous mutation of C-terminal histidines to A/Y/W (Fig. 3) severely reduced pH 
regulation, though complete removal of the CPXV203 C-terminus (191-205) did not completely 
ablate pH enhancement (Table II, Fig 3). Therefore, the C-terminal CPXV203 histidines play a 
role in CPXV203/MHCI pH regulation, but additional pH regulatory elements must exist (see 
structure section).  
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Neither CPXV203 peptides nor the minimal soluble domain bind MHCI. Following 
determination of the CPXV203/MHCI crystal structure (Chapter 6), two flexible sections of 
CPXV203 (151-181 and 184-209) and the minimal soluble domain (6-153 or 13-152) were 
selected for biosensor analysis. CPXV203 soluble peptide expression and refolding truncated 
constructs has been described previously (Chapter 2). BLI evaluation of these various 
CPXV203 constructs at pHER and pHGolgi revealed that they do not retain detectable affinity for 
MHCI (data not shown). Two minimal domains of CPXV203 were evaluated due to the presence 
of the C6-C153 disulfide immediately adjacent to the author’s interpretation of the core globular 
domain. 
 CPXV203 binds an MHCI epitope that is sensitive to amine coupling. CPXV203/MHCI 
association was found to be extremely sensitive to amine coupling of MHCI in SPR experiments.  
The sensitivity of this epitope is similar to that described for MAb B8-24-3 recognition of Lys89 
of H-2Kb8, which was also observed in SPR assays of this work. Amine coupling of H-2Kb 
reduced the CPXV203/MHCI affinity by ≥10-fold (data not shown).  This decrease in affinity 
initially resulted in the misclassification of both H-2Kd and HLA-A*2402 as null alleles, as both 
molecules were evaluated for binding following amine coupling. Later work revealed that 
CPXV203 binds H-2Kd with similar affinity to other MHCI (Table I).  Also, the fact that 
CPXV203 bound a variety of primate MHCI and two chimeric MHCI (H-2Kb-HLA-A2 and 
HLA-A2-H-2Kb) suggests that HLA-A*2402 is unlikely to be a true null allele. Finally, early 
SPR experiments with tetramerized CPXV203 (1 µM) injected over MAb(B8-24-3/25D1.16)-
captured H-2Kb dtSCT suggested weak affinity for this allele at pHER. 
 Murine CD1d – a null allele for CPXV203.  Evaluation (SPR & BLI) of a mCD1d-Fc 
chimera (R&D Systems) revealed that this molecule is not bound by CPXV203 at either pHER or 
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pHGolgi (data not shown).  In SPR assays, CPXV203 binding was evaluated for mCD1d captured 
either via amine coupling or by MAb (αFc), while BLI assays only utilized the latter capture 
technology. Interestingly, the lack of CPXV203/mCD1d interaction fits well with structural 
studies of the CPXV203/H-2Kb:hβ2m interface (see structure section). 
 Disulfide-trapped single-chain trimer (dtSCT) H-2Kb is a null allele. The linking of the 
MHCI heterotrimer by a series of flexible linkers appears to greatly inhibit CPXV203 binding, as 
essentially no interaction between CPXV203 & H-2Kb dtSCT could be demonstrated using SPR. 
Tetramerized CPXV203 at high concentration (1 µM) injected over a massively over-coupled 
flow cell (>4000 RUs) did demonstrate weak binding event in the high µM to mM range. 
Further, even this weak binding required MAb capture (B8-24-3 or 25D-1.16), as amine-
coupling resulted in no binding. Later SPR evaluation of H-2Kb pentamerized through OVA or 
OVA-hβ2m suggested that both β2m linker insertion and emersion reduce binding.  
 CPXV203 is sensitive to β2m substitution. SPR analysis of CPXV203 binding to both H-
2Kb and H-2Dk demonstrated that this association is sensitive to the species of β2m present in the 
MHCI heterotrimer (Table I).  Specifically, the presence of human β2m (hβ2m) increases the 
pHGolgi affinity of CPXV203 for MHCI by 6- and 3-fold, respectively.  Interestingly, the majority 
of the surface-exposed differences between murine and human β2m are on the face not targeted 
by CPXV203, and my later structural work clearly shows that the β2m surface contacted by 
CPXV203 is nearly invariant between the two species. At this juncture, I suggest that the 
increased affinity of CPXV203 for HC:hβ2m complexes is likely due to the particular 
heterodimer conformation supported by hβ2m, which may also account for the increased MHCI 
yield routinely observed in recombinant MHCI preparation using hβ2m as opposed to mβ2m. 
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 Peptide-groove mutation can modify CPXV203/MHCI binding. During my studies, I 
attempted to determine why the H-2Kb dtSCT was a null allele for CPXV203 by evaluating the 
effect on CPXV203/MHCI binding for various components of the SCT construct. Beyond the 
flexible linkers connecting peptide-β2m-HC, this construct also included two mutations (Y84C, 
C121S), which I began to evaluate during this work.  The first mutation is within the peptide-
binding groove and serves to opens the groove to allow the first linker to emerge and to 
covalently link the peptide to the groove, while the second mutation was introduced to remove a 
surface-exposed cysteine that might reduce refolding efficiency.  My biosensor work (SPR & 
BLI) revealed that the double mutant shows increased CPXV203/MHCI affinity at pHER (6-fold; 
see Chapter 7, Table X) and >40-fold at pHGolgi (data not shown), though the latter affinity 
enhancement is only an approximation, as significant mass-transport limitation has yet prevented 
accurate kinetic evaluation of this mutant. C121S is not believed to enhance CPXV203/MHCI 
affinity as this residue is not highly conserved in the MHCI bound by CPXV203 
(C,R,L,S,P,Q,K), dtMHCI (H-2Kb(Y84C):mβ2m, kindly provided by Dr. Ted Hansen) only 
includes Y84C yet still displays enhanced affinity, and finally this residue is not contacted by 
CPXV203 in the crystal structure (see Chapter 6). Further, the disulfide-trap does not appear to 
be required, as Y84A enhances CPXV203/MHCI affinity in an equivalent manner.  
 CPXV203 does not appear to bind murine CRT or ERp57. Recombinantly-expressed 
chaperones were site-specifically biotinylated, coupled to experimental flow cells, and evaluated 
for CPXV203 association in a variety of buffers designed to reproduce ER/Golgi conditions (see 
Buffers). Neither chaperone appears to associate with monomeric CPXV203 (data not shown), 
though a weak association cannot be ruled out, as CPXV203 tetramers were not used in these 
experiments. Initial experiments that suggested an association with CRT appear to have been due 
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to non-specific Zn crosslinking of surface-exposed histidines on CPXV203 that resulted in 
precipitation within the Biacore chip’s dextran matrix. This phenomenon was reversible with 
EDTA. Zn had a similar affect on SEC of CPXV203, as a relatively low concentration (500 µM) 
resulted in an apparent affinity for the dextran/agarose matrix. 
MPX184 exhibits weak affinity for human MHCI. MPX184 was evaluated in parallel 
with CPXV203 for binding to MHCI, though sufficient MPX184 was not available for all 
experiments. Though MPX184 appears to be null for H-2Kb and H-2Db, it did display a weak 
affinity (≥34 µM) for HLA-A*2402:hβ2m that was captured via amine-coupling (Fig. 4). The 
previously described sensitivity of CPXV203 to amine coupling suggests that MPX184/hMHCI 
affinity may be ≥10x higher than this estimate. The human MHCI material evaluated in this 
experiment was soluble, mammalian-expressed HLA-A*2402:hβ2m (50 µg) that was purchased 
from Pure Protein LLC. This material was used in a limited number of biosensor experiments at 
the inception of this project. 
 
3.4 Monoclonal antibody (MAb) blocking studies 
Initial localization of the CPXV203 binding site on MHCI used a combination of HC sequence 
conservation coupled with low-resolution serological studies. These latter studies (described in 
detail below) evaluated well-characterized αMHCI MAbs for their ability to block 
CPXV203/MHCI association, thereby identifying a general footprint for CPXV203 on the 
surface of MHCI. 
 SPR Sandwich Assay. MAb competition chips were prepared by amine-coupling (CM5) 
control MAb (Biacore αGST) to F1 and αMHCI MAbs to F2-F4 using established protocols. 
Competition (direct or steric) was then evaluated by using dual inject over F1-F4: Inj#1, MHCI 
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capture (F2-F3); Inj#2, CPXV203 tetramers or controls (buffer/neutravidin/MAbs). Free MHCI 
dissociation during Inj#2 indicated competition between capture & detection reagents, while 
binding during Inj#2 indicated capture & detection reagents do not compete. Competition 
amongst the MAbs was also evaluated to help localize the MAb footprints. 
 Antibodies. MHCI-specific monoclonal antibody (MAbs) used in SPR competition 
assays were obtained from the ATCC (H-2Kb: 25-D1.1.6, B8-24-3, Y-3), purchased from 
BioLegend (H-2Kb: AF6-88.5.3, H-2Kb/Db: 28-8-6, H-2Kd/Dd: 34-1-2S, hβ2m: 2M2), or 
provided as a kind gift (H-2Kb: 5F1-2-14) from S.  Nathenson (Albert Einstein College of 
Medicine, New York) & L. Pease (Mayo Clinic, Minnesota). MAbs that were not purchased 
from BioLegend were purified from ascites on a Bio-Rad Profinia FPLC using Protein A/G.  
 Results: Antibody footprint localization. MAb footprints were assigned based on 
available literature and SPR data from this work. The TCR-like MAb 25-D1.16 (IgG1) 
specifically binds H-2Kb loaded with OVA257-264 (SIINFEKL)9,10,11. MAb B8-24-3 (IgG1) is 
specific for folded H-2Kb, it binds around the C-terminus of the α1 helix, and it is sensitive to 
D77S, R75H, L82(P/F), & K89A mutations12,13(Pullen et al. 1989)(Pullen et al. 1989)55(Pullen et 
al. 1989),8. MAb Y-314 (IgG2a) is sensitive to H-2Kb α2-1 helix mutations (A150P, L141R, 
M138K)15, insensitive to epitope destruction via formaldehyde16, and competes with MAbs 25-
D1.16, B8-24-3, & AF6-88.5.3 in SPR analyses (data not shown).  MAb AF6-88.5.317 (IgG2a) 
binds to folded H-2Kb/mβ2m below the α2-1 helix, as indicated by hβ2m substitution18, 
sensitivity to domain swaps (KbLd)19, competition with Y-3 (SPR data not shown), and 
sensitivity to M228T mutation (SPR data not shown). MAbs 28-8-6 (IgG2a) & 34-1-2S (IgG2a) 
recognize folded H-2Kb/Db & H-2Kd/Dd/Kb (α3 domain), respectively.  MAb 2M2 (IgG1) 
recognizes a linear determinant that is available on native hβ2m (cross-reactive with bovine not 
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murine, unpublished results).  MAb 5F1-2-14 recognizes folded H-2Kb and is sensitive to α2-2 
helix mutations G162D, E166K, & N174K15.  
 CPXV203 binds MHCI below the α2-1 helix. These serological studies clearly identified 
both permissive (B8-24-3, 25-D1.16, 5F1-2-14, 2M2) and blocking (AF6-88.5.3, Y-3) antibodies 
(Fig. 5a), thus identifying the region below the α2-1 helix (Fig. 5b,c) as the region bound by 
CPXV203. These studies were used to design a series of mutants (described in Chapter 7) to 
evaluate the various surfaces in this region contacted by the MHCI-specific chaperone Tpn. 
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Figure 
1. CPXV203 directly binds MHC Ia/Ib with higher affinity at low pH. (a,b) SPR analysis of 
CXPV203/H-2Kb:hβ2m binding at pHER 7.4 (a) & pHGolgi 6.0 (b). Neutravidin was used to 
capture site-specifically biotinylated MHCI prior to injection of increasing concentrations of 
CPXV203.  Non-specific binding was addressed via reference subtraction of a neutravidin-only 
control flow cell. SPR curves were fit kinetically using a 1:1 Langmuir model. Please see Fig. 2 
for equilibrium analysis and Table I for additional MHCI alleles. (c) Equilibrium BLI analysis 
confirmed CPXV203 affinity increased for murine/primate MHC Ia/Ib alleles as pH decreased 
from 7.6 to 6.0. Neutravidin sensors captured site-specifically biotinylated MHCI prior to 
immersion in samples of varying pH with constant [CPXV203]. The [CPXV203] chosen for this 
experiment produced the lowest detectable signal at pHER 7.4 for each MHCI.  Nonspecific 
	   89	  
binding was addressed using both reference subtraction (neutravidin) and standard blocking 
reagents (1% BSA + 0.05% TWEEN). 
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Figure 2. Equilibrium SPR analysis of CPXV203/MHCI. (a,b) CXPV203/H-2Kb:hβ2m binding 
at pHER 7.4 (a) & pHGolgi 6.0 (b) fit using a 1:1 Langmuir binding model (NLLS). Solid grey 
lines indicate KD using all the data, while dashed grey lines fit only part of the available data. 
(c,d) These panels display the same equilibrium data & fits as response vs. log [CPXV203] to 
assess the appropriateness of a 1:1 model. Black arrows indicate KD,Eq values. The non-
sigmoidal behavior at pHGolgi 6.0 suggests a more complex binding phenomenon than a simple 
1:1 interaction, which likely accounts for the discrepancy in KD,Kin vs. KD,Eq (Table I). As 
independent data identifying the cause of complex binding does not exist at this time, a simple 
1:1 Langmuir binding model was used in all kinetic analyses. 
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Figure 3. Titration of C-terminal CPXV203 histidine(s) enhances affinity. This BLI experiment 
evaluated wt CPXV203(1-205), truncated CPXV203(5-190) lacking its C-terminal tail, and a 
CPXV203 mutant lacking C-terminal histidines (H196Y, H204Y). See Fig. 1c for experimental 
set up. This experiment revealed that the C-terminus of CPXV203 (191-205) enhances binding to 
MHCI at low pH through histidine protonation. Similar results were obtained for HA & 
HW mutations. BLI equilibrium affinity for CPXV203(1-205) and CPXV203(5-190) are 
within 2-fold of the SPR equilibrium affinity determined for CPXV203(1-205). 
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Figure 4. Equilibrium affinity of MPX184 for human MHCI (HLA-A*2402). (a) Preliminary 
SPR indicated a KD,Eq greater than 15 µM for MPX184/HLA-A*2402:hβ2m, so a dilution series 
from 0.01-20 µM was performed to get an estimate of the MPX184 affinity for human MHCI. 
This dilution series would have been extended to 10-100xKD, but there was insufficient material 
available for such high concentrations of MPX184.  The general SPR experimental setup is 
indicated on the right. (b) Nonlinear least-squares and Scatchard analysis (inset plot) for the 
curves in a are shown. The KD,Eq of 34 µM is a preliminary value that indicates the best affinity 
possible for this interaction. This experiment was conducted before amine-coupling sensitivity 
was identified, and so the MPX184/HLA-A*2402:hβ2m affinity may in fact be ≥10x higher, as 
was observed for CPXV203/MHCI. 
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Figure 5. Serological studies localize CPXV203/MHCI interface below the α2-1 helix. (a) An 
SPR adaption of a sandwich ELISA was used to evaluate the interface. In brief, monoclonal 
antibodies (MAb) immobilized through amine coupling were used to capture MHCI prior to an 
injection of tetramerized CPXV203.  An increased RU signal during the injection would indicate 
that the MAb did not block the CPXV203-MHCI interface, while free dissociation of MHCI 
would indicate the MAb blocked the interface (directly or sterically).  Examples of both 
outcomes are shown. (b) MHCI from my structural work is shown as described in Fig. 2 with 
labels identifying MHCI domains and the α2-1 helix.  (c) The mAb footprints are shown as 
shaded circles on MHCI.  Green indicates non-blocking antibodies, while red indicates blocking 
antibodies. MAb footprints are based on published cellular & structural studies.  The AF6-88.5.3 
footprint was refined in this work through the observation that this MAb does not recognize 
mutant H-2Kb (M228T) and that it competes with Y-3. 
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Chapter 4 
 
CPXV203 & CPXV203/MHCI oligomeric analysis 
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4.1 Introduction 
Oligomeric analysis of these proteins was pursued for a variety or reasons during this 
investigation: general characterization of recombinant material, assessment of binding 
stoichiometry, and potential effect of pH on oligomerization of proteins alone or in complex. 
Size-exclusion chromatography (SEC) was used in the preparation of all recombinant molecules, 
and so it served as the initial assay to address oligomerization (MWSEC). As MWSEC is dependent 
the hydrodynamic radius (RHydro) of the protein under investigation, multi-angle laser light 
scattering (MALLS) was employed to determine the absolute MW of each species (alone & in 
complex). Finally, dynamic light scattering (DLS) was pursued to confirm MWSEC and 
MWMALLS and to extend these investigations to evaluate the possibility of low-affinity 
oligomerization that might partially explain increased CPXV203/MHCI affinity at low pH. For a 
thorough review of protein hydrodynamics (pertinent to SEC & DLS), I refer the reader to 
chapter 7 of Proteins: a comprehensive treatise1. 
 
4.2 Size-exclusion chromatography (SEC) 
SEC was used during preparative steps to assess the oligomerization state of T4 poxvirus 
proteins and the stoichiometry of the CPXV203/MHCI complex.  These experiments used 
HiLoad 16/60 Superdex columns (75 pg & 200 pg) that had been calibrated for molecular-weight 
estimation through the use of LMW & HMW Gel Filtration Calibration Kits (GE Healthcare). 
These calibration kits assume the protein under evaluation has a globular fold and does not 
interact with the column material, thus proteins with elongated shapes (rod/box-like folds or 
disordered loops/termini) or an affinity for the gel-filtration matrix will elute as larger or smaller 
proteins, respectively. All proteins were injected at ≥1 mg/ml. Protein elution was monitored via 
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absorbance at 280 nm and peaks were analyzed by SDS PAGE. Various buffers (HBS and low 
pH/salt sizing buffer) were used to evaluate the effect of pH on oligomeric state of proteins 
(alone and in complex).  All experiments were run at 4o C. 
 Results: T4 poxvirus proteins appear to be monomeric. Both CPXV203 and MPX184 
eluted from SEC as single, monodispersed peaks with apparent molecular weights (20-25 kDa, 
respectively) that suggest these proteins exist in solution as monomers (Chapter 2: Fig. 1c). 
Evaluation of fractions from larger MW species did not indicate monomer-oligomer equilibrium 
for either protein.  Further, these proteins displayed similar elution profiles regardless of how 
they were produced (mammalian/bacterial) or whether they were tagged.  CPXV203 consistently 
eluted with an MWSEC slightly larger than predicted by 1o sequence (2-3 kDa), which may be due 
to the extended C-terminal tail identified via both LPMS and PCR truncation work. Preliminary 
experiments with mammalian expressed MYXV M-T4 suggest that it also exists as a monomer 
(~20 kDa, Chapter 2: Fig. 2b,c), though the instability of this construct severely limited the 
concentration that was evaluated. As such, it appears that all T4 poxvirus proteins evaluated in 
this work are monomers in solution. 
 Low pH enhances CPXV203/MHCI association. Attempts to demonstrate 
CPXV203/MHCI association at physiologic pH were unsuccessful, and so low pH was used to 
decrease dissociation of the complex during SEC. Initial low pH complex purification entailed 
incubating an excess (>4:1) of refolded CPXV203 with MHCI at 4oC for 30 min in HSB prior to 
running the sample over a HiLoad 16/60 Superdex 200 pg column in low pH/salt sizing buffer. 
The CPXV203/Kb:hβ2m complex clearly shifts relative to MHCI run alone in the same buffer 
(Fig. 1a), and the MWSEC of the complex suggests a 1:1 association of CPXV203/MHCI. The 
identity of the shifted peak (CPXV203/H-2Kb/hβ2m) and the relative ratio (1:1) was confirmed 
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by SDS PAGE analysis (Fig. 1b). Large-scale complex SEC purification (Fig. 1c) was optimized 
as follows: assembled >13 mg of protein (≥3:1 CPXV203:MHCI molar ratio), centrifugal 
concentration of sample to >50 µM, BE (Zeba column) into low pH/salt sizing buffer, and then 
purification in the same buffer over a HiLoad 16/60 Superdex 75 pg to increase separation of 
complex from MHCI/CPXV203. Final yield from this preparation was 2.2 mg (~50% of the 
expected yield). Finally, the lower affinity of CPXV203/Kd:hβ2m compared to 
CPXV203/Kb:hβ2m is evident by SEC, as CPXV203/Kd:hβ2m largely dissociates while 
CPXV203/Kb:hβ2m shifts (Fig. 1d). SDS PAGE analysis of the potential CPXV203/Kd:hβ2m 
hump supported complex association (data not shown). 
 High-affinity MHCI mutant does not require CPXV203 termini. The high-affinity 
MHCI mutant (H-2Kb(Y84A,C121S):hβ2m) was able to shift both wt CPXV203 (MVI-LHV) 
and the LPMS construct (RCE-FDR) to the MW of a 1:1 complex at pHER 7.4 on a HiLoad 16/60 
Superdex 75 pg column (data not shown). These runs were done in the presence of excess 
CPXV203 and at low-temperature (4o C). This observation suggests that the cause of the 
increased affinity for this mutant is not due to an MHCI interaction with the CPXV203 termini 
(residues 1-4 or 191-209).  
 
4.3 Multi-angle laser light scattering (MALLS) 
SEC-MALLS (Multi-angle laser light scattering) experiments were run to determine the absolute 
molecular mass of proteins in solution.  These experiments were run on a Wyatt Dawn 
HELEOS-II 18-angle light scattering detector and Wyatt Optilab rEX refractive index monitor 
linked to a Waters HPLC system2. The use of an inline SEC step allows for clear separation of 
various species (aggregate, oligomers, monomers), but this step can also separate weakly 
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associated complexes. MALLS experiments were run at 20oC with [protein] = 1 mg/ml. The 
location of the instrument precluded evaluation of these proteins at low temperature (4o C), 
which greatly reduced the ability to evaluate low affinity complexes. Various buffers 
(PPZ/BT/H/TBS) were used to evaluate the effect of pH on oligomeric state of proteins (alone 
and in complex). 
 Results: MALLS analysis at physiologic pH. MALLS analysis of these proteins at pHER 
7.4 revealed that MHCI and CPXV203 are monomers with MWMALLS approximately equal to the 
MW predicted by each protein’s 1o sequence (MWCalc) (Fig. 2a).  Further, analysis of the high-
affinity complex confirms the 1:1 stoichiometry suggested for wt complex in previous low-
temperature SEC experiments.  
CPXV203 & MHCI are monomeric from pH 5.5-8.5. MALLS analysis of both proteins 
alone revealed that these proteins are monomeric across the pH range from 8.5-5.5 (Fig. 2b). 
This finding suggests that the enhanced affinity of CPXV203/MHCI is not due to a protein 
intrinsic oligomerization event at low pH, though the in-line SEC step may have separated weak 
oligomers prior to MALLS analysis. 
CPXV203/MHCI displays 1:1 stoichiometry from pH 6.5-8.5. CPXV203/MHCI 
oligomerization was evaluated for both wt and high-affinity complexes as a function of pH. 
Unfortunately, RT analysis of wt complex from pH 8.5-5.5 did not reveal a clear complex shift, 
though the MWMALLS of the main peak shifted towards the MW of the complex (68.7 kDa) as pH 
decreased (data not shown). Evaluation of the high-affinity complex suggests that the complex 
does not oligomerize as affinity increases at low pH, as 1:1 stoichiometry is observed from pH 
8.5-6.5 (Fig. 2b). 
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4.4 Dynamic light scattering (DLS) 
In order to address the possibility that in-line SEC during MALLS analyses may have separated 
weak oligomers, DLS experiments were undertaken to evaluate the solution behavior of 
CPXV203 & CPXV203/MHCI as a function of pH. Dynamic light scattering, aka quasi-elastic 
light scattering (QELS) and photon correlation spectroscopy (PCS), measures light scattered 
from dissolved macromolecules/particles. This data can then be used to derive the diffusion 
coefficient (D) and hydrodynamic radius (RHydro) of the species under investigation. The RHydro 
of a macromolecule is actually the radius of a hard sphere with the same D. This value takes into 
account both the size and shape of a macromolecule, and it includes the layer of water molecules 
“trapped” around a protein. Other macromolecular radii include the radius of gyration (RGyr, 
measure of the overall spread of a molecule from its center of gravity) and the structural radius 
(RStruc, measurement of the longest axis).  The calculated radii for CPXV203 are shown in Fig. 
3a. DLS also provides a measurement of the variability of a sample (polydispersity), and this 
technique can detect the presence of aggregates at extremely low concentration, as the amount of 
scattered light increases dramatically with the size of a particle. 
 DLS experimental methods. DLS experiments were performed on a DynaPro-801TC at 
25oC with [protein] ≥ 0.5 mg/ml (≥10 µM for all proteins). BSA standard (Pierce, 2 mg/ml) was 
run as a control (3.5 ± 0.1 nm, 65 ± 3 kDa) prior to each set of DLS experiments. To minimize 
dust/aggregate artifacts, DLS cuvettes were extensively washed (5x/step: 1% Tergazyme, 
ddH2O, 1% Liquinox, ddH2O, EtOH), dried (canned air), and stored capped prior to sample 
loading. Each sample (15-20 µl) was incubated ≥20 min at 4o C, centrifuged (>16,000 x g, 4o C, 
10 min), loaded (top 12 µl of sample) into an inverted DLS cuvette using a gel-loading tip (see 
below), and finally the capped cuvette was incubated in the instrument (25o C) for 5 min to 
	   103	  
stabilize the light scattering signal. Gel loading tips were prepared by being rinsed with ddH2O 
and dried immediately prior to transfer. Sample volume, tip preparation, and cuvette inversion 
were all necessary to minimize dust/aggregate artifacts in DLS experiments. Both monomodal 
(single particle, Cumulants algorithm) and multi-modal (no population assumption, 
Regularization algorithm) were used to calculate hydrodynamic scattering radii from twenty 10 s 
measurements per trial.  As these experiments sought to evaluate complexes in equilibrium (SOS 
> 20), the Regularization algorithm was used for all reported radii & MW. Each protein was 
evaluated ≥3 times and the average RDLS and MWDLS are reported. MWDLS for each protein was 
estimated by the analysis software using a model based on spherical, globular proteins of various 
hydrodynamic radii. CPXV203/MHCI complexes were prepared using equimolar ratios with a 
final [complex] of 1 mg/ml. Various buffers (OAc/PPZ/BT/H/TBS) were used to evaluate the 
effect of pH on oligomeric state of proteins (alone and in complex). Various radii were 
calculated from the atomic coordinates of the CPXV203/MHCI structure (see Chapter 6) using 
HYDROPRO3. 
 Results. A comparison of the calculated RHydro (Fig. 3a,b) to the RDLS measured for 
various proteins as a function of pH both confirmed the previous MALLS observations that 
CPXV203 and MHCI are monomeric from pH 6.0-7.5 and extended my oligomeric 
characterization to include wt complex (Fig. 3b,c), which could not be evaluated via the MALLS 
experimental set up (RT SEC). The calculated and measured RHydro are quite similar for proteins 
alone and in complex. The shift of CPXV203 to a larger RDLS at very low pH (4.5-5.5) may be 
either due to weak oligomerization or a change in the protein’s folding/conformational status, 
like partial unfolding of the highly-positively charge C-terminus.  Though the wt complex has a 
smaller RDLS compared to the high-affinity complex (3.3 nm vs. 3.5 nm), a comparison of the 
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RDLS measured for the two MHCI reveals that this difference is likely due to a change intrinsic to 
the MHCI rather than the complex. Both wt & high-affinity MHCI were observed to be unstable 
below pH 5.4 (aggregation of both MHCI alone and in complex with CPXV203).  Surprisingly, 
this aggregation phenomenon was observed to be completely reversible with both MHCI and 
complex regaining normal RDLS upon addition Tris (pH 8.0) to 100 mM. All DLS measurements 
are summarized in Table I.  
	  
Figure 1. Purification of CPXV203/MHCI complex at low pH. (a) An initial experiment 
revealed that low pH/low salt buffer allowed the CPXV203/MHCI complex to survive SEC, as 
shown by an ~11 kDa (~2 ml) shift relative to MHCI alone run in the same buffer on the same 
day. Complex MWSEC suggests 1:1 stoichiometry. Both MHCI alone and excess CPXV203 elute 
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with MWSEC close to MWCalc. CPXV203 appears to have some affinity for the column at low 
pH/salt, as it appears to slowly leach off the column (elution volume >100 ml). (b) SDS PAGE 
analysis of the indicated fractions from a clearly show fully formed complex (magenta-blue-grey 
bar) and excess CPXV203 (magenta bars).  Incomplete disulfide reduction of CPXV203 
occasionally occurs due to the extremely high Tm (>90o+ C) of CPXV203. (c) Large-scale 
purification of complex for crystallography run on an S75 column to increase separation of 
complex from MHCI/CPXV203, 7 ml & 15 ml respectively. (d) CPXV203/Kd:hβ2m largely 
dissociates during SEC, while CPXV203/Kb:hβ2m shifts to a MW indicative of a 1:1 complex, 
thus SEC of CPXV203/MHCI complexes confirms the lower affinity observed by SPR for 
CPXV203/Kd:hβ2m vs. CPXV203/Kb:hβ2m. *Location of the expected CPXV203/Kd:hβ2m 
peak. **Kd:hβ2m peak. All peaks in a,c are labeled with protein, MWSEC, and MWCalc (in 
parenthesis). The CPXV203 & MHCI runs in c,d were run in HSB, but the peaks for these 
proteins do not appear to shift in low pH/salt sizing buffer. Peptides used for Kb and Kd were 
OVA257-264 and Flu NP147–155, respectively. 
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Figure 2. MALLS analysis of protein oligomeric state as a function of pH. (a,b) MALS was run 
on a DAWN HELEOS system.  All samples were applied at 1 mg/ml (15-42 µM) and underwent 
SEC (20o C) on a WTC-030S5 column prior to entering the DAWN system. (a) 
CPXV203/MHCI is a 1:1 complex at physiologic pH 7.4.  These proteins alone and in complex 
behave as single, well-behaved species with MWMALLS that matches the MWCalc. Complex 
analysis utilized a high-affinity MHCI mutant (Y84A, C121S) that did not dissociate during the 
course of SEC, as wt complex dissociated during SEC at pHER 7.4. Mass spectrometry 
determined MW for CPXV203 is also listed. (b) MALS evaluation of these proteins from pH 
8.5-6.5 indicates oligomeric state (alone or in complex) remains constant across pH 8.5-6.5. 
Complex analysis in this experiment again utilized the high-affinity MHCI mutant (Y84A, 
C121S), which also exhibits pH-enhanced binding at low pH (data not shown). ΔMWCalc for wt 
& mutant MHCI is <110 daltons. Both MHCI exhibit stable MWMALLS across pH 8.5-5.5.   
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Figure 3. DLS analysis of protein oligomeric state as a function of pH. (a,b) Molecular 
representations of CPXV203, MHCI, CPXV203/MHCI, and possible CPXV203 crystallographic 
dimers are shown as cartoons with the following color scheme (magenta/green, CPXV203; HC, 
blue; β2m, grey; peptide, yellow spheres). Molecules are shown in the same orientation as Fig. X 
(Chapter 6) except for the CPXV203 dimers, which were rotated -120o (y-axis). Radii in a,b are 
provided for comparison to the experimental values shown in c.  (a) Molecular radii of 
CPXV203 calculated by HYDROPRO are shown to highlight the difference between the 
hydrodynamic radius (RHydro), the radius of gyration (RGyr), and the structural radius (RStruc). (b) 
Various potential protein species are shown next to the RHydro calculated by HYDROPRO using 
the CPXV203/MHCI crystal structure. (c) Proteins alone and in complex were evaluated at the 
indicated concentrations using various buffers to determine if pH affects RDLS. Both 
CPXV203/MHCI (wt complex) and MHCI (OVA257-264: H-2Kb:hβ2m) display stable 
hydrodynamic radii from pH 5.4-7.5, while CPXV203 RDLS is stable in the ER-Golgi-TGN pH 
range but appears to increase below pH 5.4. A 5-fold higher concentration (200µM) further 
increased RDLS for CPXV203 at pH 4.5, though this RDLS is significantly smaller than those 
calculated for potential crystallographic dimers.  
	   108	  
	  
4.5 References 
1. Allen, G. Protein: a comprehensive treatise. (Elsevier: 1999). 
2. Astafieva, I.V., Eberlein, G.A. & Wang, Y.J. Absolute on-line molecular mass analysis of 
basic fibroblast growth factor and its multimers by reversed-phase liquid chromatography with 
multi-angle laser light scattering detection. J Chromatogr A 740, 215-229 (1996). 
3. Ortega, A., Amorós, D. & García de la Torre, J. Prediction of hydrodynamic and other 
solution properties of rigid proteins from atomic- and residue-level models. Biophys. J. 101, 
892-898 (2011). 
 
 
	   109	  
 
	   110	  
 
 
 
 
 
 
 
 
 
Chapter 5 
 
Conformation and stability assessment of CPXV203/MHCI 
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5.1 Introduction 
Circular dichroism (CD) spectroscopy was employed both to provide general structural 
knowledge of CPXV203 and to assess potential conformational changes that may occur 
consummate with MHCI binding or changes in pH. CD spectroscopy of proteins in the “far UV” 
spectral region (190-250 nm) determines protein 2o structure by measuring the difference in 
absorption of left-handed and right-handed polarized light by the peptide bond in defined 2o 
elements (α-helix, β-strand, turn, coil). In addition to 2o information, CD can be used to assess 
the stability of a protein by monitoring 2o structure during thermal or chemical denaturation. This 
type of stability assay can also be undertaken using dynamic light scattering (DLS). Please see 
Chapter 4 for more information on DLS. 
 
5.2 Protein 2o structure - Circular dichroism (CD) 
 CD experimental methods. CPXV203 (mammalian and bacterial), MHCI (bacterial), and 
the CPXV203/MHCI complex (bacterial) were assayed using a Jasco-810 instrument (Jasco Inc., 
Easton, MD) using standard methods1. Samples (200 µl, 5 µM) were buffer-exchanged into CD 
buffer prior to analysis in a 1 mm quartz cuvette. CD spectra were collected in triplicate from pH 
5.9-7.6. Protein 2o structure was calculated from CD spectra using DICHROWEB2. MHCI in 
these assays was OVA:H-2Kb:hβ2m, either dtSCT or native. All reagents were used at 1x 
concentration and are listed in Buffers. 
 Results: CPXV203 is primarily a β-sheet protein. The four software packages available 
on DICHROWEB all gave similar approximations of CPXV203 secondary structure (15% α-
helix, 26% β-strand, 26% turn, 40% coil for both mammalian and bacterial material (Fig. 1).  
Previous threading analysis (PHYRE3) suggested that CPXV203 may resemble various poxvirus 
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CKB proteins, which have similar α-helical & β-strand content as determined by their crystal 
structures (Table I). STRIDE4 was used to assess 2o for these crystal structures. Further, the 
CPXV203/MHCI crystal structure (see Chapter 6) revealed a similar 2o composition to that 
determined by CD, supporting the introduction of novel α-helices (h4 & h5) to the core vCCI-
fold (discussed in Chapter 6). Finally, trifluoroethanol (TFE) titration induced additional α-
helical content into CPXV203 and β-strand content into MHCI (data not shown). 
 CPXV203 & MHCI (alone or in complex) have stable 2o elements. Preliminary 
evaluation of these proteins across pH 5.9-7.6 did not reveal significant changes in 2o structural 
elements, though conformational changes that involve loops or the movement of a structural 
element without significant α/β perturbation would not necessarily change the CD spectra.  
These experiments are listed as preliminary due to the high background noise in the spectra 
arising from instrument problems (high voltage & slit assembly) encountered during recent pH 
analysis, which may have overwhelmed the signal arising from small 2o structure changes. 
   
5.3 Thermal stability – CD 
 CD thermal melts. A Jasco-810 instrument (Jasco Inc., Easton, MD) equipped with 
Peltier temperature controller was used to evaluate the stability of CPXV203 (mammalian), 
MHCI (bacterial), and CPXV203/MHCI (bacterial) using established methods5. The previous 
experimental setup was altered as follows: 2 ml sample, 10 mm cuvette, 0.5-1.0 µM protein 
concentration. MHCI in these assays was OVA:H-2Kb:hβ2m (dtSCT). All reagents were used at 
1x concentration and are listed in Buffers. 
 Results. Melting temperatures were obtained for each sample alone, CPXV203 (90.6 oC) 
& dtSCT (52.4 oC). A comparison of the CPXV203 & MHCI thermal melts is shown in Fig. 2. 
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This MHCI Tm is quite similar to previously published work 49.55 ±0.26 oC on the same 
construct evaluated using this instrument6. The extremely high Tm of CPXV203 likely explains 
the occasional lack of complete disulfide reduction during preparation of SDS PAGE samples 
(10 min incubation at 90 oC). The complex spectra were difficult to analyze due to significant 
instrument noise, but qualitative assessment did not suggest decreased MHCI stability in the 
presence of CPXV203. Thermal unfolding was not reversible for any of these proteins. 
   
5.4 Thermal stability – DLS 
 DLS thermal aggregation assays. These experiments were conducted in a manner similar 
to the previously described DLS experiments (Chapter 4) with the following changes: laser 
power was set to record 10000-25000 Cnts/s at 20 oC; after a 3 min equilibration at each 
temperature, five 10 s measurements were collected; record data every 3 oC from 20-35 oC; 
record data every 1 oC from 36-50 oC; extend temperature range to 20-60 oC and record data 
every 5 oC for CPXV203.  Thermal aggregation was monitored using both increased Cnts/s and 
RDLS (Cumulants algorithm). All reagents were used at 1x concentration and are listed in 
Buffers. 
 Results. Example DLS thermal aggregation assays for CPXV203, Kb:hβ2m, and 
CPXV203/ Kb:hβ2m is shown in Fig. 3 and all of this data has been summarized in Table II. 
Thermal stability at neutral pH assayed by DLS for MHCI was similar to previously published 
work 53.37 ±0.18 oC on the same construct evaluated using the previously described CD 
instrument6. The thermal stability of MHCI (Kb:m/hβ2m & Db:hβ2m) significantly decreased as 
pH decreased with Tagg approaching 37 oC at pHTGN, suggesting that the selection of stable 
MHCI may include both the action of tapasin and the normal pH gradient that exists in the ER-
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Golgi.  Counter intuitively, the MHCI mutant (Y84A, C121S) was observed to have higher 
thermal stability at low pH than wt MHCI. CPXV203 did not significantly aggregate in the 
temperature range that may be examined by DLS, which suggests a high thermal stability like 
that observed by CD. CPXV203 was able to stabilize H-2Kb:hβ2m at both pH 7.5 and 6.18, and 
stabilization was far more pronounced at low pH (7 oC vs. 2 oC). A similar though smaller 
stabilization of Kb:mβ2m by CPXV203 was also noted. Thermal unfolding was not reversible for 
any protein evaluated by DLS. 
 
 
Figure 1. Circular dichroism (CD) analysis of CPXV203 2o structure. Example CD spectra 
collected from 190-260 nm for CPXV203 (mammalian) in CD buffer (pH 7.12). Data was 
converted to mean residue ellipticity and analyzed using the suite of programs on 
DICHROWEB. Experimental and predicted curves from CDSSTR software package are shown 
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as examples. Listed secondary structure values are the average of CDSSTR, CONTIN, & 
SELCON. 
 
 
 
 
 
 
Figure 2. CD analysis of protein stability. Comparison of the thermal stability of MHCI (OVA-
β2m-Kb SCT Y84C) and CPXV203 assayed by CD at 220 nm. The Tm values were calculated 
using Jasco software included with the J-810 instrument. 
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Figure 3. Example DLS thermal melts at pH 6.18. MHCI in these experiments was OVA257-
264:H-2Kb:hβ2m. Tagg is reported the temperature at which the protein transitions from a well-
folded molecule into a soluble aggregate (Intensity & RDLS). This transition is normally quite 
sharp, unlike the CD thermal melts shown in Fig. 2. Inspection of the Regularization fits may 
allow one to assay aggregation over several temperature points and thereby assign an 
aggregation midpoint, though this value is normally within 0.5 oC of the value obtained by the 
above analysis. Note that CPXV203 is only beginning to show signs of aggregation at 60 oC. 
Also, CPXV203 significantly stabilizes MHCI (7 oC) and aggregates with MHCI rather than 
staying soluble. 
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Chapter 6 
 
Structural studies of CPXV203, MPX184, & CPXV203/MHCI 
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6.1 Introduction 
As further dissection of this immunevasion strategy required a higher resolution than that 
provided by my serological studies of the CPXV203/MHCI interface, I pursued crystallographic 
studies of CPXV203 alone and in complex with MHCI. It has often been anecdotally noted that a 
protein may be recalcitrant to crystallization, while a related protein may crystallize quite 
readily.  As such, I also attempted to crystallize T4 proteins from MPXV (MPX184, 64% 
identity) and MYXV (M-T4, 26% identity).  
  
6.2 General crystallization strategy.  
The general crystallization approach for each target (T4 protein or CPXV203/MHCI) involved 
an initial solubility screen (QIAGEN JCSG I) to identify a protein concentration that resulted in 
50-70% precipitation followed by large-scale screening of commercially available 96-well 
random matrix screens (384 conditions: QIAGEN JCSG I-IV) using a Mosquito crystallization 
robot (TTP Labtech). After identification of initial hits, crystals were reproduced and optimized 
by screening around the initial condition (pH, [precipitant], [salt]) and evaluating various 
additives (384 additives: Hampton Additive Screen HT, Silver Bullets HT, Silver Bullets Bio; 
Jena Bioscience pHat Buffer Screen). Additional random matrix screens (commercial & in 
house) were employed when sufficient protein was available. Though a degree of crystal 
optimization was able to utilize the crystallization robot, the majority of crystal 
reproduction/optimization was done by hand. Streak seeding, macroseeding, dehydration, and 
cross-linking were all employed as appropriate to attempt to optimize crystals. Crystallization 
was attempted at both 4oC and 20o C. Protein stocks were prepared in crystal wash buffer #1 
unless otherwise noted. All proteins used for crystallization were either tagless (bacterial) or had 
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a small, C-terminal 6His tag (mammalian). This crystallization strategy was adjusted for each 
target to accommodate the amount of protein available for crystallization.  
 
6.3 Attempts to crystallize T4 poxvirus proteins 
 CPXV203. Initial crystallization attempts of CPXV203 (mammalian, 288 conditions; 
bacterial, 1344 conditions) yielded very few conditions to pursue (mammalian, 5; bacterial, 2). 
Those few identified conditions that were identified were not obviously crystalline in nature and 
they did not reproduce. In situ proteolysis (chymotrypsin & trypsin) 1 of CPXV203 (bacterial, 
768 conditions) also did not produce any crystals. Reductive methylation2 of CPXV203 was used 
to attempt to reduce the entropic loss associated with lysine crystal contacts (Fig. 1a). Though 
ESI mass spectrometry confirmed methylation of all surface-exposed amines (N-terminus, 17 
Lys), extensive screening (bacterial, 768 conditions) yielded only a single crystallization hit in 
100 mM Na/K Phosphate (pH 6.2), 200 mM NaCl, 40% PEG 400 (Fig. 1b). Extensive 
optimization of this condition (>700 conditions) led to some improvement in crystal nucleation 
(various detergents) but limited improvement in crystal morphology (Fig. 1c,d). 
Reproduction/optimization was greatly hampered by varied growth (days – weeks) and 
morphology (needles – plates) that appeared to correlate with particular protein preparations. 
Though single crystals were unavailable for diffraction analysis, the lack of diffraction by a large 
cluster of these crystals suggests that they were not salt crystals. SDS PAGE analysis of these 
crystals was not possible due to their extremely fragile nature.   
 CPXV203 truncations. Various CPXV203 truncations were designed using LPMS, PCR 
truncation, and structural analysis of the CPXV203/MHCI crystal structure (see later section).  
Depending on the available material and time, these truncations underwent various degrees of 
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crystallization screening. The LPMS construct, CPXV203 (5-190, mRCE-FDR), was thoroughly 
screened using both native and chemically-modified23 versions of this protein (native, 596 
conditions; methylated, 384; pentylated, 384). The PCR truncation construct (CPXV203 (17-174, 
mKIG-DIQ) and the two structurally-designed constructs (6-153 and 13-152) underwent limited 
screening (96 conditions/construct) due to material & time constraints. Though an extensive 
array of truncations was evaluated, few crystallization conditions were identified and these 
crystals did not reproduce/optimize well (native, 192 conditions). It should be noted that the 
structurally-designed truncations were not exhaustively evaluated and so they may have yielded 
crystals with additional work. 
 FadA-CPXV203 fusion protein. Crystallization chaperones (Fab, scFv, DARPIN, 
lysozyme/MBP/2TEL fusions) have been described to greatly aid structural investigations of a 
variety of protein targets through potential benefits that include the introduction of favorable 
crystal contacts, masking of surfaces that impede crystallization, and the introduction of known 
structure to provide phasing information for molecular replacement (recently reviewed by 
Koide4). As CPXV203 was recalcitrant to crystallization by normal strategies and no soluble 
binding partner (other than MHCI) was available, a crystal chaperone approach was pursued 
where FadA (bacterial adhesion, 111 aa) was fused to the N-terminus of CPXV203 (FadA-
CPXV203).  Based on the crystal structure FadA5, it appeared that the crystal lattice might 
accommodate a large fusion protein (≥25 kDa), and the polymer nature of FadA seemed likely to 
promote crystallization of the fusion protein. Of note, the FadA fusion protein contains a 
mutation (F76A) described to prevent “leucine chain” polymerization during purification, though 
this mutation did not adversely affect the crystallization5. While CPXV203 (FL or truncated) is 
quite stable in low salt buffers (like crystal wash buffers), the FadA-CPXV203 was observed to 
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slowly precipitate (or polymerize) at [NaCl] concentrations below 100 mM, thus requiring a 
unique crystal stabilization buffer for this construct. Immediately prior to crystallization trials, a 
Zeba column was used to BE this construct into normal crystallization buffer. Extensive 
screening of FadA-CPXV203 (384 conditions) yielded 9 conditions that produced clear crystal 
hits (Table I), thus clearly indicating the potential of this crystallization chaperone. These hits 
were optimized to a limited degree (201 conditions), but unfortunately insufficient time was 
available to optimize these crystals to a point where they could be tested for their ability to 
diffract.  
 MPX184. Initial crystallization attempts of MPX184 (mammalian, 96 conditions; 
bacterial, 960 conditions) yielded very few conditions to pursue (bacterial, 12) and those few 
identified conditions did not reproduce/optimize (141 conditions) due to severe prep-to-prep 
variation in protein solubility and susceptibility to proteolysis. Examples of these crystals are 
shown in Fig. 2. Bacterial expression was abandoned for MPX184 due to these problems. 
Additional crystallization trials were planned for mammalian MPX184, but time was not 
available for these experiments. 
 MPX184 truncation. This LPMS construct could be refolded and purified, but it 
routinely precipitated at concentrations (>1 mg/ml).  As such, crystallization trials were not 
attempted for this construct. 
 M-T4. Initial expression material from M-T4 (mammalian, Lausanne strain) was too 
impure to warrant crystallization trials. Further expression & crystallization screening was 
delayed until material was available from the 6918 strain, as I believed this construct would be 
better behaved due to its even number of disulfides. 
 
	   123	  
6.4 Crystallization & structure determination of CPXV203/MHCI 
 Initial crystallization of CPXV203/H-2Kb:mβ2m. Initial CPXV203/MHCI complex 
crystallization trials used OVA257-264:H-2Kb:mβ2m, as this was one of the authentic ligands that 
CPXV203 was shown to down-regulate during infection. This work was pursued prior to the 
discovery of either the higher affinity of CPXV203 for H-2Kb:hβ2m or the pH regulation of 
CPXV203/MHCI association. CPXV203/H-2Kb:mβ2m complex was assembled with a molar 
excess of CPXV203 (2:1 or 3:1), incubated in crystal wash buffer at 4 oC for 30 min, and then set 
up in crystals trays.  Though random-matrix screens (384 conditions/ratio) yielded 34 conditions 
to evaluate, the majority of crystals appeared to be MHCI alone.  Further, increasing the 
CPXV203:MHCI ratio decreased the total number of crystallization hits from 25 to 9 in the same 
random-matrix screens, suggesting that the inclusion of CPXV203 was inhibiting crystallization 
of the complex. Rigorous optimization of the best complex crystallization condition (haystacks; 
0.2 M Na2SO4, 20% (w/v) PEG 3350) eventually yielded multinucleated plates that could be 
evaluated by SDS PAGE (Fig. 3a), which confirmed the presence of both CPXV203 and MHCI 
in these crystals (Fig. 3b). Unfortunately, these crystals did not diffract, and so my crystallization 
plan moved on to higher affinity complexes (hβ2m, low pH, mutant MHCI) as they were 
identified. 
 Preparation of CPXV203/H-2Kb:hβ2m for crystallization. The identification of pH-
regulated binding was one of the key observations that led to successful crystallization of a 
CPXV203/MHCI complex, as the quality and reproducibility of the complex crystals was greatly 
enhanced by purifying the CPXV203/MHCI complex at low pH. CPXV203(aMVI-LHV, SeMet-
labeled)/MHCI(OVA257-264:H-2Kb:hβ2m) complex was prepared for crystallization by incubating 
an excess (>4:1) of refolded CPXV203 with MHCI at 4oC for 30min in HSB buffer, purifying 
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the complex by SEC in the low pH/salt sizing buffer, concentrating (Sartorius Vivaspin) to 7-7.5 
mg/ml, and finally buffer-exchanging (Pierce Zeba Spin Desalting Column) into crystal wash 
buffer #2 supplemented with 0.5 mM OVA257-264. Purified complex to be used at a later date was 
concentrated and exchanged into normal HEPES sizing buffer, and then BE (Zeba column) into 
crystal wash buffer #2 supplemented with 0.5 mM OVA257-264 immediately prior to setting up 
crystal trays. Later work optimized complex purification to incrase final yield and purity through 
the following protocol changes: complex was prepared by adding a molar excess (>3-fold) of 
CPXV203 to MHCI (fractions in HSB), concentrating to >50 µM, BE (Zeba column) into low 
pH/salt sizing buffer prior to SEC, and then running the complex over a column in the same 
buffer.  
 CPXV203/H-2Kb:hβ2m crystal screening and optimization. CPXV203/H-2Kb:hβ2m 
complex crystals grew readily in a variety of conditions (Fig. 4a), possibly due to MHCI/MHCI 
crystal contacts acting as an initial nucleation point. Similar to the previous work with 
CPXV203/H-2Kb:mβ2m complex, many of these initial crystallization hits appeared to be MHCI 
alone, though significantly more appeared to require CPXV203 for crystal reproduction than was 
observed with CPXV203/H-2Kb:mβ2m. All verified complex crystals (SDS PAGE analysis, Fig. 
4c) were plagued by extremely poor diffraction (>15Å), high mosaicity (>2o), and significant 
anisotropy. Extensive optimization of a low pH crystallization condition (Fig. 4a,b; 0.1 M MES 
(pH 6.0), 10% (w/v) PEG 6000) eventually yielded diffraction ≤10 Å of a small subset of 
complex crystals. One of these datasets yielded diffraction to 3.0 Å (Fig. 4d), which allowed for 
the determination of the complex structure of CPXV203 bound to OVA257-264:H-2Kb:hβ2m with 
a final Rwork/Rfree of 24.6%/28.6% (Table II). 
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 Protein crystallization & data collection. Diffraction-quality crystals of 
CPXV203/MHCI were grown at 20 oC by streak seeding into hanging drops of 0.5 µl complex 
(7.5 mg/ml) + 0.5 µl reservoir solution (10% PEG 6000, 4% Glucose, 2% Ethylene glycol, 0.1 M 
tri-K citrate pH 5.55, 0.01% Azide).  After crystals grew to 0.025-0.1 mm (3-10 days), they were 
dehydrated by adding 4.5 µl of dehydration solution #1 to the drop and then adding dehydration 
solution #2 to the 500 µl reservoir over 2 days (100 µl/6 hr x 2, then 200 µl/6 hr x 3; extensive 
optimization of published protocols6). The final dehydration condition was cryoprotective, so no 
additional reagents were added prior to liquid N2 flash freezing. This protocol improved 
diffraction from ≥15 Å to 3-8 Å and greatly reduced mosaicity.  X-ray diffraction data was 
collected at ALS (Advance Light Source) beamline 4.2.2 on the NOIR detector to 3.0 Å 
resolution.  A total of 720 frames (1o oscillation) was collected, though the last 180 frames were 
excluded from final processing due to radiation damage. Crystals belong to space group P1 
(a,b,c = 88.07 Å, 88.09 Å, 105.99 Å; a,b,g = 76.06o, 69.32o, 66.59o) with four CPXV203/MHCI 
complexes per asymmetric unit (ASU) and a solvent content of 51.8%.  Due to high mosaicity 
(HKL2000, 1.7o), the XDS software package7 was used to index, integrate, & scale the data to 
yield a 98.3% complete dataset at 3.0 Å (Rmrgd = 10.8%, Table II). 
 Structure Determination & Refinement. BALBES8 was used to identify RBM5:H-
2Kbm8:mβ2m (PDB code 2CLZ)9 as the optimal molecular replacement model for MHCI in the 
CPXV203/MHCI complex, which was then used (without peptide/H2O) to identify four 
molecular replacement (MR) solutions using Phaser (Phenix suite10). Exhaustive attempts to 
identify a MR solution for CPXV203 proved unsuccessful (poxvirus CKBPs, PHYRE11 & I-
TASSER12 models), and the anomalous signal strength was not sufficient to identify SeMet sites 
(CRANK13, SOLVE/RESOLVE10, SHARP14) for SAD phasing. 
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Though initial MR density in the CPXV203 region (identified via MAb blocking studies) 
was quite poor, extensive cross-crystal averaging15, using DMMULTI16, improved it to the point 
where CPXV203 could be built in Coot (Fig. 6a-c)17. The averaging strategy included 4-fold 
non-crystallographic symmetry (NCS) averaging of the four CPXV203 regions (initially defined 
using NCSMASK16 as a 20 Å sphere at the center of CPXV203 density) and cross-crystal 
averaging of each MHCI domain (α1/α2, α3, β2m) with the densities from six H-2Kb/bm8 crystal 
structures: CD8αα/MHCI (1BQH)18, TCR/MHCI (1FO0)19, MHCI (2CLZ)9, TCR/MHCI 
(2OL3)20, Ly49C/MHCI (3C8K)21, MAb/MHCI (3CVH)22. Inclusion of a structure required a 
visible improvement in CPXV203 density following averaging. Rotation & translation matrices 
were calculated using SUPERPOSE23. Iterative rounds of Coot model building & mask 
optimization (MAMA24) were required to produce the final cross-crystal averaged map for 
CPXV203 model building, while the initial MHCI models were built using only the MR phases. 
Non-crystallographic symmetry was used at all stages of building/refinement, as four 1:1 
CPXV203/MHCI complexes were present in the asymmetric unit related by two non-
symmetrical two-fold axes (RMSD 0.18 Å for all Cα). Simulated annealing composite omit 
maps (Phenix Autobuild10) were used to reduce model-bias throughout model building (Fig. 7). 
The CPXV203/MHCI structure was refined (Phenix Refine10) to a final Rfree 28.6% and Rwork of 
24.6% (see Table II for complete crystallographic statistics). Overlapmap25 was used to 
calculate the real-space correlation coefficients of the CPXV203 model at various stages (MR = 
0.53, four-fold NCS = 0.61, cross-crystal averaging = 0.65, final composite omit map = 0.85). 
MolProbity26 and PROCHECK27 were used to assess model quality. The final CPXV203/MHCI 
model contains four copies each of CPXV203 (R5/C6-R190/S191/V192), H-2Kb (G1–P277), 
β2m (0M-99M), OVA257-264, and 149 water molecules. 
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 Computational analysis. The DALI server28 was used to identify structural homologues 
and to create structure-based sequence alignments.  Combinatorial extension (CE)29 was used to 
calculate root mean square deviation (RMSD) values between different proteins/domains. The 
DYNDOM30 webserver (DomainSelect) was used to calculate domain motions. LIGPLOT31 was 
used to enumerate H-bonds & atomic contacts (≤4 Å), while NCONT32 was used to identify 
long-range electrostatic contacts (3.5-5 Å).  NACCESS33 was used to analyze BSA (1.4 Å probe) 
and to characterize interfaces as polar/neutral/hydrophobic. APBS34 was used for electrostatics 
calculations. Shape complementarity was calculated using SC35 and displayed graphically using 
GRASP36. ClustalW237 was used for general sequence alignment, while the Scorecons server 
was used to calculate positional conservation within alignments38. ALINE39, TOPDRAW40, and 
PyMOL41 were used to create figures unless otherwise noted. 
 Coordinates. The coordinates for CPXV203/MHCI have been verified by both 
PROCHECK & MolProbity (Fig. 8), and as such are available for deposition to the RCSB 
Protein Data Bank as soon as the CPXV203/MHCI manuscript has been accepted for 
publication. The current location of the final refined structure is listed below. 
 
/auk1/mccoy/Cross_Xtal_Averaging/MAR_2011/phenix/refine_final_chapter/Refine_358/12261
1_cpxv203_mhci_FINAL.pdb 
 
6.5 Crystal structure of CPXV203/MHCI 
The complex structure of CPXV203 bound to OVA257-264:H-2Kb:hβ2m was determined to a 
resolution of 3.0 Å with final Rwork/Rfree of 24.6%/28.6% (Fig. 9a, Table II). Unlike the PLC-
distal interface of HCMV US2:HLA-A242, CPXV203 binds an MHCI region targeted by all host 
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proteins that engage MHCI in a non-TCR orientation (Tpn, CD8, NKRs) (Fig. 9b).  My initial 
serological studies support the large CPXV203/MHCI interface (3,333 Å2) shown in Fig. 9a and 
suggest that a smaller CPXV203/MHCI interface (883 Å2) localized to the C-terminus of the 
peptide-binding groove is a crystal contact, thus the use of both low- and high-resolution 
structural studies has clearly identified CPXV203 as the first immunevasin to bind an MHCI site 
that overlaps with PLC interactions (Tpn)43,44,45,46,47,48.      
 MHCI membrane-proximal domain movements. Like host protein/MHCI complexes 
that bind below the α2-1 helix (Fig. 9b), CPXV203 binding does not grossly change the MHCI 
fold, but rather binding shifts the α3 & β2m domains relative to free MHCI49. Comparison of 
each MHCI domain (α1/α2, α3, β2m) to free MHCI showed no significant change in Cα RMSD 
(Table II) or in surface loops contacted by CPXV203. In comparison to the lack of structural 
change observed within each domain, the movement of the membrane-proximal domains appears 
quite extreme (α3, 7.2o; β2m, 16.8o), though these movements still fall within the range observed 
in previous crystal structures of free MHCI42,50.  The mobile nature of this interface may play a 
role in the more complex binding behavior observed for CPXV203/MHCI, as some heterodimer 
arrangements would only allow for partial engagement of the tri-domain MHCI epitope by the 
single domain of CPXV203.  
 Structure of CPXV203. The core of CPXV203 is a β-sandwich consisting of two parallel 
β-sheets (β-sheet I:β1, β5, β6, β10, β11; β-sheet II:β2, β3, β4, β7, β11, β8, β9) made up of anti-
parallel strands with one parallel strand interaction (β7/β9) bridging the two segments of β-sheet 
II (Fig. 10a,b).  Ten cysteines pair to form five disulfide bridges (Fig. 10b) imbuing CPXV203 
with extremely high stability & solubility (Tm = 91 oC, ~160 mg/ml). Like vCCI proteins, the β-
sheet II of CPXV203 is entirely solvent-exposed, while β-sheet I solvent accessibility is only 
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limited by helix-5 (h5) bridging β10-β11. The position of h5 is fixed by a novel disulfide (C21-
C168) attaching h5 to the bottom of β1, a charge cluster sealing h5 to β sheet I (h5:R176; h4-
h5:D164,h5:D177, β6:E84; β1:K17), and a disulfide (C34-C183) conserved in all vCCI-like 
proteins. 
 Structural comparison with vCCI-like CKBPs. The β-sandwich topology of CPXV203 
generally follows that previously described for cowpox vCCI and other chemokine-binding 
proteins: rabbitpox (RPV) vCCI, ectromelia (ECTV) vCCI, vaccinia (VACV A41), and the C-
terminal domain of the viral tumor necrosis factor receptor (vTNFR) ECTV CrmD-CTD (Fig. 
10b, 11)51–55. This lack of electrostatic conservation is shown in Fig. 12, which compares the 
electrostatic surfaces of RPV vCCI and CPXV203. These structurally similar proteins were 
identified using the Dali server28. A comparison of CPXV203 to these poxviral CKB proteins has 
bee summarized in Table III, 
The five changes to the general vCCI topology found in CPXV203 span from those 
already described for A41 & CrmD-CTD to entirely new elements required for MHCI 
engagement. CPXV203, CrmD-CTD, and A41 all reduce the length & negative charge of the 
chemokine-binding (CKB) loop 2-3 (vCCI:R38-G43, 14 aa; A41:K39-Y40, 2 aa; CrmD-
CTD:I184-S186, 3 aa; CPXV203:R38-G43; 6 aa), but only CPXV203 and CrmD-CTD modify 
another CKB element of the vCCI fold through the loss of negative charge near the top of β-
sheet II (Fig. 10b, 11, 12). Also, CPXV203 & CrmD-CTD shorten the 6-7 loop, though 
CPXV203 retains some of the helical content found in the 6-7 loop of other vCCIs.  
 The last two departures from the vCCI architecture are quite drastic, as entire 2o 
structural elements are created/deleted. First, CPXV203 & CrmD-CTD reinvent the 7-9 junction 
by both shortening the intervening sequence (vCCI: S133-I161, 29 aa; CrmD-CTD: N247-H266, 
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20 aa; CPXV203:D110-Y128, 19 aa) and introducing a new β-strand to extend β-sheet II 
(CPXV203 β8:F118-S126, 9 aa; CrmD-CTD β8:S252-L255, 4 aa).  The absence of the vCCI 7-9 
loop increases β-sheet I solvent accessibility for both CPXV203 and CrmD-CTD, allowing the 
latter to bind its chemokine ligand (CX3CL) using β-sheet I rather than the typical use of β-sheet 
II (Fig. 13a). This change in topology removes large steric clashes expected between vCCI 7-
9/MHCI (Fig. 13b) and creates β8 that is used to contact β2m (Fig. 10b).  The second large 
structural departure replaces vCCI β13-β14 with CPXV203 α helices h4 & h5. This change is 
unique to CPXV203 and may involve the deletion of vCCI E190-D210 (20 aa) coupled with the 
insertion of CPXV203 D172-Y179 (8 aa). These changes remove potential vCCI/MHCI clashes 
(Fig. 13b) and all CPXV203/MHCI platform contacts emerge from h4-h5 (Fig. 10b). 
 CPXV203 contacts conserved elements within each MHCI domain. CPXV203 
promiscuously binds MHCI through a large, nonpolar interface divided into distinct regions that 
coordinate each MHCI domain using conserved MHC Ia/Ib features (Fig. 14, Fig. 15). Further, 
the region of CPXV203 used to contact HC α3 appears to be relatively conserved amongst T4 
poxvirus proteins, while the HC α2 and β2m contact region are more variable (Fig. 14, Fig. 16). 
A comparison of the CPXV203/MHCI interface to similar interfaces reveals that the total BSA is 
significantly larger than most other complexes, CPXV203 buries >200 Å2 more main-chain than 
any similar MHCI-binder, and only CPXV203 divides its interface nearly equally among 
platform (α1/α2), β2m, & α3 (Table IV).  Each CPXV203/domain interface (α2, β2m, α3) is 
anchored by a buried main chain-main chain (MC-MC) hydrogen bond and 2-3 main chain-side 
chain (MC-SC) hydrogen bonds (Fig. 17a-c, Table V). Through these MC/SC-MC contacts, 
CPXV203 recognizes seven backbone positions conserved by the MHCI-fold and coordinates 
conserved MHCI side chains within the α3 interface (Q226 & E229). Further, CPXV023 
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histidines in the α3 interface are opposite negatively charged MHCI contacts (D227, E229), 
which suggests that these may be pH-regulated residues. During our studies, mCD1d was 
identified as the only MHCI that was null by both functional and biophysical assays (data not 
shown), which can now be explained by the charge reversal at position 229 (mCD1d H233 – 
CPXV203 H80) and the movement of mCD1d Q230 away from the interface due to an altered 
mCD1d loop conformation (Fig. 17d). Finally, there also appears to be a significant array of 
stabilizing interactions that support the CPXV203 binding interface (Table VI), which marks 
CPXV203/MHCI association as quite different from the well-described engagement of MHCI 
through flexible loops by various host proteins. My structural inspection of the CPXV203/MHCI 
interface helped to explain promiscuous MHCI binding and suggested a variety of interface 
hotspots to mutate in order to address the functional consequences of diminished 
CPXV203/MHCI association. 
 Minimal soluble domain of CPXV203 defined structurally. An attempt was made to 
improve the CPXV203 crystallization construct in order to obtain crystals of either CPXV203 or 
CPXV203/MHCI of higher resolution to compare with the 3.0 Å structure described above.  Two 
minimal soluble domains were designed using the CPXV203 structure (6-153 and 13-152). 
These constructs include only the core β-sandwich with either 3 or 2 disulfides.  Free cysteines 
(21 and 34) were mutated to serine to prevent intermolecular disulfide cross-linking. Both of 
these proteins were successfully refolded from bacterial IBs (see Chapter 2). Preliminary BLI 
evaluation of these constructs at pHER and pHGolgi showed that they no longer associate with 
MHCI. This result supports the importance of the α2 interface, as these truncations are not 
expected to remove β2m or α3 contact regions. The remaining recombinant material was used in 
crystallization trials of CPXV203 alone (96 conditions/construct). Low precipitation within these 
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crystallization trials suggests the protein concentration used (16 mg/ml) was too low to comment 
on the likelihood of success with these constructs. Insufficient time was available to repeat these 
trials at higher protein concentrations. 
 
6.6 Crystallization of other CPXV203/MHCI complexes 
Though brute force over >15 months eventually resulted in the successful determination of the 
CPXV203/H-2Kb:hβ2m complex structure, the difficulties that plagued this structural 
investigation led me to pursue a variety of alternative CPXV203/MHCI complexes with the hope 
that one or more of these complexes might crystallize more readily and/or diffract to higher 
resolution. These alternatives inclulded truncations of both CPXV203 & MHCI, high-affinity 
mutant MHCI, and even a crystallization chaperone (FadA). Though in the end these efforts 
proved unnecessary, I believe that there is much that was learned from these efforts, and I hope 
that my observations may prove useful to future Fremont lab crystallization efforts. I have 
included notes on three of these pursuits that may aid future structural investigations. 
 Results: CPXV203/H-2Kb(Y84A,C121S):hβ2m. This CPXV203/MHCI complex was 
purified at physiological pH and produced both low and high pH crystallization hits (384 
random-matrix conditions, 360 optimization trials). All crystals examined by SDS PAGE proved 
to be complex, unlike the previously described wt complexes that often were MHCI alone. As 
these complex crystals diffracted more consistently than wt complexes, multiple ≤5Å datasets 
were collected, but significant anisotropy and mosaicity impeded structure solution of the high-
affinity complex. The UCLA diffraction anisotropy server56 was used to truncate data to 3.5 Å, 
which allowed for MR of two complexes per ASU. The overall complex appears similar to the 
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low pH complex structure.  Time was not available to build this complex or further optimize 
these crystals. 
 CPXV203/H-2Kd:β2m crystallization trials. This CPXV203/MHCI complex was 
pursued using both complex formed with an excess of CPXV203 (3:1 CPXV203/H-2Kd:mβ2m; 
96 conditions) and “SEC-purified” complex (CPXV203/H-2Kd:hβ2m; 384 conditions). The latter 
complex also had a large excess of CPXV203 (see Chapter 4) due to dissociation of 
CPXV203/MHCI during purification at low pH. Neither set of trials yielded any crystal hits. 
Control crystallization trials with H-2Kd:mβ2m produced crystals that diffracted below 3 Å. If a 
future attempt was made to crystallize this complex, I would suggest removing HC residues 
beyond residue 274 (greatly promotes crystallization of H-2Kb:β2m) and including the Y84A 
mutation. 
 FadA-CPXV203/H-2Kb:hβ2m crystallization trials. This complex was able to produce 
complex crystals (confirmed by SDS PAGE, data not shown) suggesting that this crystallization 
chaperone can accommodate a fusion protein up to 68.6 kDa. Though diffraction (≤4 Å) was 
routinely obtained from these crystals (even on the home source), they were also plagued by 
severe mosaicity. Optimization of these crystals to reduce mosaicity was not undertaken, as the 
low pH complex structure solution began to coalesce as I was in the process of optimizing this 
complex.  
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Figure 
1. Crystallization of reductively methylated CPXV203. (a) The organic mechanism for reductive 
methylation is shown for reference.  Formaldehyde acts as the alkylating agent, while the 
dimethylamine borane complex (ABC) acts as the reducing agent.  Surface exposed primary 
amines (lysine residues and the protein’s amino terminus) are reductively methylated overnight 
at 4 oC.  The reaction is quenched by SEC purification in Tris sizing buffer. Reductive 
pentylation occurs by a similar reaction mechanism involving glutaraldehyde instead of 
formaldehyde. (b) Crystals of methylated CPXV203 appeared as star clusters within three days 
for well-behaved protein preparations.  (c) Extensive variation of the initial condition reproduced 
the crystal form in a number of variants (7 wells), though only four are shown here. (d) 
Optimization identified eleven additives that reproduced the initial crystal form with varying 
degrees of nucleation and precipitation.  One of the detergent hits is shown as an example. 
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Figure 2. Crystallization of bacterially-expressed MPX184. Representative images of the crystal 
forms observed in initial crystallization hits for MPX184. Bunched needles/haystacks appeared 
in 12 different conditions, though most conditions included 0.2 M Ca2+. These crystals were 
difficult to reproduce and resisted optimization.  
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Figure 3. Crystallization of CPXV203/H-2Kb:mβ2m. (a) Initial needle/haystack crystalline form 
of the CPXV203/H-2Kb:mβ2m complex was optimized to multinucleated plates. (b) Optimized 
crystals were washed and then analyzed by SDS PAGE. Three distinct bands (H-2Kb, CPXV203, 
mβ2m) are present, thus confirming that these crystals contain CPXV203/MHCI complex.  
MHCI and CPXV203 controls are shown for comparison. The MHCI in these crystals contained 
OVA257-264. 
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Figure 4. Crystallization of CPXV203/H-2Kb:hβ2m. (a) Initial reproductions of CPXV203/H-
2Kb:hβ2m identified in random-matrix screens. (b) Extensive optimization (crystallization 
condition & iterative streak seeding) produced plates that could be further evaluated. (c) SDS 
PAGE analysis of extensively washed crystals from similar conditions to a clearly show 
CPXV203/MHCI complex with an estimated ratio of 1:1. (d) Example diffraction image from 
the 3.0 Å dataset that was used to determine the CPXV203/MHCI structure.  
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Figure 6. Cross-crystal averaging improvement of electron density. Proteins are shown as 
ribbons: CPXV203 (magenta), H-2Kb (blue), β2m (grey), and OVA257-264 (yellow, spheres). (a-c) 
Electron density (2σ) in the CPXV203 region is shown using phases from molecular replacement 
(a), cross-crystal averaging (b), or the final model (c). The Cα trace of CPXV203 is shown in 
(c). Though the contiguous density available for model building was significantly improved by 
NCS, successful building required the improvement in estimated phases from cross-crystal 
averaging against a large number of MHCI complexes and free MHCI. 
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Figure 7. Electron density comparison. The cross-crystal averaged electron density (1σ) for part 
of CPXV203 β6 (black box) is shown to illustrate the electron density that was available to 
initiate CPXV203 model building using a stretch of residues with bulky side chains (H80, Y82, 
E84, F85). SA-OMIT and 2Fo-Fc maps are shown for comparison. All electron density images 
were produced in PyMOL using isomesh at the designated σ. 
 
 
Figure 8. MolProbity & PROCHECK evaluation of CPXV203/MHCI. MolProbity output (a) 
and PROCHECK (b) outputs confirm the high quality of the final CPXV203/MHCI structure. 
The CPXV203/MHCI structure is within the 99th percentile of similar structure (3.0 ± 0.25 Å) 
evaluated by MolProbity. 
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Figure 9. Crystal structure of CPXV203 bound to MHCI. (a) Ribbon diagram of the complex 
structure of CPXV203 (magenta), H-2Kb (blue), β2m (grey), and OVA257-264 (yellow, spheres). 
Arrow indicates insertion of MHCI in membrane. No N-linked glycosylation sites are present 
near the interface. Membrane proximal domain shifts, α3 (7.2o) & β2m (16.8o), are within the 
range observed in previous crystal structures of free MHCI42,50 (b) Comparison of 
CPXV203:MHCI binding orientation to other MHCI binders: viral (US2), chaperone (Tpn), co-
stimulatory (CD8αα), & NK receptors (Ly49C/LIR-1). Chains colored as in a. Proposed Tpn 
contact loops (α2 128-136, α3 222-229) are colored magenta with contacts identified by 
mutagenesis shown as spheres. Black arrows indicate membrane insertion of each MHCI binder. 
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Figure 10. CPXV203 contacts MHCI using both novel & conserved 2o structural elements. (a) 
Ribbon diagram of CPXV203 (R5-S191) colored according to 2o structure (cyan α helices, blue 
310 helices, green β strands, grey loops, & yellow disulfide bonds).  CPXV203 orientation is 
identical to Fig. 9a. (b) Topology diagram of CPXV203 with 2o structure coloring as in a.  
Disulfide bonds are shown as flattened balls-&-sticks with residue positions listed. The core β 
sandwich is divided into its β sheets by a dashed, grey line.  Structural elements not found in 
vCCI (PDB: 1CQ3) are highlighted in black, including the absence of a highly negatively-
charged chemokine-binding (CKB) loop.  MHCI domain contacts (colored according to Fig. 9a) 
are highly localized to these unique structural elements. 
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Figure 11. Structure-based alignment of vCCI-like proteins. Dali alignment of CPXV203 with 
CKB proteins from cowpox virus (CPXV) vCCI51, rabbitpox (RPV) vCCI53, ectromelia virus 
(ECTV) vCCI52, vaccinia virus (VACV) A4154, and the C-terminal domain (CTD) of CPXV 
CrmD55. Experimentally observed 2o structure is indicated (CPXV203, above; vCCI, below), 
residue conservation has been colored by similarity (ACILMPV DE FHWY HKR NQST), 
structurally-conserved residues are capitalized, symbols indicating side chain solvent 
accessibility are shown (CPXV203, above; vCCI, below). Contact residues identified through 
structural studies (CPXV203, CrmD-CTD, RPV vCCI) or mutagenesis (ECTV vCCI) are 
indicated above (MHCI) or below (CK) the alignments. CPXV203 histidines are marked with an 
asterisk, except for pH-regulated interface histidines that are labeled with blue/red circles. PDB 
IDs for proteins in this alignment: 1CQ3, 2FFK, 2GRK, 2VGA, 3ON9. Side chain solvent 
accessibility was defined using NACCESS (1.4 Å probe); black circles, <30% accessible; grey 
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circles, 30-60% accessible; white circles, >60% accessible. 2o structure was calculated using 
STRIDE. 
 
 
Figure 12. CPXV203 does not conserve negative CKB surfaces. Electrostatic surface potential (-
5 to +5 kT/e) is mapped onto the rabbitpox vCCI (a) and CPXV203 (b) surfaces using APBS in 
PyMOL to highlight the disparate modes of binding used by these proteins to bind their 
respective ligands.  Chemokine contacts are labeled on vCCI, while structurally-conserved, 
surface-exposed residues are labeled on CPXV203.  The structurally-conserved, chemically-
similar residues T187/T137 have been bolded.  Insets are shown for the ligands (MIP-1β, 
MHCI) following APBS calulation and a 180o rotation. PDB used in this figure: RPV vCCI 
(2FFK). 
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Figure 13. Structural comparison of CPXV203 to vCCI-like proteins. (a) CPXV203 & poxvirus 
CKB proteins (RPV vCCI & ECTV CrmD-CTD) use three distinct surfaces for ligand binding. 
Each complex is shown as a ribbon diagram: CPXV203 (magenta), H-2Kb (blue), β2m (grey), 
OVA257-264 (yellow, spheres), CKBP (magenta), CK (cyan). Each poxvirus CKBP was aligned to 
CPXV203 using CE29. View from Fig. 9 has been rotated 90o (y-axis). CKB loop & β-sheets are 
indicated. (b) Poxvirus CKBPs vCCI & CrmD-CTD were modeled onto the CPXV203/MHCI 
complex to evaluate potential steric clashes due to structural elements found in CKBPs (blue) but 
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absent in CPXV203.  All topological differences between CKBPs & CPXV203 are listed. 
Connolly surfaces are shown for the severe clashes (≤2 Å).	  	  
	  
Figure 14. CPXV203 binds conserved elements within each MHCI domain. The 
CPXV203/MHCI complex is shown as a Connolly surface (1.4 Å probe). Relative to Fig. 9, 
MHCI was rotated -30o (y-axis), while CPXV203 was rotated 60o (y-axis). Each domain-specific 
interaction is circled on both molecules.  The US2 & E3-19K binding sites are also indicated. (a) 
CPXV203/MHCI surfaces are colored by chain (see Fig. 9) or by contact (see legend).  
CPXV203/MHCI interfaces are labeled according to the contacted MHCI domain. Each MHCI 
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domain is contacted by a CPXV203 surface that is localized to distinct structural region. 
Comparison of the CPXV203 & US2/E3-19K sites clearly shows the lack of binding site overlap 
between PLC-proximal & PLC-distal immune evasion proteins. (b) Conservation of interface 
residues is shown for CPXV203-susceptible MHCI & T4 poxvirus proteins (Fig. 15 & 16). 
Backbone contacts for each interface are indicated (*). CPXV203 contacts highly-conserved 
MHCI surfaces, as opposed to US2 (prominent variable residues between α2-α3). Conservation 
of MHCI contact residues in the T4 family are highly localized to the α3 interface, which 
contains 4/6 CPXV203 backbone contact positions. 	  
	  
Figure 15. Sequence alignment of MHCI. (a,b) Sequence regions have been restricted to 
CPXV203/MHCI contact regions. Residue conservation has been colored by similarity 
(ACILMPV DE FHWY HKR NQST). MHCI 2o structure, Tpn/CD8/NKR contacts, and side 
chain solvent accessibility (see Fig. 11) are above the alignments. CPXV203/MHCI contacts are 
boxed in magenta, while MHCI backbone contacts are indicated with an asterisk above the 
alignment. (a) MHCI HC were included in this alignment if they are down-regulated or bound by 
	   148	  
CPXV203. Murine CD1d was identified as a null allele in the course of this work (data not 
shown), and so it is shown below the other alleles to highlight the lack of sequence conservation 
in CPXV203/MHCI contact regions. D227 & E229 are indicated with blue/red circles, as 
CPXV203 H75 & H80 are believed to contact these Tpn contact residues in a pH-regulated 
manner. (b) β2m sequences of potential poxvirus hosts are shown (primate, rodent, livestock). 
Tpn contacts are based on published mutagenesis work43,46,44,45, while LigPlot was used to 
identify CD8 & NKR contacts from all available complex structures (CD8/MHCI: 1AKJ, 1BQH, 
1NEZ, 3DMM; Ly49/MHCI: 1QO3, 3C8K; LIR/MHCI: 1P7Q, 2DYP). 
 
	  
Figure 16. T4 poxvirus protein family alignment. The sequence of CPXV203 was aligned to T4 
poxvirus proteins with a broad range of sequence identity; Taterapox (TATV,96%), Monkeypox 
(MPXV, 64%), Yokapox (YPV, 60%), Deerpox (DPV, 34%), and Myxoma (MYXV, 26%). 
Virus strains are indicated in parentheses. Residue conservation has been colored by similarity 
(ACILMPV DE FHWY HKR NQST). CPXV203 2o structure, side chain accessibility (see Fig. 
11), and MHCI contacts are indicated. CPXV203 E162 is labeled with a blue/grey circle to 
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indicate it is used in both the α2 & β2m interfaces. CPXV203 histidines are marked as in Fig. 
11. Many 2o structure prediction programs predict a C-terminal α-helix (shown in white), which 
is partially supported by what appears to be the beginning of a helix (aa 188-191) in the 
CPXV203/MHCI structure. Cysteine residues (10 conserved positions) are boxed in yellow, 
while the conserved C-terminal KDEL-variant is boxed in red. Predicted N-linked glycosylation 
sites are boxed in green.  As CPXV203 N146 is not solvent-accessible, its lack of glycosylation 
(mass spec & PNGase tx) is not surprising.  
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Figure 17. Magnified view of each CPXV203/MHCIdomain interface. (a,b,c) The 
CPXV203/MHCI complex is shown (as in Fig. 2) with each interface shown using sticks colored 
by chain/element (C, blue/grey,magenta; O, red; N).  Side-chains are shown for all contact 
residues, and MHCI backbone contacts are indicated (*).  Residues that appear to be involved in 
putative hydrogen-bond networks (interface contacts: yellow dots, conformation stabilizers: grey 
dots) are labeled. MHCI backbone positions are indicated (*). Interface views were rotated 
(relative to Fig. 2) for optimal viewing: a 10o (y); b 90o (y); c ~90o (x), ~150o (z). (a) CPXV203 
contacts the underside of the MHCI peptide-binding platform (α1/α2) through burial of large 
hydrophobic residues (I160 & Y161) immediately following helix-5 (h5). (b) CPXV203 uses 
parallel histidines from β-sheets I & II to coordinate β2m backbone carbonyl oxygens. The β2m 
interface MC-MC hydrogen bond is above the shown view. (c) CPXV203 extensively interacts 
with conserved MHCI residues Q226 & E229. CPXV203 H75 & H80 are directly opposite 
	   151	  
conserved, acidic MHCI residues D227 & E229. (d) Comparison of MHCI crystal structures 
clearly shows conservation of the α3 loop conformation with the exception of CD1d.  The α3 
domains (181-274) of numerous MHCI structures (murine & human, Ia & Ib) were aligned by 
combinatorial extension.  A subset of those structures is shown here. 
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Chapter 7 
 
Mutagenesis of the CPXV203/MHCI binding site 
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7.1 Mutagenesis of the CPXV203/MHCI binding site 
Mutations were introduced into the CPXV203/MHCI interface for biophysical & functional 
evaluation at a variety of points during this project based on the available information (MHCI 
conservation  MAb/SPR studies  crystal structure).  Initially these studies were designed to 
evaluate the location of the CPXV203 binding site using only biophysical studies, and later they 
employed both functional & biophysical approaches to probe the contribution of each interface 
and to identify contact residues that contribute to pH regulation.  
 
7.2 Functional significance of CPXV203/MHCI interface mutations. 
Xiaoli Wang MD, PhD (laboratory of Dr. Ted Hansen) completed all of the functional studies in 
this section. These studies are reported here as they were designed collaboratively using the 
biophysical and structural studies described in this doctoral work. These studies evaluated the 
functional consequences of interface mutation via flow cytometry & immunoprecipitation 
assays. 
 Cell lines. Murine embryo fibroblast (MEF) B6/WT3 (WT3) and mutant MEFs including 
TAP1-deficient cells (FT1-), Tapasin-deficient cells  (Tpn-/-), calreticulin-deficient cells (CRT-/-), 
β2m-deficient cells (B6.B2M-) and triple knockout fibroblasts (Kb-/- Db-/- β2m-/-; 3KO) were all 
derived from C57BL/6 (H-2b) embryos and have been described previously1.  The H-2Kb and 
CPXV203 mutants were stably expressed in the indicated cells by retroviral expression vectors 
pMXsIG2 and pMIN1, respectively.  Cells transduced by pMIN were selected by neomycin while 
GFP+ cells from pMIG transduced lines were enriched by cell sorting.   
 Immunoprecipitations, immunoblot, & cross-linking. For co-immunoprecipitations, 
cells were lysed in PBS with 1.0% digitonin (Wako, Richmond, VA) and protease inhibitor 
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cocktails (Roche) for 60 min.  Post-nuclear lysates were then incubated with indicated 
antibodies+Protein A-sepharose (Sigma) or anti-HA sepharose (sigma) for HA tagged CPXV203 
for 1h.   After washes, co-precipitated proteins were eluted by boiling in LDS sample buffer 
(Invitrogen).  For cross-linking treatment, cells were incubated with 1-2mM DSP (Thermo) in 
PBS for 2h at 4oC. The cross-linking was terminated with 25 mM Tris-HCl pH7.4 before the 
cells were lysed in PBS with 1.0% NP-40.  Following immunoprecipitation cross-linked proteins 
were eluted by boiling in LDS sample butter with 2.5% ΒΜΕ.  Immunoblot of precipitated 
proteins was performed following SDS-PAGE separation.  Specific proteins were visualized by 
chemiluminescence using the ECL system (Thermo).  
 Flow cytometry. All flow cytometric analyses were performed using a FACS Calibur 
(Becton Dickinson).  Data were analyzed using FlowJo software (Tree Star).  Staining was 
performed as described3.  PE-conjugated goat anti-mouse IgG (BD Pharmingen, San Diego, CA) 
was used to visualize MHCI staining.  PE-conjugated anti-mouse CD1d (eBioscience) was used 
to detect surface CD1d.  GFP signal representing CPXV203 transduced cells were collected in 
the FITC channel.   
 Results. The functional relevance of specific interaction sites within the 
CPXV203/MHCI binding interface was determined by extensive mutagenesis of both CPXV203 
and H-2Kb. Mutants were assayed for loss of function by rescue of surface Kb expression or lack 
of physical association by co-IP. Single mutations in either Kb or CPXV203 from all three 
interaction sites discussed in Chapter 6 were tested [α2 (Kb Q115A, A125R, T134K; CPXV203 
Y161A), β2m (CPXV203 H119A) and α3 (Kb Q226A, D227K, E229Y; CPXV203 H75A, F76A, 
H80A), but only α3 interface mutations Kb E229Y and CPXV203 F76A significantly rescue Kb 
surface expression (Fig. 1a,b). Furthermore, double mutations within the α3 interface (Kb 
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D227K/E229Y, CPXV203 H75A/H80A, Kb Q226A/CPXV203 F76A, Kb E229Y/CPXV203 
H75A, Kb E229Y/CPXV203 F76A) or the simultaneous mutation of interfaces α2 & α3 
(CPXV203 Y161A, F76A) significantly enhanced Kb rescue with some mutants displaying 
complete ablation of CPXV203 function (Fig. 1a-c). Furthermore, single α3 interface mutations 
were found to ablate physical association of Kb with HA-tagged CPXV203 (Fig. 1d), though it 
should be noted that the HA-tag might impair CPXV203/Kb association, as the impaired physical 
association was far more dramatic than Kb rescue. Regardless, this mutagenic work demonstrates 
the critical importance of the α3 interface in CPXV203 association and retrieval of MHCI.   
 
7.3 Biosensor evaluation confirms CPXV203/MHCI interface 
All mutant proteins (CPXV203 & MHCI) appeared to be properly folded, as they purified in a 
manner identical to the wt versions (see Chapter 2). Please see previous biosensor sections for 
detailed experimental methods. 
 Results: BLI analysis confirms the tri-domain binding site. Equilibrium analysis (BLI, 
pHER 7.4) of CPXV203 & MHCI mutants confirmed the three site binding geometry and clearly 
distinguished the CPXV203 binding site from those of E3-19K, US2, and MAb Y-3 (blocks 
CPXV203/MHCI) (Fig. 1e, Table I). Further, alanine mutation of several CPXV203 residues 
within interface α3 had a pronounced deficit in binding (similar to co-IP), which supports the 
importance of the α3 interface and suggests histidines within this interface may be critical to 
CPXV203/MHCI binding. 
   Kinetic consequences of interface histidine protonation. Interface histidines CPXV203 
H75 & H80 were selected for kinetic analysis (SPR) based on their chemical environment, 
functional deficits associated with alanine mutation, and BLI analysis. Alanine mutation of either 
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histidine ablated the off-rate (kd) enhancement at low pH, while maintaining a similar on-rate 
(ka) enhancement (Fig. 1f, Table II). Thus, titration of α3 interface histidines extends 
CPXV203/MHCI half-life (6.1 s to 73 s), while a separate interaction must account for the faster 
association (ka). Unfortunately, the extremely weak affinity of the double histidine mutant 
prohibited accurate kinetic analysis, though BLI supports the greater functional deficit observed 
for this mutant (Table I). Previous truncation work (see Chapter 3) suggests that the second pH-
regulated interface involves the CPXV203 C-terminus, but the MHCI side of this interface 
remains unknown. 
 
7.4 Computationally-designed CPXV203 null mutant 
In addition designing mutants through analysis of biophysical results or structural inspection, a 
computational approach was pursued to identify potential interaction hotspots within the 
CPXV203/MHCI interface. The Rosetta software suite4 was used to perform in silico alanine-
scanning mutagenesis5 on the CPXV203/MHCI interface. This program identifies interface 
residues (≤10 Å between CPXV203 and HC/β2m) from the atomic coordinates of the 
CPXV203/MHCI complex and then individually mutates each interface residue to alanine before 
repacking the local interface (≤8 Å from the mutation) and calculating the change in binding 
energy. This type of analysis could have been performed using a user-friendly web server 
version of this software (Robetta)6, but the results (including the initial CPXV203/MHCI 
structure) are immediately made available to the scientific community.  As such, I undertook this 
analysis using local computer resources, which required significant investment in learning the 
Rosetta architecture and programming language.  
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Results. This analysis identified two mutations (HC G120A, CPXV203 G77A) that 
increased the energetic score of the complex by >100-fold (290 and 160, respectively) compared 
to the average energetic score calculated for 228 other models (1.5 ± 1.0). The HC mutation is 
within the HC/β2m heterodimer interface, and so it was not investigated further. The CPXV203 
G77A mutation was successfully produced recombinantly and then analyzed in BLI experiments. 
This CPXV203 mutation drastically reduces (>86-fold) the affinity of CPXV203 for MHCI 
(Table II). This minimal mutation (GA) in the β5-β6 loop implies that this loop conformation 
is essential to CPXV203/α3 engagement, which further supports the interface determined 
crystallographically.  Finally, this single mutation should appears to be an ideal MHCI null-
binder for future in vivo studies investigating additional CPXV203 functional roles. 
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Figure 1 Mutagenesis supports a tri-domain interface and pH regulation. (a,b,c) 3KO cells stably 
transduced with β2m & H-2Kb (3KO-β2m-Kb) were transduced with CPXV203-IRES-GFP to 
evaluate the effect of CPXV203/MHCI interface mutation on surface H-2Kb remaining relative 
to untransduced cells. Comparable expression of wt & mutant proteins was determined using co-
expressed GFP and/or western blotting. Each figure represents the data from two independent 
experiments. ** P<0.01; ***P<0.001 when compared with wt. Limited MHCI escape was 
observed for two single α3 interface mutations (Kb E229Y or CPXV203 F76A), while 
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significant Kb escape required double mutation of the α3 interface (Kb D227K/E229Y, 
CPXV203 H75A/H80A, Kb Q226A/CPXV203 F76A, Kb E229Y/CPXV203 H75A, Kb 
E229Y/CPXV203 F76A) or simultaneous mutation of interfaces α2 & α3 (CPXV203 F76A, 
Y161A) (d) Most mutant CPXV203-HA exhibited a decreased ability to co-IP H-2Kb even 
though surface H-2Kb (%) did not increase significantly.  CPXV203/H-2Kb mutations that 
significantly increased surface H-2Kb expression also exhibited a decrease in total H-2Kb 
(lysate), indicative of the release of MHCI retention2. (e) Kinetic analysis (SPR) of alanine 
mutation of α3 interface histidines (CPXV203 H75 & H80) summarized by on-rate (ka, (+)-axis) 
and off-rate (kd, (-)-axis). (f) Summary of mutagenic analysis (functional & biosensor) mapped 
to CPXV203/MHCI structure shown as cartoon loops (blue, HC; grey, β2m; magenta, 
CPXV203) except for the peptide (yellow spheres). Mutated residues (Cα spheres) were colored 
to indicate whether they had a significant effect (red) or no significant effect (grey). CPXV203 & 
MHCI have been translated apart (x-axis) to highlight corresponding interface mutations.  
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8.1 Introduction  
Viral infection of mammalian hosts can be greatly facilitated by viral proteins that confer the 
ability to evade CTL detection & clearance1, and not surprisingly, viruses have evolved a wide 
variety of strategies (degradation, impaired folding, retention) to reduce cell surface presentation 
of viral peptides on MHCI2. The cellular, structural, & biophysical results reported here provide 
a complete picture of such a strategy, as CPXV203 was shown to directly bind fully assembled 
MHCI in a manner that is regulated via the normal pH gradient that exists between the ER and 
Golgi compartments (Fig. 1).  Though CPXV203 makes contacts to three distinct MHCI sites, 
pH regulation of the complex half-life is critically dependent on CPXV203 histidines in close 
proximity to α3 residues important for both Tpn & CD8 association.  Surprisingly, CPX203 is 
not related any other MHCI-binding protein, but rather it is most structurally similar to the 
poxvirus chemokine binding (vCCI-like) proteins.  
 
8.2 Poxvirus CKB evolution  
CPXV203 is the first member of the T4 poxvirus protein family3 to be structurally characterized, 
and so the structural similarity between CPXV203 and vCCI-like family members has revealed a 
previously unknown evolutionary link between these poxvirus protein families. As the T4 family 
is found in more chordopoxvirinae genera (capripox, centapox, cervidpox, leporipox, orthopox, 
& yokapox) than vCCI-like proteins (leporipox & orthopox), the poxvirus CKB fold likely arose 
from a gene duplication of the more evolutionarily distant T4 poxvirus protein fold. Regardless 
of the details, the adaptation of this protein fold to structurally distinct ligands and unrelated 
functional outcomes (CPXV203/MHCI – virostealth, vCCI/CK – viromimicry, M-T4/apoptotic 
factor4 – virotransduction) provides a wondrous example of immune evasion evolution in 
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Poxviridae and suggests the integral role that CPXV203 plays in antigen presentation disruption 
may not be its only function. Future investigations should evaluate possible additional T4 
poxvirus protein function(s) performed by CPXV203 through the use of MHCI-null binders 
identified in this work. 
 
8.3 Promiscuous MHCI binding 
CPXV203 evolved into an extremely promiscuous MHCI-binding protein by targeting MHCI 
sites that are conserved via a number of host proteins that engage MHCI for adaptive (Tpn, CD8) 
and innate (NKRs) immune responses. For instance, many α2 contacts (R111, Q115, E128, 
T134) are conserved through Tpn (α2 128-136)5,6,7 and Ly49 (R111, Q115, D122)8 interactions, 
while the β2m contacts primarily involve structurally conserved backbone positions that overlap 
LIR/MHCI sites9,10. The direct overlap of CD8 & Tpn contact sites (CD8: Q22611,12,13; Tpn: 
D227 & E22914) in the solvent-accessible CD loop of the α3 domain likely accounts for the 
critical nature of the α3 interface to CPXV203/MHCI binding. All available complex structures 
(CD8/MHCI, 4; Ly49/MHCI, 2; LIR/MHCI, 2) were utilized in these analyses. As the 
mammalian host has a limited ability to modify this interface to avoid viral interference, I would 
suggest that uncharacterized immune evasion proteins may bind MHCI in a similar fashion to 
CPXV203. 
 
 
8.4 Regulating protein/protein interactions within the ER-Golgi pH gradient.  
Previous investigations of pH-dependent endosomal (PRL/PRLr15, FcRn/Fc16,17) and ERGolgi 
(RAP/LRP)18 trafficking have repeatedly identified histidine residues as the pH sensitive 
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component of these regulatory mechanisms.  Unlike other amino acids, histidine is well suited to 
serve this function, as small pH shifts (pH 6.0-7.5) can drastically change the charge & hydrogen 
bonding potential of this residue. As such, my investigation of CPXV203/MHCI pH regulation 
began by focusing on interface histidines, which revealed a significant contribution of CPXV203 
H75 & H80 to complex half-life at low pH. I suggest that these titratable histidines evolved to 
endear CPXV203 with the ability to regulate fully assembled MHCI in a manner that is 
complementary to regulation of PLC-associated MHCI by CPXV012. 
 
8.5 Coordinated antigen presentation sabotage 
For CPXV to completely block antigen presentation, it must prevent the expression of both Tpn–
dependent and –independent MHCI, and so CPXV012 & CPXV203 have evolved to target 
distinct MHCI assembly states using retention mechanisms that are cooperative yet independent 
of one another. CPXV012 targets MHCI during chaperone-mediated assembly, thus limiting its 
reach to those MHCI that require the PLC to bind peptides.  The MHCI that are able to bind 
peptide in the presence of CPXV012 are left to CPXV203, as it binds fully assembled MHCI 
through domain-specific conformational determinants conserved in most MHCI. Among these 
interactions, the α3 interface appears particularly important based on the presence of His 
residues that impart pH regulation to the CPXV203/MHCI interaction.  This pH dependence 
suggests that CPXV203/MHCI interacts most avidly in the Golgi and not the ER, thus greatly 
limiting the pool of MHCI that CPXV203 must retrieve. Though this mechanism appears 
superficially similar to CRT/KDELR retrieval of unstable MHCI from the Golgi19, CPXV203 
retrieval is quite different, as CRT promotes MHCI quality control while CPXV203 targets 
quality MHCI products. MHCI retrieved by CPXV203 or detained by CPXV012 do not appear 
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to accumulate within the ER, which suggests that these MHCI are identified by ER quality 
control chaperones and eliminated by ERAD without the need for specific viral targeting (US2, 
US11, mK3). By using the endogenous KDELR & ERAD pathways, the CPXV203 mechanism 
appears particularly resistant to attempts by the host to escape MHCI down-regulation via 
mutation, as these changes would likely decrease cellular fitness. These studies support 
CPXV203 binds mature MHCI in the Golgi and releases it in the ER to accumulate and 
eventually be degraded via non-viral mechanisms, thus suggesting that CPXV203 could be used 
as a viral tool to probe natural ERAD pathways that dispose of properly-folded proteins that 
accumulate in the ER due to mistrafficking. 
 
 
Figure 1. CPXV203 co-opts the KDELR to retrieve MHCI from the Golgi. Comparison of the 
separate but complementary strategies employed by CPXV12 & CPXV203 to down-regulate 
MHCI. CPXV12 impairs nascent MHCI folding by inhibiting TAP, while CPXV203 selectively 
binds mature MHCI in the low pH environment found in the ERGIC-Golgi and then uses the 
KDELR to return to the ER where KDELR/CPXV203/MHCI can rapidly dissociate.  Listed 
organelle pH values have been reported previously20,21,22,23.  
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Structural basis of MHCI antigen presentation sabotage  
by a cowpox encoded protein  
 
 
William H. McCoy IV, Xiaoli Wang, Wayne M. Yokoyama, Ted H. Hansen, & Daved H. 
Fremont 
 
A.I.1 ABSTRACT 
Viral dissemination can be greatly facilitated by immune evasion proteins that subvert MHCI 
antigen presentation, thereby conferring the ability to evade cytotoxic T-lymphocyte (CTL) 
detection and clearance.  Here we show that the cowpox virus encoded CPXV203 protein 
inhibits MHCI surface expression by directly binding mature MHCI heterodimers, thus bridging 
MHCI to the KDEL receptor (KDELR) rescue pathway via the viral protein’s C-terminal ER-
retention sequence (KTEL). Similar to KDELR/KDEL binding, CPXV203/MHCI binding was 
found to be pH-dependent, insuring high-affinity association of KDELR/CPXV203/MHCI in the 
Golgi for retrieval to the ER. Ensuing structural studies of CPXV203/MHCI revealed that 
CPXV203 binds MHCI through conserved tapasin, CD8, & NKR interaction sites. Mutagenesis 
of the CPXV203/MHCI interface followed by cellular & biophysical studies identified the 
critical importance of CPXV203 recognition of the MHCI α3 domain and CPXV203 histidines 
that confer pH-dependent binding.  
 
A.I.2 INTRODUCTION 
Antiviral immunity relies on major histocompatibility complex class I (MHCI) molecules to alert 
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the adaptive immune system to viral invasion through the presentation of viral (non-self) 
peptides.  MHCI is a heterotrimer comprised of a heavy chain (HC), a β2-microglobulin (β2m) 
light chain, and a peptide (8-10 aa) typically derived from proteasomal degradation of cytosolic 
proteins (viral & host). The three domains of HC (α1- α3) are divided into the peptide-binding 
platform (α1/α2) and the membrane-proximal IgC (α3). The peptide cargo of MHCI is 
transported from the cytosol to the endoplasmic reticulum (ER) via the action of the transporter 
associated with antigen processing (TAP). Upon ER entry, peptide is loaded onto the HC/β2m 
heterodimer via the chaperone assembly known as the peptide loading complex (PLC) made up 
of TAP, tapasin, ERp57, and calreticulin (CRT)1.  Stable, peptide-loaded MHCI dissociate from 
the PLC and travel to the cell surface where they may engage virus-specific cytotoxic T 
lymphocytes (CTLs) capable of exerting antiviral effector functions (cytotoxicity & cytokine 
secretion)2.  
 Though viruses are known to disrupt antigen presentation at every stage from HC 
transcription to mature MHCI at the cell surface, viral proteins that interact with MHCI lumenal 
domains appear to function exclusively within the ER, as is the case for Adenovirus (AdV) E3-
19K & human cytomegalovirus (HCMV) US2. E3-19K, the first protein reported to decrease 
MHCI cell-surface expression3, impairs MHCI egress from the ER via both direct binding4 and 
TAP-inhibition5, while US2 targets MHCI for ER-associated degradation (ERAD)6. Both viral 
proteins can associate with MHCI from a variety of species (murine & human) 6,7,8,9, exhibit 
distinct class Ia allele preferences10,11, and null HC alleles have been identified9,10,11,12,13. While a 
structural understanding of E3-19K has remained elusive, MHCI chimeras & site-directed 
mutagenesis have localized the E3-19K binding site to a PLC-distal location near the N-terminus 
of the peptide-binding groove10,12. The only structural study of MHCI sabotage revealed that 
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US2 uses an Ig-like fold to bind an adjacent MHCI surface14. Though these two unrelated viral 
proteins exhibit sensitivity to polymorphism at similar MHCI surfaces, it is not yet known 
whether all viral proteins that target MHCI lumenal domains share a similar binding profile. 
Until recently, orthopoxviruses were not known to target the antigen presentation system. 
Work by the Früh & Yokoyama labs revealed that an orthopoxvirus, cowpox virus (CPXV), 
expresses two unrelated immune evasion proteins, CPXV12 and CPXV203, that use 
complementary mechanisms to block antigen presentation in both human and mouse cells15,16,17.  
CPXV12 appears to be a severely truncated C-type lection domain that has evolved to associate 
with the PLC and impair peptide loading of MHCI16. By contrast, CPXV203 is a member of the 
T4 poxvirus protein family that sequesters mature MHCI proteins within the ER by a mechanism 
dependent upon its C-terminal KTEL sequence15, a motif known to bind the KDEL receptor 
(KDELR)18 that functions in Golgi retrieval of several soluble ER resident proteins19. In vivo 
infection studies demonstrated that mutant viruses lacking both CPXV12 and CPXV203 showed 
attenuated virulence in a manner dependent upon CTLs16.  This two-pronged strategy of limiting 
peptide supply and retrieving assembled MHCI proteins effectively blocks the presentation of 
cowpox antigens at the cell surface. 
Work by Byun et al. (2007) revealed that CPXV203 does not inhibit peptide-loading (like 
E3-19K) or directly target ERAD (like US2), but instead CPXV203 operates by localizing 
mature MHCI (post-PLC) to the ER via as yet unidentified lumenal interactions15.  Though direct 
binding of CPXV203/MHCI & retrieval by KDELR could account for MHCI down-regulation, it 
is also possible that a host protein (e.g. Tpn, CRT, ERp57, BiP) may bridge CPXV203 to MHCI, 
thus explaining the ability of CPXV203 to down-regulate all MHCI that have been evaluated (H-
2Db,k,H-2Kb,d,k, & HLA-A3,-A9,-B7,-B35)15. Alternatively, two PLC components, CRT and 
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ERp57, utilize KDEL domains to remain in the ER, thus creating the potential for disrupted PLC 
function due to KDELR competition. The study of viral sabotage of antigen presentation has 
often provided significant insight into physiologic pathways of relevance to antigen 
presentation20, suggesting that studies probing the details of CPXV203-mediated MHCI retrieval 
will likely provide further insight into adaptive immunity.  
 To define the basis of how CPXV203 associates with MHCI and limits their surface 
expression, we employed biophysical & crystallographic studies to demonstrate that CPXV203 
directly binds mature MHCI. Biosensor studies revealed that CPXV203/MHCI binding is pH 
regulated (µM <--> nM) to promote Golgi retrieval of MHCI by the KDELR.  This pH 
dependent mechanism predicted histidine interfacial residues that were later observed in our 
structure of CPXV203/MHCI. CPXV203 was observed to bind conserved sites (Tpn, CD8, 
NKRs) spread across three MHCI domains (α2, α3, β2m), an epitope that should only exist in 
mature MHCI. Cellular assays confirmed CPXV203 solely targets assembled MHCI after it has 
dissociated from the PLC. Mutagenesis confirmed the functional relevance of the interface and 
identified critical contacts within the α3 interface, where CPXV203 histidines (H75 & H80) 
interact with Tpn contacts (D227 & E229). The evolution of CPXV203/MHCI pH dependent 
binding suggests a substantial survival advantage to the virus, which may be due to coordinated 
antigen presentation sabotage with CPXV12. 
 
A.I.3 RESULTS 
CPXV203 directly binds MHCI in a pH-dependent manner. 
 A direct association between CPXV203/MHCI was investigated using recombinant 
proteins in biophysical assays. Initially, direct binding was shown for CPXV203/H-2Kb:β2m 
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(KD,Kin = 480 nM) using standard surface-plasmon resonance (SPR) conditions (25o C, pHER 7.4) 
and fit to a 1:1 Langmuir model (Fig. 1a). The expansion of these studies to additional MHCI 
molecules revealed that CPXV203 exhibits similar affinity (KD,Kin = 480-11,000 nM) for all 
murine Ia alleles (D, K, L), a murine Ib allele (TL), and a primate allele (Ceat-B*12) 
(Supplementary Table I). Equilibrium & kinetic analyses produced similar dissociation 
constants with differences likely due to a more complex binding mechanism (see below). Direct 
CPXV203/MHCI association fit well with the previously published data that CPXV203 down-
regulates murine H-2D & -2K alleles, though the affinities were weaker than those previously 
reported for ER retention E3-19K (11-18 nM)10. 
 The affinity difference between CPXV203 & E3-19K led to our evaluation of a variety of 
buffer conditions that might more closely reproduce ER/Golgi conditions (divalent cations: Ca2+, 
Mg2+, Zn2+; ATP; pH 6-8). Of these changes, only low pH augmented CPXV203/MHCI affinity 
with a decrease to pHGolgi 6.0 increasing CPXV203/MHCI affinity ~50-fold (KD,Kin = 10 nM, 
Fig. 1b) through both an increased on-rate (ka) and a decreased off-rate (kd). In fact, low pH 
CPXV203/MHCI affinity (KD,Kin) for all tested murine & primate MHCI (Supplementary Table 
I) was very similar to the high affinity described for HCMV US2:HLA-A2 (pHER 7.4)21, AdV 
E3-19K (pHER 7.4)10, and the nanomolar affinity reported for KDELR/KDEL (pH 5.0)22. This 
pH enhancement was confirmed using a separate biophysical technique, biolayer interferometry 
(BLI), where the equilibrium response of CPXV203/MHCI was monitored as a function of pH 
(7.6-6.0) (Fig. 1c). Low pH equilibrium analysis was suggestive of a more complex binding 
mechanism (Supplementary Fig. 1), and so biophysical studies were pursued to evaluate 
binding stoichiometry & protein conformation as a function of pH. Light scattering experiments 
using a high-affinity MHCI mutant demonstrated 1:1 stoichiometry for CPXV203/MHCI from 
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pH 6.5-8.5 (Supplementary Fig. 2), while circular dichroism studies revealed that the 
conformation of these proteins (alone or in complex) did not change as a function of pH (data not 
shown). As the source of complex binding has yet to be identified, all of our data was 
conservatively fit using the simple 1:1 Langmuir model used in our pHER studies. These 
biophysical studies demonstrated that CPXV203 directly binds diverse MHCI ligands and that 
CPXV203/MHCI association is pH-regulated to favor association in the Golgi rather than the 
ER. 
 
Structure of CPXV203/MHCI complex 
 As further dissection of this immune evasion strategy required knowledge of the 
CPXV203/MHCI interface, we initially used low-resolution serological studies to localize the 
interface to a region below the α2-1 helix of the peptide-binding platform (Supplementary Fig. 
3) followed by crystallographic studies of CPXV203 alone and in complex with MHCI. 
Exhaustive attempts to crystallize CPXV203 (or the related protein MPX184) alone were 
unsuccessful, while CPXV203/MHCI complex crystals grew in a variety of conditions possibly 
due to MHCI/MHCI crystal contacts acting as an initial nucleation point.  Unfortunately, all 
complex crystals were plagued by extremely poor diffraction (>15Å), high mosaicity (>2o), and 
significant anisotropy, but extensive optimization of a low pH crystallization condition allowed 
us to determine the complex structure of CPXV203 bound to OVA257-264:H-2Kb:hβ2m to a 
resolution of 3.0 Å with final Rwork/Rfree of 24.6%/28.6% (Fig. 2a, Table I). Initial molecular 
replacement (MR) phases (MHCI alone) were greatly improved through extensive cross-crystal 
averaging23 (Supplementary Fig. 4), as exhaustive attempts to find a suitable MR model for 
CPXV203 proved unsuccessful. Non-crystallographic symmetry was used at all stages of 
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building/refinement, as four 1:1 CPXV203/MHCI complexes were present in the asymmetric 
unit related by two non-symmetrical two-fold axes (RMSD 0.18 Å for all Cα). Unlike the PLC-
distal interface of HCMV US2:HLA-A224, CPXV203 binds an MHCI region targeted by all host 
proteins that engage MHCI in a non-TCR orientation (Tpn, CD8, NKRs) (Fig. 2b). Comparison 
of bound MHCI to free MHCI25 did not reveal any significant changes to the MHCI fold (domain 
Cα RMSD, Table I; α3/β2m shifts, Fig. 2a). Our initial serological studies support the large 
CPXV203/MHCI interface (3,333 Å2) shown in Fig.2a and suggest that a smaller 
CPXV203/MHCI interface (883 Å2) localized to the C-terminus of the peptide-binding groove is 
a crystal contact, thus the use of both low- and high-resolution structural studies has clearly 
identified CPXV203 as the first viral protein to bind an MHCI site that overlaps with PLC 
interactions (Tpn)26,27,28,29,30,31.  
 
Structure of CPXV203 
 The single domain of CPXV203 (209 aa) is a globular β-sandwich that is extensively 
stabilized by disulfides conserved in all T4 poxvirus protein family members (Supplementary 
Fig. 5). The core of CPXV203 is a β-sandwich consisting of two parallel β-sheets (β-sheet I: 
β1, β5, β6, β10, β11; β-sheet II: β2, β3, β4, β7, β11, β8, β9) made up of anti-parallel strands 
with one parallel strand interaction (β7/β9) bridging the two segments of β-sheet II (Fig. 3a,b).  
Ten cysteines pair to form five disulfide bridges (Fig. 3b) imbuing CPXV203 with extremely 
high stability (unpublished results: Tm = 91o C). Three of these disulfides appear to stabilize the 
h4-loop-h5 arrangement. Disulfide (C6-C153) restricts h4 via Nterm/h1, while h5 is fixed by a 
disulfide (C21-C168) attaching h5 to the bottom of β1, a charge cluster sealing h5 to β sheet I 
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(h5: R176; h4-h5: D164, h5: D177, β6: E84; β1: K17), and a disulfide (C34-C183) linking h5 to 
β sheet II. A search for structurally similar proteins, Dali server32, revealed that the CPXV203 β-
sandwich core distantly resembles poxvirus chemokine binding proteins (CKBPs), like vCCI 
(RMSD 3.1 Å2, 139 aa)33 (Supplementary Fig. 6). 
 
Structural comparison with vCCI-like CKBPs 
 CPXV203 and poxvirus chemokine-binding proteins (vCCI33,34,35, A4136; CrmD-CTD37) 
have evolved three distinct ligand binding surfaces on opposite faces of the β-sandwich core 
domain through a variety of structural adaptations (Supplementary Fig. 7a).	  For instance, vCCI 
& A41 employ negative patches near the top of β-sheet II (absent in CrmD-CTD & CPXV203) 
to bind chemokines. vCCI extends this patch via a large, negatively charged loop (CKB loop 2-
3) that is absent in non-vCCI proteins (vCCI:R38-G43, 14 aa; A41:K39-Y40, 2 aa; CrmD-
CTD:I184-S186, 3 aa; CPXV203:R38-G43; 6 aa) (Supplementary Table II). In comparison, 
CPXV203 & CrmD-CTD engage their ligands using β-sheet I elements, and so these proteins 
reinvent the vCCI/A41 7-9 junction (large, flexible loop limiting β-sheet I ASA) by both 
shortening the intervening sequence (vCCI: S133-I161, 29 aa; CrmD-CTD: N247-H266, 20aa; 
CPXV203: D110-Y128, 19 aa) and introducing a new β-strand to extend β-sheet II (CPXV203 
β8:F118-S126; CrmD-CTD β8:S252-L255). CPXV203 further modifies the vCCI core by 
replacing vCCI β13-β14 with CPXV203 α helices h4 & h5, a change that may involve the 
deletion of vCCI E190-D210 (20 aa) coupled with the insertion of CPXV203 D172-Y179 (8 aa). 
For CPXV203, these topological changes remove potential steric clashes (vCCI 7-9/MHCI & 
β13-β14/MHCI (Supplementary Fig. 7b), increase solvent-accessibility of the conserved β5-β6 
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loop (source of nearly all α3 contacts), and create the primary sources for both platform (h4-h5) 
and β2m (β8 & β10) contacts (Fig. 3b, Supplementary Table III). Thus, significant 
modifications of the vCCI-fold allow CPXV203 to engage MHCI using domain-specific 
CPXV203 surfaces localized to distinct structural elements.	  
 
CPXV203 contacts conserved elements within each MHCI domain.  
CPXV203 promiscuously binds MHCI through a large, nonpolar interface divided into distinct 
regions that coordinate each MHCI domain using highly conserved MHC Ia/Ib features (Fig. 
4a,b, Supplementary Fig. 8). A comparison of the CPXV203/MHCI interface to similar 
interfaces reveals that the total BSA is significantly larger than most other complexes, CPXV203 
buries >200 Å2 more main-chain than any similar MHCI-binder, and only CPXV203 divides its 
interface nearly equally among platform (α1/α2), β2m, & α3 (Fig. 4a, Supplementary Table 
IV).  CPXV203 recognizes MHCI elements that are extremely well conserved in all murine 
pMHCI: overall, 86%; CPXV203 contacts, 91%; CPXV203 side chain (SC) contacts, 95%; 5 
invariant SC contacts. Further, CPXV203 recognizes structural features of the MHCI -fold by 
anchoring each CPXV203/domain interface (α2, β2m, α3) through a buried main chain-main 
chain (MC-MC) hydrogen bond and 2-3 main chain-side chain (MC-SC) hydrogen bonds 
(Supplementary Fig. 9a-c, Supplementary Table III). Through these MC/SC-MC contacts, 
CPXV203 recognizes seven backbone positions conserved by the MHCI-fold and coordinates 
conserved MHCI side chains within the α3 interface (Q226 & E229) required for Tpn & CD8 
association. Further, the presence of CPXV203 histidines opposite negatively charged α3 
residues (H75-D227, H80-E229) suggests these may be pH-regulated interactions, though only 
H80-E229 is close enough to form a salt bride (3.3 Å vs. 7.9 Å). During our studies, mCD1d was 
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identified as the only MHCI that escapes CPXV203 retrieval (Supplementary Fig. 10), which 
can now be explained by the charge reversal at position 229 (mCD1d H233 – CPXV203 H80) 
and the movement of mCD1d Q230 away from the interface due to an altered mCD1d loop 
conformation (Supplementary Fig. 9d). This structural investigation has helped to explain 
promiscuous MHCI retrieval by CPXV203, and it suggests that CPXV203 specifically targets a 
tri-domain interface only presented by mature MHCI. 
 
CPXV203 requires MHCI assembly for recognition. 
As both pH regulation and the complex structure suggested CPXV203 engages MHCI after it has 
left the PLC, cellular studies were undertaken to ascertain what MHCI assembly state(s) is 
targeted by CPXV203. Physical association of CPXV203 with HC was monitored in β2m-
deficient cells to determine whether physical association requires β2m. CPXV203 only co-
precipitated with Kb HC in cells with β2m (Fig. 5a), thus indicating that heterodimer assembly is 
required for CPXV203/MHCI binding. SPR studies support this conclusion, as CPXV203 did 
not bind β2m alone (pH 6.0/7.4, data not shown). To provide direct evidence that CPXV203 
targets assembled MHCI, CPXV203 was expressed by retroviral transduction of MEFs lacking 
TAP/Tpn, which express low levels of MHCI assembled with TAP/Tpn-independent peptides. 
While the TAP inhibitor CPXV12 did not affect these MHCI, CPXV203 dramatically reduced 
their cell surface expression(Fig. 5b), thereby supporting the association of CPXV203 with 
assembled MHCI. CPXV203 function was also unaffected in cells lacking CRT (Fig. 5c), 
suggesting CPXV203 does not expand CRT-retrieval of unstable MHCI to include (or 
specifically target) mature MHCI. Finally, CPXV203 does not interfere with expression of PLC 
components, as shown by normal TAP/Tpn association and normal steady-state levels of CRT 
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(Fig. 5d).  These experiments clearly demonstrate that CPXV203 associates with fully assembled 
MHCI that has dissociated from the PLC, and, further, that the CPXV203 retrieval mechanism 
does not require PLC components. 
 
Mutagenesis demonstrates the critical importance of the α3 interface.   
The functional relevance of specific interaction sites within the CPXV203/MHCI binding 
interface was determined by mutagenesis of both CPXV203 and H-2Kb. Mutants were assayed 
for loss of function by rescue of surface Kb expression or lack of physical association by co-IP. 
Single mutations in either Kb or CPXV203 from all three interaction sites shown in Fig. 4 were 
tested [α2 (Kb Q115A, A125R, T134K; CPXV203 Y161A), β2m (CPXV203 H119A) and α3 
(Kb Q226A, D227K, E229Y; CPXV203 H75A, F76A, H80A), but only α3 interface mutations 
Kb E229Y and CPXV203 F76A significantly rescued Kb surface expression (Fig. 6a,b). 
Furthermore, double mutations within the α3 interface (Kb D227K/E229Y, CPXV203 
H75A/H80A, Kb Q226A/CPXV203 F76A, Kb E229Y/CPXV203 H75A, Kb E229Y/CPXV203 
F76A) or the simultaneous mutation of interfaces α2 & α3 (CPXV203 Y161A, F76A) 
significantly enhanced Kb rescue with some mutants displaying complete ablation of CPXV203 
function (Fig. 6 a-c). Physical association (CPXV203-HA/Kb) was impaired far more 
dramatically by single α3 interface mutations than Kb rescue (Fig. 6d), though it should be noted 
that the HA-tag might impair association. Regardless, this mutagenic work demonstrates the 
critical importance of the α3 interface in CPXV203 association and retrieval of MHCI.   
 Since interface mutation clearly affected the CPXV203 function, biosensor studies were 
undertaken to probe the contribution of each interface and to identify contact residues that 
contribute to pH regulation. Equilibrium analysis (BLI, pHER 7.4) of CPXV203 & MHCI 
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mutants confirmed the three site binding geometry shown in Fig. 4 and clearly distinguished the 
CPXV203 binding site from those of E3-19K, US2, and MAb Y-3 (blocks CPXV203/MHCI) 
(Supplementary Table V). Alanine mutation of several CPXV203 residues within interface α3 
(including histidine residues 75 & 80) had a pronounced deficit in binding (similar to co-IP).  
CPXV203 H75 & H80 were selected for kinetic analysis (SPR) based on their chemical 
environment and previously described sensitivity to alanine mutation (functional & association). 
Alanine mutation of either histidine ablated the off-rate (kd) enhancement at low pH, while 
maintaining a similar on-rate (ka) enhancement (Fig. 6e, Supplementary Table VI). Thus, 
titration of α3 interface histidines extends the CPXV203/MHCI half-life (6.1 s to 73 s), while a 
separate interaction must account for the faster association (ka) at low pH. Unfortunately, the 
extremely weak affinity of the double mutant prohibited accurate kinetic analysis, though BLI 
supports the greater functional deficit observed for this mutant (Supplementary Table V).  
These investigations suggest CPXV203 promiscuously engages MHCI through critical 
pH-regulated interactions with α3 residues that have been conserved across species as essential 
Tpn (D227, E229) & CD8 (Q226) contacts, while the α2 & β2m interfaces contribute to 
complex stability with individual contacts being less essential to MHCI retrieval. 
 
A.I.4 DISCUSSION 
Viral infection of mammalian hosts can be greatly facilitated by viral proteins that confer the 
ability to evade CTL detection & clearance38, and not surprisingly, viruses have evolved a wide 
variety of strategies (degradation, impaired folding, retention) to reduce cell surface presentation 
of viral peptides on MHCI20. The cellular, structural, & biophysical results reported here provide 
a complete picture of such a strategy, as CPXV203 was shown to directly bind fully assembled 
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MHCI in a manner that is regulated via the normal pH gradient that exists between the ER and 
Golgi compartments (Fig. 7).  Though CPXV203 makes contacts to three distinct MHCI sites, 
pH regulation of the complex half-life is critically dependent on CPXV203 histidines in close 
proximity to α3 residues important for both Tpn & CD8 association.  Surprisingly, CPX203 is 
not related any other MHCI-binding protein, but rather it is most structurally similar to the 
poxvirus chemokine binding (vCCI-like) proteins.  
 
Poxvirus CKB evolution. 
CPXV203 is the first member of the T4 poxvirus protein family39 to be structurally 
characterized, and so the structural similarity between CPXV203 and vCCI-like family members 
has revealed a previously unknown evolutionary link between these poxvirus protein families. 
As the T4 family is found in more chordopoxvirinae genera (capripox, centapox, cervidpox, 
leporipox, orthopox, & yokapox) than vCCI-like proteins (leporipox & orthopox), the poxvirus 
CKB fold likely arose from a gene duplication of the more evolutionarily distant T4 poxvirus 
protein fold. Regardless of the details, the adaptation of this protein fold to structurally distinct 
ligands and unrelated functional outcomes (CPXV203/MHCI – virostealth, vCCI/CK – 
viromimicry, M-T4/apoptotic factor40 – virotransduction) provides a wondrous example of 
immune evasion evolution in Poxviridae and suggests the integral role that CPXV203 plays in 
antigen presentation disruption may not be its only function. In the future, we plan to investigate 
additional T4 poxvirus protein function(s) performed by CPXV203 through the use of MHCI-
null binders identified in this work. 
 
Promiscuous MHCI binding 
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CPXV203 evolved into an extremely promiscuous MHCI-binding protein by targeting MHCI 
sites that are conserved via a number of host proteins that engage MHCI for adaptive (Tpn, CD8) 
and innate (NKRs) immune responses.  For instance, many α2 contacts (R111, Q115, E128, 
T134) are conserved through Tpn (α2 128-136)26,27,30 and Ly49 (R111, Q115, D122)41 
interactions, while the β2m contacts primarily involve structurally conserved backbone positions 
that overlap LIR/MHCI sites42,43. The direct overlap of CD8 & Tpn contact sites (CD8: 
Q22624,44,45; Tpn: D227 & E22928) in the solvent-accessible CD loop of the α3 domain likely 
accounts for the critical nature of the α3 interface to CPXV203/MHCI binding. As the 
mammalian host has a limited ability to modify this interface to avoid viral interference, we 
would suggest that other uncharacterized immune evasion proteins may bind MHCI in a similar 
fashion to CPXV203. 
 
Regulating protein/protein interactions within the ER-Golgi pH gradient. 
Previous investigations of pH-dependent endosomal (PRL/PRLrREF, FcRn/Fc46,47) and 
ERGolgi (RAP/LRP)48 trafficking have repeatedly identified histidine residues as the pH 
sensitive component of these regulatory mechanisms.  Unlike other amino acids, histidine is well 
suited to serve this function, as small pH shifts (pH 6.0-7.5) can drastically change the charge & 
hydrogen bonding potential of this residue. As such, we began our investigation of 
CPXV203/MHCI pH regulation by focusing on interface histidines, which revealed a significant 
contribution of CPXV203 H75 & H80 to complex half-life at low pH. We suggest that these 
titratable histidines evolved to endear CPXV203 with the ability to regulate fully assembled 
MHCI in a manner that is complementary to regulation of PLC-associated MHCI by CPXV12. 
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Coordinated antigen presentation sabotage. 
For CPXV to completely block antigen presentation, it must prevent the expression of both Tpn–
dependent and –independent MHCI, and so CPXV12 & CPXV203 have evolved to target 
distinct MHCI assembly states using retention mechanisms that are cooperative yet independent 
of one another. CPXV12 targets MHCI during chaperone-mediated assembly, thus limiting its 
reach to those MHCI that require the PLC to bind peptides.  The MHCI that are able to bind 
peptide in the presence of CPXV12 are left to CPXV203, as it binds fully assembled MHCI 
through domain-specific conformational determinants conserved in most MHCI. Among these 
interactions, the α3 interface appears particularly important based on the presence of His 
residues that impart pH regulation to the CPXV203/MHCI interaction.  This pH dependence 
suggests that CPXV203/MHCI interacts most avidly in the Golgi and not the ER, thus greatly 
limiting the pool of MHCI that CPXV203 must retrieve. Though this mechanism appears 
superficially similar to CRT/KDELR retrieval of unstable MHCI from the Golgi, CPXV203 
retrieval is quite different, as CRT promotes MHCI quality control while CPXV203 targets 
quality MHCI products. MHCI retrieved by CPXV203 or detained by CPXV12 do not appear to 
accumulate within the ER, which suggests that these MHCI are identified by ER quality control 
chaperones and eliminated by ERAD without the need for specific viral targeting (US2, US11, 
mK3). By using the endogenous KDELR & ERAD pathways, the CPXV203 mechanism appears 
particularly resistant to attempts by the host to escape MHCI down-regulation via mutation, as 
these changes would likely decrease cellular fitness. Our studies support CPXV203 binds mature 
MHCI in the Golgi and releases it in the ER to accumulate and eventually be degraded via non-
viral mechanisms, thus suggesting that CPXV203 could be used as a viral tool to probe natural 
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ERAD pathways that dispose of properly-folded proteins that accumulate in the ER due to 
mistrafficking. 
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Figure 1. CPXV203 directly binds MHC Ia/Ib with higher affinity at low pH. (a,b) SPR analysis 
of CXPV203/H-2Kb:hβ2m binding at pHER 7.4 (a) & pHGolgi 6.0 (b). Neutravidin was used to 
capture site-specifically biotinylated MHCI prior to injection of increasing concentrations of 
CPXV203.  Non-specific binding was addressed via reference subtraction of a neutravidin-only 
control flow cell. SPR curves were fit kinetically using a 1:1 Langmuir model. Please see 
Supplementary Fig. 2 for equilibrium analysis and Supplementary Table I for additional 
MHCI alleles. (c) Equilibrium BLI analysis confirmed CPXV203 affinity increased for 
murine/primate MHC Ia/Ib alleles as pH decreased from 7.6 to 6.0. Neutravidin sensors captured 
site-specifically biotinylated MHCI prior to immersion in samples of varying pH with constant 
[CPXV203]. The [CPXV203] chosen for this experiment produced the lowest detectable signal 
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at pHER 7.4 for each MHCI.  Nonspecific binding was addressed using both reference subtraction 
(neutravidin) and standard blocking reagents (1% BSA + 0.05% TWEEN). 
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Figure 2. Crystal structure of CPXV203 bound to MHCI. (a) Ribbon diagram of the complex 
structure of CPXV203 (magenta), H-2Kb (blue), β2m (grey), and OVA257-264 (yellow, spheres). 
Arrow indicates insertion of MHCI in membrane. No N-linked glycosylation sites are present 
near the interface. Membrane proximal domain shifts, α3 (7.2o) & β2m (16.8o), are within the 
range observed in previous crystal structures of free MHCI24,49 (b) Comparison of 
CPXV203:MHCI binding orientation to other MHCI binders: viral (US2), chaperone (Tpn), co-
stimulatory (CD8αα), & NK receptors (Ly49C/LIR-1). Chains colored as in a. Proposed Tpn 
contact loops (α2 128-136, α3 222-229) are colored magenta with contacts identified by 
mutagenesis shown as spheres. Black arrows indicate membrane insertion of each MHCI binder. 
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Figure 3. CPXV203 contacts MHCI using both novel & conserved 2o structural elements. (a) 
Ribbon diagram of CPXV203 (R5-S191) colored according to 2o structure (cyan α helices, blue 
310 helices, green β strands, grey loops, & yellow disulfide bonds).  CPXV203 orientation is 
identical to Fig. 2a. (b) Topology diagram of CPXV203 with 2o structure coloring as in a.  
Disulfide bonds are shown as flattened balls-&-sticks with residue positions listed. The core β 
sandwich is divided into its β sheets by a dashed, grey line.  Structural elements not found in 
vCCI (PDB: 1CQ3) are highlighted in black, including the absence of a highly negatively-
charged chemokine-binding (CKB) loop.  MHCI domain contacts (colored according to Fig. 2a) 
are highly localized to these unique structural elements.  
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Figure 4. CPXV203 binds conserved elements within each MHCI domain. The 
CPXV203/MHCI complex is shown as a Connolly surface (1.4 Å probe). Relative to Fig. 2, 
MHCI was rotated -30o (y-axis), while CPXV203 was rotated 60o (y-axis).. Each domain-
specific interaction is circled on both molecules.  The US2 & E3-19K binding sites are also 
indicated. (a) CPXV203/MHCI surfaces are colored by chain (see Fig. 2) or by contact (see 
legend).  CPXV203/MHCI interfaces are labeled according to the contacted MHCI domain. Each 
MHCI domain is contacted by a CPXV203 surface that is localized to distinct structural region. 
Comparison of the CPXV203 & US2/E3-19K sites clearly shows the lack of binding site overlap 
between PLC-proximal & PLC-distal immune evasion proteins. (b) Conservation of interface 
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residues is shown for CPXV203-susceptible MHCI & T4 poxvirus proteins (see Supplementary 
Fig. 5 & 8). Backbone contacts for each interface are indicated (*). CPXV203 contacts high-
conserved MHCI surfaces, as opposed to US2 (prominent variable residues between α2-α3). 
Conservation of MHCI contact residues in the T4 family are highly localized to the α3 interface, 
which contains 4/6 CPXV203 backbone contact positions. 
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Figure 5. CPXV203 downregulation of MHCI is β2m-dependent but PLC-independent. (a) 
Hemagglutinin-tagged CPXV203 (CPXV203-HA) stably expressed in β2m-/- cells was unable to 
co-IP HC. (b) MEFs lacking TAP/Tpn were transduced with CPXV203/CPXV12-IRES-GFP and 
then MHCI surface expression was monitored by flow-cytometry. CPXV203 did not require 
these PLC components to downregulate MHCI, while CPXV12 is TAP/Tpn-dependent.  (c) 
Extension of the studies in b to CRT-/- cells showed that CPXV203 function is independent of 
the CRT. (d) Stable expression of CPXV203 did not impair TAP/Tpn association as monitored 
by co-IP, and CPXV203 did not reduce steady-state levels of CRT found in cell lysate. 
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Figure 6. Mutagenesis supports a tri-domain interface and pH regulation. (a,b,c) 3KO cells 
stably transduced with β2m & H-2Kb (3KO-β2m-Kb) were transduced with CPXV203-IRES-
GFP to evaluate the effect of CPXV203/MHCI interface mutation on surface H-2Kb remaining 
relative to untransduced cells. Comparable expression of wt & mutant proteins was determined 
using co-expressed GFP and/or western blotting. Each figure represents the data from two 
independent experiments. ** P<0.01; ***P<0.001 when compared with wt. Limited MHCI 
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escape was observed for two single α3 interface mutations (Kb E229Y or CPXV203 F76A), 
while significant Kb escape required double mutation of the α3 interface (Kb D227K/E229Y, 
CPXV203 H75A/H80A, Kb Q226A/CPXV203 F76A, Kb E229Y/CPXV203 H75A, Kb 
E229Y/CPXV203 F76A) or simultaneous mutation of interfaces α2 & α3 (CPXV203 F76A, 
Y161A) (d) Most mutant CPXV203-HA exhibited a decreased ability to co-IP H-2Kb even 
though surface H-2Kb (%) did not increase significantly.  CPXV203/H-2Kb mutations that 
significantly increased surface H-2Kb expression also exhibited a decrease in total H-2Kb 
(lysate), indicative of the release of MHCI retention15. (e) Kinetic analysis (SPR) of alanine 
mutation of α3 interface histidines (CPXV203 H75 & H80) summarized by on-rate (ka, (+)-axis) 
and off-rate (kd, (-)-axis). (f) Summary of mutagenic analysis (functional & biosensor) mapped 
to CPXV203/MHCI structure (same colors as Fig. 2) shown as cartoon loops except for the 
peptide (spheres). Mutated residues (Cα spheres) were colored to indicate whether they had a 
significant effect (red) or no significant effect (grey). CPXV203 & MHCI have been translated 
apart (x-axis) to highlight corresponding interface mutations.  
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Figure 7. CPXV203 co-opts the KDELR to retrieve MHCI from the Golgi. Comparison of the 
separate but complementary strategies employed by CPXV12 & CPXV203 to down-regulate 
MHCI. CPXV12 impairs nascent MHCI folding by inhibiting TAP, while CPXV203 selectively 
binds mature MHCI in the low pH environment found in the ERGIC-Golgi and then uses the 
KDELR to return to the ER where KDELR/CPXV203/MHCI can rapidly dissociate.  Listed 
organelle pH values have been reported previously50,51,52,53.  
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Supplementary Figure 1. Equilibrium SPR analysis of CPXV203/MHCI. (a) CXPV203/H-
2Kb:hβ2m binding at pHER 7.4 (a) & pHGolgi 6.0 (b) fit using a 1:1 Langmuir binding model 
(NLLS). Solid grey lines indicate KD using all the data, while dashed grey lines fit only part of 
the available data. Please see methods for experimental details. (c,d) These panels display the 
same equilibrium data & fits as response vs. log [CPXV203] to assess the appropriateness of a 
1:1 model. KD values are indicated by black arrows. The non-sigmoidal behavior at pHGolgi 6.0 
suggests a more complex binding phenomenon than a simple 1:1 interaction, which likely 
accounts for the discrepancy in KD,Kin vs. KD,Eq (Supplemental Table I). As independent data 
supporting a more complex model does not exist at this time, a simple 1:1 Langmuir binding 
model was used in all kinetic analyses. 
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Supplementary Figure 2. Oligomeric state of CPXV203, MHCI, and complex as a function of 
pH. (a,b) MALS was run on a DAWN HELEOS system.  All samples were applied at 1 mg/ml 
(15-42 µM) and underwent SEC (20oC) on a WTC-030S5 column prior to entering the DAWN 
system. (a) CPXV203/MHCI is a 1:1 complex at physiologic pH 7.4.  These proteins alone and 
in complex behave as single, well-behaved species with MALS MW that matches the calculated 
MW. Complex analysis utilized a high-affinity MHCI mutant (Y84A, C121S; see 
Supplementary Table VI) that did not dissociate during the course of SEC, as wt complex 
dissociated during SEC at pHER 7.4. Mass spectrometry determined MW for CPXV203 is also 
listed. (b) MALS evaluation of these proteins from pH 8.5-6.5 indicates oligomeric state (alone 
or in complex) remains constant across pH 8.5-6.5. Complex analysis in this experiment again 
utilized the high-affinity MHCI mutant (Y84A, C121S), which also exhibits pH-enhanced 
binding at low pH (data not show).   MALS analysis of wt complex (data not shown) showed a 
reduction in complex dissociation as pH decreased, which correlates with the increased affinity 
observed in biosensor experiments.   
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Supplementary Figure 3. Serological studies localize CPXV203/MHCI interface below the α2-
1 helix. (a) An SPR adaption of a sandwich ELISA was used to evaluate the interface. In brief, 
monoclonal antibodies (MAb) immobilized through amine coupling were used to capture MHCI 
prior to an injection of tetramerized CPXV203.  An increased RU signal during the injection 
would indicate that the MAb did not block the CPXV203-MHCI interface, while free 
dissociation of MHCI would indicate the MAb blocked the interface (directly or sterically).  
Examples of both outcomes are shown. (b) MHCI from our structural work is shown as 
described in Fig. 2 with labels identifying MHCI domains and the α2-1 helix.  (c) The mAb 
footprints are shown as shaded circles on MHCI.  Green indicates non-blocking antibodies, while 
red indicates blocking antibodies. MAb footprints are based on published cellular & structural 
studies (see Methods).  The AF6-88.5.3 footprint was refined in this work through the 
observation that this MAb does not recognize mutant H-2Kb (M228T) and that it competes with 
Y-3. 
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Supplementary Figure 4. Electron density of CPXV203 at various stages. (a-c) Electron density 
(2σ) in the CPXV203 region is shown using phases from molecular replacement (a), cross-
crystal averaging (b), or the final model (c). MHCI is displayed as in Fig. 4. The Cα trace of 
CPXV203 is shown in (c). Though the contiguous density available for model building was 
significantly improved by NCS, successful building required the improvement in estimated 
phases from cross-crystal averaging against a large number of MHCI complexes and free MHCI. 
(d) The cross-crystal averaged electron density (1σ) for part of CPXV203 β6 (black box) is 
shown to illustrate the electron density that was available to initiate CPXV203 model building 
using a stretch of residues with bulky side chains (H80, Y82, E84, F85). SA-OMIT and 2Fo-Fc 
maps are shown for comparison. All electron density images were produced in PyMOL using 
isomesh at the designated σ. 
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Supplementary Figure 5. T4 poxvirus protein family alignment. The sequence of CPXV203 
was aligned to T4 poxvirus proteins with a broad range of sequence identity; Taterapox 
(TATV,96%), Monkeypox (MPXV, 64%), Yokapox (YPV, 60%), Deerpox (DPV, 34%), and 
Myxoma (MYXV, 26%). Virus strains are indicated in parentheses. Residue conservation has 
been colored by similarity (ACILMPV DE FHWY HKR NQST). CPXV203 2o structure, side 
chain accessibility, and MHCI contacts are indicated. CPXV203 E162 is labeled with a blue/grey 
circle to indicate it is used in both the α2 & β2m interfaces. CPXV203 histidines are marked 
with an asterisk, except for pH-regulated interface histidines (see Fig. 6) that are labeled with 
blue/red circles. Many 2o structure prediction programs predict a C-terminal α-helix (shown in 
white), which is partially supported by what appears to be the beginning of a helix (aa 188-191) 
in the CPXV203/MHCI structure. Cysteine residues (10 conserved positions) are boxed in 
yellow, while the conserved C-terminal KDEL-variant is boxed in red. Predicted N-linked 
glycosylation sites are boxed in green.  As CPXV203 N146 is not solvent-accessible, its lack of 
glycosylation (mass spec & PNGase tx) is not surprising. Side chain solvent accessibility was 
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defined using NACCESS (1.4 Å probe); black circles, <30% accessible; grey circles, 30-60% 
accessible; white circles, >60% accessible. 
 
 
Supplementary Figure 6. Structure-based alignment of vCCI-like proteins. Dali alignment of 
CPXV203 with CKB proteins from ectromelia virus (ECTV) vCCI, cowpox virus (CPXV) vCCI, 
rabbitpox (RPV) vCCI, vaccinia virus (VACV) A41, and the C-terminal domain (CTD) of 
CPXV CrmD. Experimentally observed 2o structure is indicated (CPXV203, above; vCCI, 
below), residue conservation has been colored by similarity (ACILMPV DE FHWY HKR 
NQST), structurally-conserved residues are capitalized, symbols indicating side chain solvent 
accessibility  (see Supplementary Fig. 5) are shown (CPXV203, above; vCCI, below). Contact 
residues identified through structural studies (CPXV203, CrmD-CTD, RPV vCCI) or 
mutagenesis (ECTV vCCI) are indicated above (MHCI) or below (CK) the alignments. 
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CPXV203 histidines are marked as in Supplementary Fig. 5. PDB IDs for proteins in this 
alignment: 2GRK, 1CQ3, 2FFK, 2VGA, 3ON9.  
 
 
Supplementary Figure 7. Structural comparison of CPXV203 to vCCI-like proteins. (a) 
CPXV203 & poxvirus CKB proteins (RPV vCCI & ECTV CrmD-CTD) use three distinct 
surfaces for ligand binding. Each complex is shown as a ribbon diagram: CPXV203 (magenta), 
H-2Kb (blue), β2m (grey), OVA257-264 (yellow, spheres), CKBP (magenta), CK (cyan). Each 
poxvirus CKBP was aligned to CPXV203 using CE54. View from Fig. 4 has been rotated 90o (y-
axis). CKB loop & β-sheets are indicated. (b) Poxvirus CKBPs vCCI & CrmD-CTD were 
modeled onto the CPXV203/MHCI complex to evaluate potential steric clashes due to structural 
elements found in CKBPs (blue) but absent in CPXV203.  All topological differences between 
CKBPs & CPXV203 are listed. Connolly surfaces are shown for the severe clashes (≤2 Å). 
	   215	  
 
 
Supplementary Figure 8. Sequence alignment of MHCI. (a,b) Sequence regions have been 
restricted to CPXV203/MHCI contact regions.  MHCI 2o structure, Tpn/CD8/NKR contacts, and 
side chain solvent accessibility  (see Supplementary Fig. 4) are above the alignments. 
CPXV203/MHCI contacts are boxed in magenta, while MHCI backbone contacts are indicated 
with an asterisk above the alignment. (a) MHCI HC were included in this alignment if they are 
down-regulated or bound by CPXV203. Murine CD1d was identified as a null allele in this study 
(see Supplementary Fig. 10), and so it shown below the other alleles to highlight the lack of 
sequence conservation in CPXV203/MHCI contact regions. D227 & E229 are indicated with 
blue/red circles, as CPXV203 H75 & H80 are believed to contact these Tpn contact residues in a 
pH-regulated manner. (b) β2m sequences of potential poxvirus hosts are shown (primate, rodent, 
livestock). Tpn contacts are based on published mutagenesis work26,29,27,28, while LigPlot was 
used to identify CD8 & NKR contacts from all available complex structures (CD8/MHCI: 1AKJ, 
1BQH, 1NEZ, 3DMM; Ly49/MHCI: 1QO3, 3C8K; LIR/MHCI: 1P7Q, 2DYP). 
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Supplementary Figure 9. Magnified view of each CPXV203/MHCIdomain interface. (a,b,c) The 
CPXV203/MHCI complex is shown (as in Fig. 2) with each interface shown using sticks colored 
by chain/element (C, blue/grey,magenta; O, red; N).  Side-chains are shown for all contact 
residues, and MHCI backbone contacts are indicated (*).  Residues that appear to be involved in 
putative hydrogen-bond networks (interface contacts: yellow dots, conformation stabilizers: grey 
dots) are labeled. MHCI backbone positions are indicated (*). Interface views were rotated 
(relative to Fig. 2) for optimal viewing: a 10o (y); b 90o (y); c ~90o (x), ~150o (z). (a) CPXV203 
contacts the underside of the MHCI peptide-binding platform (α1/α2) through burial of large 
hydrophobic residues (I160 & Y161) immediately following helix-5 (h5). (b) CPXV203 uses 
parallel histidines from β-sheets I & II to coordinate β2m backbone carbonyl oxygens. The β2m 
interface MC-MC hydrogen bond is above the shown view. (c) CPXV203 extensively interacts 
with conserved MHCI residues Q226 & E229. CPXV203 H75 & H80 are directly opposite 
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conserved, acidic MHCI residues D227 & E229. (d) Comparison of MHCI crystal structures 
clearly shows conservation of the α3 loop conformation with the exception of CD1d.  The α3 
domains (181-274) of numerous MHCI structures (murine & human, Ia & Ib) were aligned by 
combinatorial extension.  A subset of those structures is shown here. 
 
 
A.I.6 METHODS 
Antibodies  
MHCI-specific monoclonal antibody (MAbs) used in SPR competition assays were obtained 
from the ATCC (H-2Kb: 25-D1.1.6, B8-24-3, Y-3), purchased from BioLegend (H-2Kb: AF6-
88.5.3, H-2Kb/Db: 28-8-6, H-2Kd/Dd: 34-1-2S, hβ2m: 2M2), or provided as a kind gift (H-2Kb: 
5F1-2-14) from S.  Nathenson (Albert Einstein College of Medicine, New York) & L. Pease 
(Mayo Clinic, Minnesota). MAbs that were not purchased from BioLegend were purified from 
ascites on a BioRad Profinia FPLC using Protein A or G. MAb footprints were assigned based 
on available literature and SPR data from this work. The TCR-like MAb 25-D1.16 (IgG1) 
specifically binds H-2Kb loaded with OVA257-264 (SIINFEKL)55,56,57. MAb B8-24-3 (IgG1) is 
specific for folded H-2Kb, it binds around the C-terminus of the α1 helix, and it is sensitive to 
D77S, R75H, L82(P/F), & K89A mutations58,59,60. MAb Y-361 (IgG2a) is sensitive to H-2Kb α2-
1 helix mutations (A150P, L141R, M138K)62, insensitive to epitope destruction via 
formaldehyde63, and competes with MAbs 25-D1.16, B8-24-3, & AF6-88.5.3 in SPR analyses 
(unpublished results).  MAb AF6-88.5.364 (IgG2a) binds to folded H-2Kb/mβ2m below the α2-1 
helix, as indicated by hβ2m substitution65, sensitivity to domain swaps (KbLd)66, competition 
with Y-3 (SPR data not shown), and sensitivity to M228T mutation (SPR data not shown). MAbs 
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28-8-6 (IgG2a) & 34-1-2S (IgG2a) recognize folded H-2Kb/Db & H-2Kd/Dd/Kb (α3 domain), 
respectively.  MAb 2M2 (IgG1) recognizes a linear determinant that is available on native hβ2m 
(cross-reactive with bovine not murine, unpublished results).  MAb 5F1-2-14 recognizes folded 
H-2Kb and is sensitive to α2-2 helix mutations G162D, E166K, & N174K62. MAbs used in flow-
cytometry & IP assays have been described previously. 
 
Peptides 
Peptides for in vitro MHCI refolding were synthesized by Fmoc chemistry and then subjected to 
reverse-phase HPLC for purification.  Peptides were chosen based on available MHCI crystal 
structures or personal suggestions by A. Stout (NIH Tetramer Core Facility). Peptides were 
resuspended at >1 mM in ddH2O, DMSO, or 6M GdnHCl, as dictated by peptide solubility. The 
peptides used in this study are as follows: H-2Kb (OVA257-264, SIINFEKL)67, H-2Kd 
(TYQRTRALV, Flu NP147–155)68, H-2Kk (SV40560–568, SEFLLEKRI)69, H-2Dd (Env-modified 
PA9, IGPGRAFYA)70, H-2Dk (Middle T-antigen389-397, RRLGRTLLL), H-2Dq (Her2395-404, 
PDSLRDLSVF), H-2Ld (p29,YPNVNIHNF)71, Ceat-B*12 (nef20-28, LLRARGETY), Mamu-
A*01 (Tat28–35, TTPESANL)72, Patr-B*0802 (Polyprotein1527-1536, AGCAWYELTP), H-2Q9-H-
2Db (Minor capsid protein VP324-32, HALNVVHDW), H-2Kb-HLA-A*0201 (OVA257-264, 
SIINFEKL)67, HLA-A*0201-H-2Kb (Insulin2-10, ALWMRLLPL). 
 
Cell lines  
Murine embryo fibroblast (MEF) B6/WT3 (WT3) and mutant MEFs including TAP1-deficient 
cells (FT1-), Tapasin-deficient cells  (Tpn-/- ), calreticulin-deficient cells (CRT-/- ), β2m-deficient 
cells (B6.B2M-) and triple knockout fibroblasts (Kb-/- Db-/- β2m-/-; 3KO) were all derived from 
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C57BL/6 (H-2b) embryos and have been  described previously73.  The H-2Kb and CPXV203 
mutants were stably expressed in the indicated cells by retroviral expression vectors pMXsIG15 
and pMIN73, respectively.  Cells transduced by pMIN were selected by neomycin while GFP+ 
cells from pMIG transduced lines were enriched by cell sorting.   
 
Immunoprecipitations, immunoblot and cross-linking 
For co-immunoprecipitations, cells were lysed in PBS with 1.0% digitonin (Wako, Richmond, 
VA) and protease inhibitor cocktails (Roche) for 60 min.  Post-nuclear lysates were then 
incubated with indicated antibodies+Protein A-sepharose (Sigma) or anti-HA sepharose (sigma) 
for HA tagged CPXV203 for 1h.   After washes, coprecipitated proteins were eluted by boiling in 
LDS sample buffer (Invitrogen).  For cross-linking treatment, cells were incubated with 1-2mM 
DSP (Thermo) in PBS for 2h at 4oC. The cross-linking was terminated with 25mM Tris-HCl 
pH7.4 before the cells were lysed in PBS with 1.0% NP-40.  Following immunoprecipitation 
cross-linked proteins were eluted by boiling in LDS sample butter with 2.5% β-Mercaptoethanol.  
Immunoblot of precipitated proteins was performed following SDS-PAGE separation.  Specific 
proteins were visualized by chemiluminescence using the ECL system (Thermo).  
 
Flow cytometry 
All flow cytometric analyses were performed using a FACS Calibur (Becton Dickinson).  Data 
were analyzed using FlowJo software (Tree Star).  Staining was performed as described74.  PE-
conjugated goat anti-mouse IgG (BD Pharmingen, San Diego, CA) was used to visualize MHCI 
staining.  PE-conjugated anti-mouse CD1d (eBioscience) was used to detect surface CD1d.  GFP 
signal representing CPXV203 transduced cells were collected in the FITC channel.   
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Protein cloning, expression, purification 
CPXV203ΔKTEL (aa 1-205, MVI-LHV) was amplified from Cowpox virus (Brighton Red) 
genomic DNA (kindly provided by R. M. L.Buller), ligated into the mammalian expression 
vector pHLsec (AgeI-KpnI), expressed via large-scale transient transfection (HEK293F)75, and 
then purified using NiNTASEC. Mammalian CPXV203ΔKTEL was also produced using its 
authentic signal peptide (aa -16-205, MRS-LHV) to verify the signal peptide cleavage site (IYS-
MVI) predicted by SignalP3.076. Bacterial CPXV203ΔKTEL (maMVI-LHV) & CPXV203-BirA 
(maMVI-LHV-[Thr-BirA-6His]77) were produced from inclusion bodies (IBs) using established 
methods (pET28a78, autoinduction79, arginine refolding80) followed by IEXSECHIC. A 
truncated, soluble CPXV203 domain (aa (0)5-190, mRCE-FDR) identified using limited 
proteolysis followed by mass spec (LPMS)81 was also refolded from IBs. SDS PAGE, mass spec 
(24955, ND, 23838 (SeMet-labeled), 27361, ND), and N-terminal sequencing (etgMV…, 
MVIRR…, aMVIR…, ND, ND) confirmed the expected MW & construct boundaries for 
mammalian (no glycans indicated) & bacterial CPXV203 constructs. Recombinant MHCI were 
produced by refolding bacterial IBs as previously described80. H-2Kb (aa 0-280, mGPH-PST)/H-
2Kd (aa 0-283, mGPH-VSN) constructs were produced in house, while H-2Dd, H-2Dk, H-2Dq, H-
2Kk, H-2Ld, Mamu-A*01, Patr-B*0802, H-2Q9-H-2Db, H-2Kb-HLA-A*0201, HLA-A*0201-H-
2Kb were produced by the NIH Tetramer Core Facility. H-2Db biotinylated monomer (LCMV 
Gp33, KAVYNFATC) was purchased from Beckman Coulter. Chimeric mCD1d-Fc was 
obtained from R&D Systems. All MHCI include human β2m (hβ2m, aa 0-99, mIQR-RDM) 
unless otherwise noted. MHCI captured via neutravidin in biosensor assays include a C-terminal 
biotin ligase site. Mutations were introduced using QuikChange/Phusion site-directed 
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mutagenesis kits. CPXV203/MHCI proteins (wt & mutants) were purified to >95% homogeneity 
and produced single, monodispersed SEC peaks (4oC; HEPES sizing buffer: 150 mM NaCl, 10 
mM HEPES pH 7.5, 0.01% Azide) corresponding to the MW of a monomer/heterotrimer, 
respectively. Selenomethionine (SeMet)-labeled protein were produced in E. coli using 
autoinduction79, and >90% incorporation was verified by mass spec. Signal-peptide/cloning 
artifacts are indicated as lower-case aa. 
 
 
Crystallization & data collection 
CPXV203(aMVI-LHV, SeMet-labeled)/MHCI(OVA257-264:H-2Kb:hβ2m) complex was prepared 
for crystallization by incubating an excess (>4:1) of refolded CPXV203 with MHCI at 4oC for 
30min in low pH/salt sizing buffer (50 mM NaCl, 30 mM MES pH 5.6, 0.01% Azide), purifying 
the complex by SEC in the same buffer, concentrating (Vivaspin) to 7-7.5 mg/ml, and finally 
buffer-exchanging (Pierce Zeba Spin Desalting Column) into crystal wash buffer (20 mM 
Ammonium acetate pH 6.9, 0.01% azide) supplemented with 0.5 mM OVA257-264. Diffraction-
quality crystals of CPXV203/MHCI were grown at 20oC by streak seeding into hanging drops of 
0.5 µl complex (7.5 mg/ml) + 0.5 µl reservoir solution (10% PEG 6000, 4% Glucose, 2% 
Ethylene glycol, 0.1 M tri-K citrate pH 5.55, 0.01% Azide).  After crystals grew to 0.025-0.1 mm 
(3-10 days), they were dehydrated by adding 4.5 ul of dehydration solution #1 (15% PEG 6000, 
5% Glucose, 2.5% Ethylene glycol, 0.1 M tri-K citrate pH 5.55, 0.01% Azide) to the drop and 
then adding dehydration solution #2 (40% PEG 6000, 30% Glucose, 15% Ethylene glycol, 0.1 M 
tri-K citrate pH 5.55, 0.01% Azide) to the 500 µl reservoir over 2 days (100 µl/6 hr x 2, then 200 
µl/6 hr x 3; extensive optimization of published protocols82). The final dehydration condition 
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was cryoprotective, so no additional reagents were added prior to liquid N2 flash freezing. This 
protocol improved diffraction from >20 Å to 3-8 Å and greatly reduced mosaicity.  X-ray 
diffraction data was collected at ALS (Advance Light Source) beamline 4.2.2 on the NOIR 
detector to 3.0 Å resolution.  A total of 720 frames (1o oscillation) was collected, though the last 
180 frames were excluded from final processing due to radiation damage. Crystals belong to 
space group P1 (a,b,c = 88.07 Å, 88.09 Å, 105.99 Å; α,β,γ = 76.06o, 69.32o, 66.59o) with four 
CPXV203/MHCI complexes per asymmetric unit (ASU) and a solvent content of 51.8%. Due to 
high mosaicity (1.7o), the XDS software package83 was used to index, integrate, & scale the data 
to yield a 98.3% complete dataset at 3.0 Å (Rmrgd = 10.8%, Table I). Exhaustive attempts to 
crystallize CPXV203 and the T4 protein from Monkeypox (MPX-Zaire-1979) MPX184 (64% 
identity) alone were unsuccessful (mammalian/bacterial, reductive methylation84/pentylation85, 
in situ proteolysis86, LPMS81 truncations native/methylated/pentylated). 
 
Structure determination & refinement  
BALBES87 was used to identify RBM5:H-2Kb:mβ2m (PDB code 2CLZ)88 as the optimal 
molecular replacement model for MHCI in the CPXV203/MHCI complex, which was then used 
(without peptide/H2O) to identify four molecular replacement (MR) solutions using Phaser 
(Phenix suite89). Exhaustive attempts to identify a MR solution for CPXV203 proved 
unsuccessful (poxvirus CKBPs, PHYRE90 & I-TASSER91 models), and the anomalous signal 
strength was not sufficient to identify SeMet sites (SOLVE/RESOLVE89, SHARP92) for SAD 
phasing. Though initial MR density in the CPXV203 region (identified via MAb blocking 
studies) was quite poor, extensive cross-crystal averaging23, using DMMULTI93, improved it to 
the point where CPXV203 could be built in Coot94. The averaging strategy included 4-fold non-
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crystallographic symmetry (NCS) averaging of the four CPXV203 regions (initially defined 
using NCSMASK93 as a 20 Å sphere at the center of CPXV203 density) and cross-crystal 
averaging of each MHCI domain (α1/α2, α3, β2m) with the densities from six H-2Kb/bm8 crystal 
structures: CD8αα/MHCI (1BQH)95, TCR/MHCI (1FO0)96, MHCI (2CLZ)88, TCR/MHCI 
(2OL3)97, Ly49C/MHCI (3C8K)98, MAb/MHCI (3CVH)99. Inclusion of a structure required a 
visible improvement in CPXV203 density following averaging. Rotation & translation matrices 
were calculated using SUPERPOSE100. Iterative rounds of Coot model building & mask 
optimization (MAMA101) were required to produce the final cross-crystal averaged map for 
CPXV203 model building, while the initial MHCI models were built using only the MR phases.  
Simulated annealing composite omit maps (Phenix Autobuild89) were used to reduce model-bias 
throughout model building. The CPXV203/MHCI structure was refined (Phenix Refine89) to a 
final Rfree 28.6% and Rwork of 24.6% (see Table I for complete crystallographic statistics). 
Overlapmap102 was used to calculate the real-space correlation coefficients of the CPXV203 
model at various stages (MR = 0.53, four-fold NCS = 0.61, cross-crystal averaging = 0.65, final 
composite omit map = 0.85). PROCHECK103 was used to assess model quality. The final 
CPXV203/MHCI model contains four copies each of CPXV203 (R5/C6- R190/S191/V192), H-
2Kb (G1–P277), β2m (0M-99M), OVA257-264,; and 149 water molecules. 
 
Structure analysis & figures 
The DALI server32 was used to identify structural homologues and to create structure-based 
sequence alignments.  Combinatorial extension (CE)54 was used to calculate root mean square 
deviation (RMSD) values between different proteins/domains. The DYNDOM104 webserver 
(DomainSelect) was used to calculate domain motions. LIGPLOT105 was used to enumerate H-
	   224	  
bonds & atomic contacts (≤4 Å), while NCONT106 was used to identify long-range electrostatic 
contacts (3.5-5 Å).  NACCESS107 was used to analyze BSA (1.4 Å probe) and to characterize 
interfaces as polar/neutral/hydrophobic. APBS108 was used for electrostatics calculations. Shape 
complementarity was calculated using SC109 and displayed graphically using GRASP110. 
ClustalW2111 was used for general sequence alignment, while the Scorecons server was used to 
calculate positional conservation within alignments112. ALINE113, TOPDRAW114, and PyMOL115 
were used to create figures unless otherwise noted. 
 
Biosensor Measurements 
Surface plasmon resonance (SPR) experiments were run on a Biacore T100 (GE Healthcare) in 
either standard HBS-EP+ (10 mM HEPES (pH 7.4), 150 mM NaCl, 3.4 mM EDTA, 0.005% v/v 
Triton X-100, 0.01% Azide) or low pH MBS-EP+ (25 mM MES (pH 6.0), 150 mM NaCl, 3.4 
mM EDTA, 0.005% v/v Triton X-100, 0.01% Azide). MHCI chips were generated by activating 
Biacore CM5 chips (0.2 M EDC/50 mM NHS, 5 µl/min, 7 min), coupling 0.1 mg/ml neutravidin 
(20 mM Na citrate (pH 4.5), 5 µl/min, 7 min), saturating available sites (1 M ethanolamine-HCl 
(pH 8.0), 5 µl/min, 7 min), washing away non-covalently bound protein (0.1% SDS, 5 µl/min, 1 
min), and then capturing site-specifically biotinylated MHCI ligand (equilibrium: <1000 RUs, 
kinetics: <500 RUs). Flow cell 1 (F1) (neutravidin) was used as the control flow cell, as non-
specific binding to neutravidin was observed to be equivalent to neutravidin-captured control 
proteins (scTCR, WNV DIII, various MAbs). Experiments were performed at 20 µl/min and 
25oC. Proper SPR experimental technique was followed in all assays116. Reversing ligand-
analyte orientation produced kinetic & equilibrium constants within 2-fold. MAb competition 
chips were prepared by amine-coupling (CM5) control MAb (Biacore αGST) to F1 and αMHCI 
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MAbs to F2-F4. Competition (direct or steric) was then evaluated by using dual inject over F1-
F4: Inj#1, MHCI capture (F2-F3); Inj#2, CPXV203 tetramers or controls 
(buffer/neutravidin/MAbs). Free MHCI dissociation during Inj#2 indicated competition between 
capture & detection reagents, while binding during Inj#2 indicated capture & detection do not 
compete. Biolayer-interferometry (BLI)117 was used as a separate biophysical approach to 
evaluate CPXV203/MHCI binding. BLI affinity/kinetic experiments were run using a similar 
approach to the above SPR assays: HBS-EP+/MBS-EP+ supplemented with 0.05% (v/v) 
TWEEN & 1% BSA, immobilized MHCI on streptavidin sensors, soluble CPXV203. These 
assays confirmed the previously observed SPR equilibrium binding constants (within 2-fold). 
General CPXV203/MHCI pH dependence was evaluated by monitoring the increase in BLI 
signal (CPXV203 binding) as pH decreased (7.6-6.0) for seven immobilized MHCI proteins (H-
2Dk, H-2Kb, H-2Kk, H-2Ld, TL, Mamu-A*01, & Patr-B*0802).  [CPXV203] was held constant, 
while pH was varied via NaH2PO4/ Na2HPO4 ratio (50 mM Na Phosphate, 150 mM NaCl, 3.4 
mM EDTA, 0.005% v/v Triton X-100, 0.05% (v/v) TWEEN, 1% BSA 0.05% Azide).  
 
Light scattering & Circular Dichroism 
SEC-MALLS(Multi-angle laser light scattering) experiments were run to determine the absolute 
molecular mass of proteins in solution.  These experiments were run on a Wyatt Dawn 
HELEOS-II 18-angle light scattering detector and Wyatt Optilab rEX refractive index monitor 
linked to a Waters HPLC system118. Dynamic light scattering (DLS) experiments were 
performed using a DynaPro-801TC as previously described119. MALLS & DLS experiments 
were run at 20oC with [protein] = 1 mg/ml.  Various buffers (H/M/TBS) were used for MALLS 
& DLS experiments to evaluate the effect of pH on oligomeric state of proteins (alone and in 
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complex). Protein 2o structure and Tm were assayed using a Jasco-810 instrument (Jasco Inc., 
Easton, MD) equipped with Peltier temperature controller using standard methods120, 121. 
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A.IV.1 Introduction 
A biophysical investigation into amino-terminally extended peptides bound to MHCI was 
initiated due to the observation by members of the Carreno lab that in vitro expansion of both 
HCMV- and cancer-specific CTLs could be amplified by the addition of a single N-terminal 
asparagine residue to the peptide. Their experiments sought to isolate a polyclonal CTL 
population specific for a chosen health threat (HCMV or melanoma), expand these CTLs using 
DCs expressing HLA-A2 SCT, and then use these cells to treat the chosen condition.  Please 
refer to previous publications for a thorough review of SCT design, expression, and evaluation1–
4. The peptides presented in these constructs were CMV pp65 (495-503, NLVPMVATV) and the 
melanoma peptide G209-2M (gp100 209-217: T210M, IMDQVPGSV), both of which have been 
crystallized with HLA-A2 previously5–7.  These 9mer peptides are bound to HLA-A2 using 
traditional P2 (L/M) and P9 (V) anchor residues, and they should present P1/P4/P5/P8 TCR 
contacts (N/P/M/T and I/Q/V/S, respectively). Like any other MHCI, N-terminal addition of an 
amino acid to these peptides would be expected to change the epitope presented to CTLs through 
significant side chain and backbone perturbations.  
Amino-terminal extension of these peptides began as an unintended cloning artifact used 
as a negative control in CTL expansion studies, but upon evaluation, the amino-terminally 
extended SCT (AT-SCT) was observed to greatly improve CTL expansion over SCT for both 
viral & cancer systems. Flow-cytometry of these DCs using a high-affinity scTCR tetramer 
(Altor Bioscience) specific for pp65/HLA-A2 revealed that SCT stained quite well, while the 
AT-SCT did not appear to be recognized by the scTCR. In fact, AT-SCT & single-chain dimer 
(β2m-HLA-A2, SCD) loaded with endogenous peptides stained equivalently in these 
experiments, suggesting the amount of TCR-reactive AT-SCT must either be below the detection 
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limit of this reagent or non-existent. The scTCR reagent recognized both SCT and disulfide-
trapped SCT (dtSCT) equivalently, while it displayed increased staining (~16-fold) for dtAT-
SCT, suggesting stabilization of a TCR-reactive species.  
While peptides often extend beyond the ends of the peptide-binding groove of MHCII 
molecules, the architecture of the MHCI groove normally coordinates the peptide N- and C-
termini, resulting in longer peptides bulging at their center8–10. Though uncommon, examples of 
MHCI with extended peptides have been described11–13 and even structurally-characterized14,15. 
It is important to note that these two structural investigations both described peptides extended 
by a single glycine, whose inherent flexibility did not significantly perturb normal peptide-MHCI 
binding outside of the loss of N/C-terminal hydrogen bonds. Long, glycine-rich C-terminal 
extensions have been utilized to link the peptide to β2m, though HC Y84A/C mutation was 
incorporated to alleviate linker perturbation of the pMHCI epitope2. Importantly, the pp65/G209-
2M constructs described above do not include this mutation, and so they may present an altered 
pMHCI epitope. 
Our collaborators brought this phenomenon to our attention in order to formulate a 
structural hypothesis as to why an N-terminal peptide extension might increase CTL expansion 
in their system.  Initially, I proposed that either variable signal peptide cleavage or ERAAP 
trimming16,17 might inefficiently process the AT-SCT into SCT, resulting in DCs that present 
sufficient SCT for CTL expansion but not enough to exhaust the cells or possibly induce 
apoptosis (potentially occurring when DCs present SCT alone). Various computational 
approaches were utilized to evaluate signal peptide cleavage as well as the potential 
consequences of N/C-terminal extension of both peptides.  In addition, I attempted to produce 
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recombinant forms for both pp65 SCT and AT-SCT with Michelle	  Hapak for tetramer decay 
assays to address the previously observed affinity difference between these MHCI. 
 
A.IV.1 Protein expression & purification 
The production of recombinant SCT and AT-SCT constructs was pursued in order to prepare 
reagents for tetramer decay experiments that could assess any general change in the affinity of 
the CTL population for SCT vs. AT-SCT.  
 E. coli expression and refolding of SCT. Bacterial expression of IBs and MHCI 
refolding/purification were previously described in Chapter 2. All MHCI constructs in this 
project were refolded using protocol #2, and additional purification strategies were based on 
strategies develop for H-2Kb:β2m. My participation in this part of the project involved the initial 
pp65 SCT and AT-SCT expression trials (2 trials/construct: media preparation, IB purification, 
MHCI refolding, & SEC/IEX/HIC purification).  Following these initial trials, I helped Michelle 
Hapak (Carreno lab) to design and run additional expression & purification trials to attempt to 
optimize the refolding yield of these constructs. 
Results. The 9mer (SCT) and 10mer (AT-SCT) constructs of HLA-A2 did not refold with 
sufficient efficiency to allow for purification of quality material for flow-cytometry or 
biophysical analysis (Fig. 1a). Comparison of the initial refolding attempts to the H-2Kb dtSCT 
suggested that there was a serious barrier to refolding for the HLA-A2 constructs, as no peak of 
an appropriate MWSEC was present for these constructs. Also, the total soluble material from 
equivalent preparations (IB from 1/5 L of culture) was 8-fold smaller for pp65 SCT/AT-SCT 
when compared to the control, even though every step of expression and purification for these 
constructs was done in parallel. I estimate the yield/purity for these preparations was <100 µg 
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with <<50% properly folded. Attempts to increase the amount of properly folded MHCI by 
increasing the amount of IBs (1.6 L of culture) and the time spent refolding (1  2 days) was 
not successful for either AT-SCT (Fig. 1b) or SCT (data not shown). SDS PAGE analysis 
suggests that the majority of the soluble material in these preparations contains inappropriate 
intermolecular disulfides (Fig. 1c). The lack of refolding by CMV pp65 SCT was surprising yet 
potentially very informative, as it may suggest a common impediment to in vitro folding of these 
SCT constructs. 
Advice for future SCT expression in E. coli. A primary concern that came to my 
attention during this work was whether the N-terminal methionine was effectively removed 
during expression of the HLA-A2 SCT constructs, as its presence effectively converts both 
constructs into AT-SCTs that may or may not be able to be refolded. The efficiency of N-
terminal methionine removal is dependent on the nature of downstream residues, and a number 
of non-preferred residues, have been identified, including Asn18.  As such, I highly suggest N-
terminal sequencing these IBs. If the N-terminal methionine is present, then future protein 
expression should evaluate protocol changes designed to optimize removal of this residue. 
Specifically, a mutant form of methionine aminopeptidase (METAP) that is far more efficient at 
N-terminal methionine removal upstream of non-preferred residues (including Asn) could be co-
expressed with the SCT constructs19.  It might also be possible to fuse the SCT construct to a 
self-cleaving protease, Npro20.  Npro should refold and release SCT with an authentic N-
terminus in standard arginine refolding buffer, though the refolding efficiency of SCT in such a 
protein milieu may not be especially high.  If N-terminal sequencing reveals that the N-terminal 
methionine was removed, then the HLA-A2 SCT/AT-SCT constructs may need to be mutated to 
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open the C-terminus of the peptide-binding groove (HC Y84A) in order to produce recombinant 
material. 
 
A.IV.3 Computational analysis 
 Signal peptide cleavage assessment. This analysis served to address the hypothesis that 
the enhanced priming phenotype of AT-SCT might be due to signal peptide cleavage at multiple 
locations within the peptide, thus creating a variety of pMHCI with a fraction able to stimulate 
CTLs specific for pp65/HLA-A2 or G209-2M/HLA-A2 due to preferred cleavage following 
LYA. As these analyses predict AT-SCT is expressed with the N0 residue (Fig. 2a), an 
alternative hypothesis was proposed to describe how AT-SCT might be processed post-
translocation into SCT. Specifically, ERAAP-trimming of AT-SCT into SCT was suggested, 
which lead to N-terminal sequencing of surface pp65 AT-SCT/SCT constructs by the 
Carreno/Hansen groups. This work confirmed both constructs reach the cell surface with the 
expected N-termini, though a minor population of ERAAP-trimmed material could have escaped 
detection due to either the detection limit of N-terminal sequencing or the limited sample 
quantity (AT-SCT, 0.5 pmol; SCT, 6 pmol).  At this point, the data supports that both AT-SCT 
and SCT reach the cell surface, but no evidence yet directly shows that the extended 10mer 
peptide is able to occupy the peptide-binding groove.   
 Evaluation of altered peptide register in Coot. In order to address the question of 
whether the amino-terminally extended peptides could occupy the HLA-A2 peptide-bind groove, 
I modeled each peptide variant into the available, high-resolution pp65/HLA-A2/β2m (1.60 Å, 
PDB: 3GSO)6 and G209-2M/HLA-A2/β2m (1.80 Å, PDB: 1TVH)5 structures in Coot. The 
initial pMHCI models did not modify the peptide backbone, but rather they were built through in 
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silico mutation followed by rotamer optimization. The 10mer was extended from the C-terminus 
of the peptide-binding groove. No significant steric clashes were predicted for these peptides, 
though the anchor residues for the 10mer were not ideal.  Importantly, this modeling clearly 
shows that the potential TCR contact residues are quite different in for the 9mer (pp65, 
N/P/M/T; G209-2M, I/Q/V/S) and 10mer models (pp65, N/V/P/A/V*; G209-2M, N/D/Q/F/V*), 
suggesting that AT-SCT form responsible for CTL expansion cannot be loaded in the manner 
proposed by this model. 
Computational model of SCT and AT-SCT. Further modeling was pursued to address 
the possibility of altered peptide-binding modes by HLA-A2 in the SCT format. FlexPepDock21, 
a high-resolution peptide-docking implementation of the Rosetta framework, was used to model 
the 9mer (NLVPMVATV) and 10mer (NNLVPMVATV) pp65 peptides onto the peptide-
binding platform of the 1.6 Å structure of the 9mer complex, pp65/HLA-A2/β2m (PDB: 
3GSO)6. Two 10mer complexes (N-terminal & C-terminal extensions) were created within 
Coot22 using the 3GSO experimental data for real-space refinement prior to running 
FlexPepDock. As expected, peptide extensions (N- or C-termini) weaken the affinity of the 
complex as estimated by the FlexPepDock energetic score for the top 10 structures of each 
model (9mer, -359; 10merNterm, -225; 10merCterm, -221). Also, the RMSD from the initial 
structure (Fig. 3a) illustrates the larger variety of models predicted for the less-energetically 
favored complexes.  
A comparison of the top ten models for the control 9mer to the 10mer models with a C-
terminal extension clearly supports the previous Coot modeling in that this peptide register 
presents significantly altered TCR contacts (Fig. 3b,c). Surprisingly, the N-terminally extended 
10mer models could be divided into a small subset (Fig. 3d) that appear likely to significantly 
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perturb TCR recognition and a larger subset that maintain the primary TCR contacts (Fig. 3e). 
Though the latter group introduces two novel TCR contacts, the possibility exists that a 
significant percentage of cells in a CTL population may still respond to the AT-SCT form 
shown.  In conclusion, I would suggest that the enhanced CTL expansion observed for AT-SCT 
in the Carreno lab may be due to a mixture of pMHCI conformations similar to those shown in 
Fig. 3c-e, which may be more effective than SCT alone due to lower cell surface presentation of 
the stimulating epitope. 
 
 
 
Figure 1. Refolding CMV pp65 SCT and AT-SCT from IBs. (a) Comparison of recombinant 
yields from various SCT constructs prepared in parallel using the same amount of IB (material 
from 1/5 L of culture). The control SCT is the OVA-mβ2m-Kb dtSCT (Y84C, C121S). Neither 
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pp65 construct appeared to refold efficiently according to both MWSEC and absorbance. The 
dominant pp65 peaks eluted with a MWSEC that suggests a dimer of SCT/AT-SCT caused by a 
β2m swap, while the control eluted at the MWSEC expected for an MHCI with a series of flexible 
linkers (RHydro  MWSEC). Further, the pp65 peak heights are ~8x smaller than the control 
peak.  Finally, SDS PAGE analysis of the pp65 fractions suggested that the majority of soluble 
material contained misappropriate intermolecular disulfides. (b) The amount of IB and refolding 
timeline were both increased (1/5 L to 1.6 L, 1 day to 2 days) to attempt to increase the yield of 
properly folded pp65 constructs. The amount and MWSEC of the aggregate for both pp65 
constructs was observed to increase dramatically without a significant increase in properly folded 
material. The SEC profile from the CMV pp65 AT-SCT is shown as an example of this result. 
(c) SDS PAGE analysis (±BME) of the SEC purification in b clearly showed that majority of the 
material contained misappropriate intermolecular disulfides. Colored bars indicate the fractions 
examined on this gel. The 50 kDa band present in the –BME fractions may have been properly 
folded AT-SCT, but additional purification (HIC/IEX) yielded too little of this material to 
conclusively determine it’s folding status. 
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Figure 2. Signal peptide cleavage programs predict desired N-termini. (a) A variety of 
computational programs (SignalP3.023, Signal-BLAST24, Phobius25, and Signal-3L26) were used 
to predict the signal peptide cleavage position for SCT & AT-SCT constructs (CMV pp65 & 
G209-2M).  All four programs predict cleavage following LYA of the β2m signal peptide used 
in these constructs, suggesting that the constructs are processed as intended. The only construct 
that might have some degree of 2o site cleavage is actually the CMVpp65 SCT itself. (b) 
Example outputs from SignalP3.0 for the CMV pp65 constructs are shown to compare predicted 
N-termini for the SCT and AT-SCT constructs.  Note the increased S-score for SCT that may 
permit a degree of 2o site cleavage, while the AT-SCT clearly begins with NNL according to C, 
S, & Y scores. 
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Figure 3. Modeling CMV pp65 peptides on HLA-A2. FlexPepDock21 was used to model the 
9mer (NLVPMVATV) and 10mer (NNLVPMVATV) peptides onto the peptide-binding 
platform of the 9mer complex, pp65/HLA-A2/β2m (PDB: 3GSO)6. Two 10mer complexes (N-
terminal & C-terminal extensions) were created within Coot22 prior to running FlexPepDock. 
Each simulation creates 200 models that are ranked according to the Rosetta energy score, and 
the top ten models (lowest scores) are provided as output (score, rmsBB, PDB). (a) The 
distribution of the models generated for each complex is shown as a plot of energetic score vs. 
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rmsBB (RMSD from the starting structure). While the control 9mer complex exhibits a tight 
distribution with a low energy score, the 10mer complexes have much higher energy scores with 
a broader population distribution. (b-e) Models for each complex are shown: 3GSO HC, blue 
Connolly surface; green sticks, 3GSO peptide; grey sticks, FlexPepDock models). TCR contacts 
& anchor residues are indicated. Bolded TCR contacts are not present in 3GSO. (b) The control 
simulation (9mer) presents the expected TCR contacts. Peptide positions (P1/2/4/5/8/9) are 
indicated. (c) The C-terminal extension replaces 3/4 TCR contacts and adds a novel C-terminal 
contact. (d,e) The N-terminal models can be split into those that greatly perturb (d) and those 
that maintain (e) the main TCR contacts. Both groups introduce novel N-terminal TCR contacts, 
though these new contacts appear to have less disruptive potential in e. Arrows above TCR 
contacts indicate significant movement (3-6 Å) towards the TCR. 
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A.III.1 Doctoral candidate contribution to manuscript.  
A series of computational models were created of HLA-B*0702 loaded with the influenza A 
(H1N1) peptide NP418-426 (PR8: LPFDRTTVM) to complement in vitro studies assessing the 
effect of peptide variation on CTL cross-recognition as assayed by IFNγ ELISPOT.  Modeling of 
this MHCI was required as no crystallographic information was available at the time of 
publication. InsightII was used to create five MHCI models using a variety of HLA-B molecules 
(HLA-B*2709, -B*1501, -B*3501, B*5301, and -B*5703)1–5. The model that most favorably 
accommodated the NP418-426:HLA-B*0702 sequence was based on the structure of HLA-B*2709 
(PDB 1K5N)1. This model indicates that amino acids at P4, P5, and P8 are solvent exposed and 
point away from the peptide binding cleft, while amino acids at P6 are directed toward the α1 
helix of the binding groove. This modeling work suggested that the virus escapes CTL detection 
through variation of exposed TCR contact residues (P4, P5) or by varying the overall peptide 
conformation (P6).  
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A.III.2 Abstract 
To escape immune recognition, viruses acquire amino acid substitutions in class I human 
leukocyte antigen (HLA)-presented cytotoxic T-lymphocyte (CTL) epitopes. Such viral escape 
mutations may (i) prevent peptide processing, (ii) diminish class I HLA binding, or (iii) alter T-
cell recognition. Because residues 418 to 426 of the hypervariable influenza A virus 
nucleoprotein (NP418-426) epitope are consistently bound by class I HLA and presented to CTL, 
we assessed the impact that intraepitope sequence variability has upon T-cell recognition. CTL 
elicited by intranasal influenza virus infection were tested for their cross-recognition of 20 
natural NP418-426 epitope variants. Six of the variant epitopes, of both H1N1 and H3N2 origin, 
were cross-recognized by CTL while the remaining NP418-426 epitope variants escaped targeting. 
A pattern emerged whereby variability at position 5 (P5) within the epitope reduced T-cell 
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recognition, changes at P4 or P6 enabled CTL escape, and a mutation at P8 enhanced T-cell 
recognition. These data demonstrate that substitutions at P4 and/or P6 facilitate influenza virus 
escape from T-cell recognition and provide a model for the number, nature, and location of viral 
mutations that influence T-cell cross-recognition. 
 
 A.III.3 Introduction  
Cytotoxic T-lymphocytes (CTL) kill virus-infected cells and release antiviral cytokines upon 
recognition of short viral peptides displayed on the cell surface by the class I HLA molecule6. 
Virus-derived peptides are processed in the cytoplasm by proteasome degradation of viral 
proteins7, shuttled into the lumen of the endoplasmic reticulum (ER) by the transporter-
associated protein, and loaded into the basket-like groove of the class I molecule. Class I HLA 
molecules await peptide loading in the ER and demonstrate specificity for viral peptides with 
particular anchor residues representing a good fit for the class I HLA binding groove. Once 
stable class I HLA-peptide complexes are formed, the class I molecule and its peptide cargo are 
transported via the Golgi apparatus to the cell surface, where the complex is anchored to the 
plasma membrane8,6,9,10. CTL then survey class I HLA-presented peptides on the cell surface. 
Viral peptides must therefore be processed, specifically bound by class I HLA, and presented at 
the plasma membrane for CTL to distinguish infected cells from uninfected tissue. 
A high mutation rate is one of many mechanisms utilized by viruses to escape detection 
by the immune system. Mutations within the genome allow viruses to accumulate and select for 
amino acid substitutions that (i) inhibit proteasome processing and viral peptide generation11,12, 
(ii) alter anchor residues within viral peptides to diminish class I HLA binding 
specificity13,14,15,16, or (iii) reduce immune recognition of the class I HLA-peptide complex by 
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varying amino acids that come in contact with the T-cell receptor17,18,19,20,21. While viral 
mutations might be advantageous for escaping immune detection, such flexibility can cost the 
virus in terms of replicative fitness. In order to maintain reproductive fitness and structural 
integrity, viruses must temper their use of genetic flexibility as a means of immune escape. 
Influenza viruses have the well-documented ability to escape detection by various 
immune epitopes13,18,19. A priori, investigators often assume that variable regions of the virus 
represent poor immune targets because such regions will not be consistently processed, 
presented, or recognized22,23. However, we along with others continue to find that a 
hypervariable stretch of the influenza virus nucleoprotein consisting of residues 418 to 426 
(NP418-426) is presented to CTL by different HLA-B alleles (B*0702 and B*3501) in spite of 
extensive viral variability within this epitope24,18,19,25. Moreover, NP418-426 is a dominant immune 
epitope24,18,19,25. The consistent processing and presentation of NP418-426 by class I HLA can be 
explained by the finding that different influenza virus isolates cannot mutate the proline located 
at position 2 (P2) within the epitope because elimination of this proline reduces viral fitness2627. 
Little to no variability is found at the methionine P9 anchor as well. These facts lead to the 
unique observation that strain-to-strain variability does not abrogate class I HLA presentation of 
the influenza virus NP418-426 epitope and that CTL respond to this consistently presented viral 
epitope in an immunodominant fashion. 
In this study we took advantage of the anchor residue conservation that prompts the 
NP418-426 epitope to be consistently presented to CTL by investigating the functional impact that 
influenza virus intraepitope variability has on CTL recognition. The amino acid alignment of 
human influenza A (H1N1 and H3N2) virus nucleoprotein molecules identifies 20 unique NP418-
426 peptide sequences which demonstrate amino acid diversity between the anchors. We infected 
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HLA-transgenic mice intranasally with influenza virus and tested CTL from these animals for 
their ability to recognize each of the 20 NP418-426 variants. These 20 NP418-426 sequences represent 
a natural “recombinant library” of viral epitopes that the immune system has and will face. The 
resulting data demonstrate a gradient of viral substitutions whereby CTL recognition diminishes 
depending upon the number of viral substitutions and their location within the epitope. 
Understanding how intraepitope variability impacts CTL recognition is discussed in terms of 
eliciting immune responses to variants of influenza. 
 
A.III.4 Materials and Methods 
Amino acid alignments. Full-length sequences of human influenza A (H1N1 and H3N2) 
virus NP were initially accessed from the NCBI Influenza Virus Resource database on 26 
November 26 200728. Following removal of identical protein sequences, the NP sequences were 
aligned, identifying 20 unique amino acid sequences at positions 418 to 426 of the NP molecule. 
Synthetic peptides were generated for the 20 NP418-426 amino acid sequences and single amino 
acid NP418-426 variants at ≥95% purity by the Molecular Biology Research Facility at the 
University of Oklahoma Health Sciences Center and Mimotopes and utilized in enzyme-linked 
immunospot (ELISPOT) and peptide binding assays. 
A second amino acid alignment was performed on human influenza A (H1N1 and H3N2) 
virus NP full-length protein sequences accessed from the NCBI Influenza Virus Resource 
database on 17 April 2008 revealing an additional human influenza A (H3N2) virus NP418-426 
sequence (LPFEKPTVM)28. 
Influenza PR8 virus infection of mice. All animal studies were approved by the 
Institutional Animal Care and Use Committee at the University of Oklahoma Health Sciences 
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Center. Six- to eight-week-old male and female HLA-B*0702 transgenic H-2KbDb double-
knockout C57BL/6 mice (obtained from the laboratory of Francois Lemonnier at the Institut 
Pasteur) were inoculated intranasally with a 1,000 50% egg infectious dose (EID50) of mouse-
adapted influenza A/Puerto Rico/8/34 (PR8) virus (kindly provided by the laboratory of David 
Woodland at the Trudeau Institute) or sterile endotoxin-free saline (mock infection) at a volume 
of 10 µl per nostril. Mice were monitored daily for weight loss. Splenocytes were harvested at 12 
days postinfection and passed through a cell strainer, and lymphocytes were isolated by 
centrifuging cells over a lympholyte-M density gradient (Cedar Lane). Lymphocytes were stored 
at −180°C in 90% fetal bovine serum and 10% dimethyl sulfoxide. 
Lymphocytes were measured for peptide specific gamma interferon (IFN-γ) secretion via 
ELISPOT assay. Briefly, 105 lymphocytes were incubated with 10 µg/ml synthetic influenza 
virus peptide, medium alone (negative control), 10 µg/ml synthetic human immunodeficiency 
virus Nef peptide RPMTYKAAL (negative control), and 4 µg/ml concanavalin A (positive 
control) in RPMI 1640 culture medium supplemented with 10% fetal bovine serum and 1% 
penicillin-streptomycin for 24 h at 37°C in triplicate wells of a 96-well membrane 
(polyvinylidene difluoride)-bottomed plate coated with anti-IFN-γ antibody (Cell Sciences). The 
assay was performed according to the manufacturer's instructions. The number of IFN-γ spots 
produced per well was enumerated with a Zeiss KS ELISPOT reader. The data generated are 
illustrated as the number of spot-forming units (SFU) per 105 lymphocytes. 
Peptide binding assay. An HLA-B*0702 PolyScreen kit (Pure Protein) was used to 
determine peptide concentrations necessary to inhibit 50% polarization (IC50). Briefly, 
fluorescein isothiocyanate-labeled reference peptide and soluble HLA (sHLA) were incubated 
with each peptide until equilibrium of peptide replacement was reached. The fluorescent 
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polarization of the control peptide as read on an Analyst AD plate reader (Molecular Devices) 
and a dose-response curve were used to calculate peptide IC50 values29–31. 
Molecular modeling. HLA-B structures from the Protein Data Bank (PDB) were first 
restricted to those bound to nonamer peptides. When multiple structures were available for a 
single HLA-B allele, the highest-resolution structure was selected. Five structures (1XR8-HLA-
B*15013, 1K5N-HLA-B*27091, 2CIK-HLA-B*35012, 1A1O-HLA-B*53014, and 2BVP-HLA-
B*57035; PDB codes precede the HLA designations) were loaded into InsightII (Accelrys), and 
each of the selected structures was used to build a model of HLA-B*0702 bound to the PR8 
peptide LPFDRTTVM via the homology and consensus module. This module threads the 
unknown structure's amino acid sequence through the known structure without altering the 
position of the peptide backbone. Side chain clashes were minimized by varying rotamers. These 
models then underwent visual inspection of the PR8 peptide to eliminate side chain clashes, 
which were then minimized via manual or auto-rotamer adjustments of peptide or HLA groove 
residues. Models were compared to identify general trends in peptide conformation and side 
chain placement. The model that best accommodated the HLA-B*0702 PR8 sequence (1K5N-
HLA-B*2709)1 with a minimum of unfavorable peptide-HLA interactions was then exported as a 
PDB file. The final figure was generated using this PDB file imported into PyMOL32. 
 
A.III.5 Results 
The amino acid sequence of NP418-426 is highly variable in influenza A H1N1 and 
H3N2 virus strains. Data demonstrating that an epitope is presented by class I HLA in spite of 
viral divergence are scarce. Our direct epitope discovery data (Fig. 1), combined with CTL-
driven studies in other laboratories, provide the rare demonstration that HLA-B molecules 
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consistently present the NP418-426 epitope regardless of influenza virus strain-to-strain 
variability33,18,19,25,34. Influenza virus variability does not impact proteolytic processing, 
translocation into the ER, or loading into class I HLA. Given steady epitope presentation, we 
took advantage of the considerable amino acid variability within NP418-426 of different influenza 
A virus subtypes to generate “nature's” recombinant NP418-426 epitope library for subsequent 
testing of CTL tolerance to various intraepitope substitutions. The data are positioned to provide 
fundamental insights for how efficiently CTL cope with viral epitope diversification. 
We began with an amino acid alignment of influenza A (H1N1 and H3N2) virus NP 
molecules from human isolates from 1918 to 2007 to assess the variety and nature of NP418-426 
peptide sequences among influenza A virus subtypes28. Alignments were compared to the PR8 
virus. The alignment revealed 20 NP418-426 variant sequences (13 of subtype H1N1 and 11 of 
subtype H3N2) (Table 1). Four NP418-426 peptide sequences (LPFDRTTIM, LPFERATVM, 
LPFDKSTVM, and LPFDKSTIM) are apparent in both H1N1 and H3N2 influenza virus strains. 
The influenza A H1N1 virus isolates varied at P4 to P6 and at P8 within the NP418-426 epitope, 
and subtype H3N2 isolates had mutated amino acids at P4 to P9. P6 exhibited the greatest 
diversity in amino acids accommodated at a particular position within the NP418-426 ligand for 
both influenza A H1N1 and H3N2 virus isolates although H1N1 and H3N2 strains displayed a 
tendency for different amino acids at this position (in subtype H1N1, Thr; in subtype H3N2, 
Ser). In addition, influenza A H1N1 virus isolates demonstrated a propensity for Asp at P4 and 
Ile at P8 while reported influenza A H3N2 virus strains favored Glu at P4 and equally displayed 
Ile and Val at P8. Based on the frequency of particular amino acids at P4 to P8 within the NP418-
426 epitope, influenza A H1N1 and H3N2 virus isolates exhibit the consensus sequence 
LPFDKTTIM (H1N1) and LPFEKST(I/V)M (H3N2) (substitutions are underlined). These data 
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demonstrate the following: (i) the breadth of NP418-426 peptide sequences among human influenza 
A H1N1 and H3N2 virus isolates; (ii) the substantial variability at internal amino acid positions 
within the NP418-426 ligand; and (iii) despite 40 years of concurrent circulation within the human 
population, the segregation of the assortment of NP418-426 peptide sequences at P4, P6, and P8 
between human influenza A H1N1 and H3N2 strains. 
NP418-426 variants exhibit various degrees of CTL cross-reactivity during PR8 virus 
infection of HLA-B*0702 transgenic mice. Upon identification of 20 NP418-426 peptide 
sequences among influenza A H1N1 and H3N2 strains, we tested splenocytes isolated from 
influenza PR8 (H1N1) virus-infected HLA-B*0702 transgenic H-2Kb−/−Db−/− mice for NP418-426-
specific T-cell cross-reactivity measured by IFN-γ production. Ten HLA-B*0702 transgenic 
mice were inoculated intranasally with 1,000 EID50 of murine-adapted PR8 and monitored daily 
for weight loss (data not shown), and splenocytes were isolated 12 days postinfection. Synthetic 
peptides were generated for 20 human influenza A virus NP418-426 sequences (nine H1N1 strain, 
seven H3N2 strain, and four H1N1/H3N2 strain sequences) (Fig. 2 and Table 1) and incubated 
at 10 µg/ml with 105 lymphocytes for 24 h in triplicate wells of an anti-IFN-γ antibody-coated 
plate. Lymphocytes incubated with medium only and with 10 µg/ml HLA-B*0702 human 
immunodeficiency virus Nef peptide RPMTYKAAL (data not shown) served as negative 
controls, and lymphocytes cultured with 4 µg/ml concanavalin A served as a positive control. 
The parental PR8 NP418-426 epitope (LPFDRTTVM) and six NP418-426 variant peptides 
(LPFDRTTIM, LPFDKTTIM, LPFDRPTIM, LPFDKSTIM, LPFDKSTVM, and LPFDKATIM) 
were clearly recognized, eliciting an average of at least 20 SFU/105 lymphocytes in 10 PR8 
virus-infected mice (Fig. 2 and Table 1). Of these six NP418-426 variant peptides, three NP418-426 
peptides are derived from H1N1 influenza A virus strains, and three NP418-426 ligands have been 
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identified in both influenza A H1N1 and H3N2 strains. One NP418-426 variant, LPFDRTTIM, 
exhibited greater IFN-γ T-cell reactivity than PR8 NP418-426 LPFDRTTVM, generating an 
average of 168.5 and 103.6 SFU/105 lymphocytes, respectively. Thirteen NP418-426 variant 
peptides (five H1N1 strain, seven H3N2 strain, and one H1N1/H3N2 strain peptides) generated 
between 4 and 10 SFU/105 lymphocytes during murine PR8 virus infection, including the NP418-
426 variant found in the newly emerged H1N1 flu (swine flu) strain (LPFERATVM). All NP418-
426 peptide sequences restricted to H3N2 influenza A virus strains elicited an average IFN-γ T-
cell response below 10 SFU/105 lymphocytes (Table 1). 
In Table 1 H1N1, H1N1/H3N2, and H3N2 NP418-426 peptide sequences were aligned to 
the PR8 peptide (LPFDRTTVM) in ascending order by the average number of IFN-γ spots 
(SFU/105 lymphocytes) for 10 PR8 virus-infected HLA-B*0702 transgenic mice, indicating 
amino acid positions involved in the PR8 NP418-426-specific T-cell response. Substantial NP418-
426-specific T-cell cross-reactivity was observed only for NP418-426 variants derived from either 
influenza A H1N1 strains or H1N1/H3N2 strains. All NP418-426 peptides whose sequences were 
limited to influenza A H3N2 strains failed to generate a sizeable IFN-γ T-cell response. 
Amino acid substitutions at P4 to P6 decreased IFN-γ T-cell reactivity during murine 
PR8 virus infection while exchanging Val at P8 for Ile increased the IFN-γ ELISPOT response 
(Tables 1 and 2). IFN-γ ELISPOT responses of PR8 virus-infected HLA-B*0702 transgenic 
mice to NP418-426 variant peptides indicate that amino acids at P4 to P6 and at P8 dictate antigen-
specific T-cell cross-reactivity. The majority of amino acid substitutions at these positions 
decrease IFN-γ T-cell reactivity; only a Val → Ile substitution at P8 increased the NP418-426-
specific IFN-γ ELISPOT response. Tremendous amino acid variability is observed at P6 of the 
NP418-426 epitope. At P6 variant NP418-426 peptides exhibit both conservative (Thr → Ser) and 
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nonconservative (mutations of Thr to Ala, Pro, Gln, and Ile) amino acid substitutions. 
Considerably less amino acid variability is observed at P4, P5, and P8 in terms of the variety of 
different amino acids detected at these positions and the conservative nature of amino acid 
substitutions (Asp → Glu at P4, Arg → Lys at P5, and Val → Ile at P8). The data generated 
indicate that both conservative and nonconservative amino acid substitutions within the NP418-426 
epitope can impact T-cell recognition and that the influenza virus exhibits the most flexibility at 
P6. 
NP418-426-specific CTL cross-reactivity is not correlated with HLA-B*0702 binding 
affinity. We next determined whether the binding affinity of NP418-426 variant peptides to HLA-
B*0702 correlated with the NP418-426-specific IFN-γ T-cell responses observed above; it is 
possible that NP418-426 peptides exhibiting a higher affinity for HLA-B*0702 may be presented 
on the surfaces of target cells in greater abundance for CTL recognition. Therefore, we measured 
the relative HLA-B*0702 binding affinity of the 20 naturally occurring NP418-426 synthetic 
peptides in a competitive binding assay29–31. Various concentrations of synthetic NP418-426 
peptide were incubated with sHLA-B*0702 and an HLA-B*0702 fluorescein isothiocyanate-
labeled reference peptide, and the IC50 of synthetic NP418-426 was recorded. Table 1 illustrates the 
relative HLA-B*0702 binding affinity of the synthetic NP418-426 variant peptides [high-affinity 
binders, log(IC50 nM) of <3.7; medium-affinity binders, log(IC50 nM) of 3.7 to 4.7, low-affinity 
binders, log(IC50 nM) of 4.7 to 5.5; very-low-affinity binders, log(IC50 nM) of ≥6.0]. The PR8 
NP418-426 peptide LPFDRTTVM had the highest binding affinity for HLA-B*0702 [1.8 log(IC50 
nM)]. The average HLA-B*0702 binding affinity for variants generating at least 10 SFU/105 
lymphocytes during murine PR8 virus infection is equivalent to NP418-426 variants which elicited, 
on average, less than 10 SFU/105 lymphocytes, indicating that the binding affinity of the NP418-
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426 variant peptides did not correspond to a gain or loss in T-cell cross-reactivity. These data 
demonstrate that all variants tested have a high binding affinity and suggest that T-cell cross-
reactivity to variant NP418-426 peptide sequences is heavily influenced by interaction with P4 to 
P6 and P8 of NP418-426. 
Amino acid residues at P4 to P6 and P8 within the NP418-426 epitope dictate CTL 
recognition. Naturally occurring variants of NP418-426 often differ by multiple amino acid 
substitutions, making it difficult to ascertain how a given amino acid substitution or position 
within the epitope contributes to T-cell recognition. In order to unravel the individual impact that 
naturally occurring NP418-426 amino acid substitutions have upon T-cell cross-reactivity following 
PR8 virus infection, we synthesized epitopes differing by a single amino acid from the parental 
NP418-426. Lymphocytes isolated from the spleens of nine HLA-B*0702 transgenic mice 
inoculated intranasally with PR8 virus were assessed for IFN-γ ELISPOT reactivity to NP418-426 
peptides containing a single amino acid substitution at P4 to P6 with respect to the sequence of 
PR8 NP418-426 (Fig. 3A and B; Table 2). The introduction of these single amino acid 
substitutions into the PR8 NP418-426 epitope had a negligible impact on HLA-B*0702 binding 
(Table 2). Surprisingly, at P4 both conservative (Asp → Glu) and nonconservative (Asp → Gly) 
amino acid substitutions eliminated PR8 NP418-426 IFN-γ ELISPOT cross-reactivity. On average, 
the LPFERTTVM and LPFGRTTVM (substitutions are underlined) synthetic peptides generated 
fewer than 10 SFU/105 lymphocytes. At P5, the conservative Arg → Lys amino acid substitution 
dramatically reduced IFN-γ ELISPOT reactivity but did not completely eliminate CTL 
recognition. Splenocytes incubated with the LPFDKTTVM synthetic peptide generated an 
average of 20.1 SFU/105 lymphocytes in comparison to PR8 NP418-426, which generated an 
average of 161.4 SFU/105 lymphocytes. As stated above, naturally occurring H1N1 and H3N2 
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NP418-426 variants exhibit the most variability at P6. The five P6 single amino acid NP418-426 
variants varied in IFN-γ ELISPOT reactivity. The conservative Thr → Ser substitution did not 
substantially increase or decrease CTL recognition while the nonconservative substitutions of 
Ala, Pro, and Ile for Thr drastically decreased IFN-γ ELISPOT reactivity, and the Thr → Gln 
variant virtually eliminated IFN-γ ELISPOT reactivity. Substitutions at P4 and P6 substantially 
altered the cross-recognition of natural NP418-426 variants. 
Although the majority of the 20 naturally occurring H1N1 and H3N2 NP418-426 variant 
sequences exhibit variability at amino acids at P4 to P6 and P8, a conservative amino acid 
substitution is found at P7 and P9 in one variant each. The IFN-γ ELISPOT response of 
lymphocytes isolated from the spleens of four PR8 virus-infected HLA-B*0702 transgenic mice 
indicates that the Thr → Ile substitution at P7 does not substantially alter CTL recognition while 
the Met → Ile amino acid substitution results in decreased IFN-γ ELISPOT reactivity (Fig. 3C 
and D; Table 2). The paucity of NP418-426 variants containing a P7 Thr → Ile substitution in 
nature is most likely due to the minimal impact of such a substitution on CTL cross-recognition. 
In contrast, although a Met → Ile amino acid substitution at P9 decreases NP418-426 cross-
reactivity (Fig. 3C and D; Table 2) and has not been shown to alter viral fitness27, this 
substitution is not common in influenza H1N1 and H3N2 virus NP molecules (Fig. 4). 
These data indicate that amino acid residues at P4 to P6 and P8 of the NP418-426 epitope 
mediate CTL recognition. Amino acid substitutions located at P4 eliminated IFN-γ ELISPOT 
cross-reactivity while variability at P5 drastically reduced CTL recognition. Conservative 
variability at P6 did not substantially impact CTL cross-reactivity while nonconservative amino 
acid substitutions substantially decreased or virtually eliminated IFN-γ ELISPOT reactivity. 
Influenza virus strains containing the P8 Val → Ile single amino acid substitution have been 
	   269	  
isolated in the human population and were shown to have increased IFN-γ ELISPOT reactivity in 
the previous section (Fig. 2 and Table 1). CTL cross-recognition is largely mediated by the 
position and less by the nature of the amino acid substitution(s). 
Molecular modeling of the HLA-B*0702 PR8 NP418-426 peptide complex. The data 
presented thus far indicate that amino acids at P4 to P6 and P8 within the NP418-426 ligand are key 
determinants of NP418-426-specific T-cell cross-reactivity. It is plausible that amino acids at these 
positions may influence T-cell cross-reactivity by directly contacting the T-cell receptor or by 
altering the conformation of the NP418-426 peptide in the class I HLA-B*0702 binding groove. To 
address the orientation of NP418-426 amino acid residues at P4 to P6 and P8, the PR8 NP418-426 
ligand (LPFDRTTVM) was modeled in the HLA-B*0702 binding groove (Fig. 4). The PDB 
structures of five HLA-B molecules (HLA-B*2709, -B*1501, -B*3501, B*5301, and -B*5703)1–
5 were loaded into InsightII, and each structure was used to model the HLA-B*0702 
LPFDRTTVM peptide complex via the homology and consensus module. Without altering the 
position of the peptide backbone, side chain clashes were minimized by manual or auto-rotamer 
adjustments of the peptide or HLA binding groove residues. The model that most favorably 
accommodated the HLA-B*0702 LPFDRTTVM sequence was based on the structure of HLA-
B*2709 (PDB 1K5N)1. Molecular modeling indicates that amino acids at P4, P5, and P8 are 
solvent exposed and point away from the peptide binding cleft while amino acids at P6 are 
directed toward the alpha-1 helix of the binding groove. Therefore, amino acid substitutions at 
P4, P5, and P8 are poised to dictate T-cell cross-reactivity by directly interacting with the T-cell 
receptor (TCR). This may explain why both nonconservative and conservative amino acid 
substitutions at these positions dramatically impact NP418-426-specific IFN-γ ELISPOT cross-
reactivity in the PR8 murine model. In contrast, a nonconservative substitution at P6 is more 
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likely to shift the conformation of the NP418-426 peptide in the HLA-B*0702 binding groove by 
interacting with residues of the alpha-1 helix, indirectly altering T-cell recognition. 
 
A.III.6 Discussion 
CTL responses decrease morbidity and mortality and are key to viral clearance during human 
influenza A virus infection. As a foil to CTL detection, amino acid substitutions in peptide 
anchor positions and at CTL receptor contact residues hinder influenza virus class I HLA 
presentation and CTL recognition, respectively13,18,19. Over time, influenza A viruses have 
emerged with anchor position substitutions in epitopes NP380-383/HLA-B*0801 and NP383-
391/HLA-B*2705 that act to abolish class I HLA binding. Amino acid variability at P4 to P9 of 
the immunodominant HLA-B*0702 and -B*3501 influenza A virus NP418-426 epitope has been 
reported to modulate but not abolish recognition by CTL clones specific for older/newer 
influenza virus strains. Our laboratory has substantiated by direct peptide elution that 
hypervariability does not inhibit presentation of the NP418-426 epitope for three viral strains and 
two HLA-B alleles25. Epitope NP418-426 represents a natural recombinant system that maintains 
processing, binding, and presentation so that the impact of intraepitope variability on CTL 
targeting can be examined. To our knowledge, no one has identified a consistently presented 
hypervariable epitope such that the give and take between CTL and natural viral mutations can 
be assessed. 
The IFN-γ ELISPOT reactivity of 20 natural NP418-426 influenza virus variants 
demonstrated that amino acid substitutions at P4 to P6 and P8 impact T-cell recognition. The 
contribution of individual amino acid substitutions at P4 to P9 of the NP418-426 peptide was 
determined by measuring the IFN-γ ELISPOT reactivity of lymphocytes isolated from the 
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spleens of PR8 virus-infected HLA-B*0702 transgenic mice incubated with synthetic PR8 NP418-
426 peptides containing single amino acid substitutions. Data revealed that conservative and 
nonconservative amino acid variability at P4 eliminated CTL recognition. Likewise, conservative 
amino acid substitutions at P5 and P8 were able to dramatically modulate the NP418-426-specific 
IFN-γ CTL response. The conservative Arg → Lys P5 substitution substantially decreased CTL 
IFN-γ cross-reactivity while the Val → Ile P8 substitution increased CTL recognition following 
PR8 infection. In contrast, only nonconservative P6 substitutions impacted CTL cross-
recognition. The conservative Thr→ Ser P6 substitution yielded no substantial in the NP418-426-
specific IFN-γ CTL response. 
We were somewhat surprised that conservative biochemical substitutions such as Asp → 
Glu at P4 or a P5 Arg → Lys diminished recognition by the TCR. One can envision a scenario 
whereby a P4 Asp → Glu substitution would not cost a pathogen much in terms of viral fitness 
or protein structure, yet this conservative substitution would provide the virus with a level of T-
cell escape. The intraepitope location of a substitution is also key, and these data illustrate the 
dominant role that P4 plays in NP-specific immunity. Here, we see that subtle amino acid 
substitutions, when positioned correctly, can diminish immune recognition of a pathogen-derived 
epitope. 
The results obtained here must be interpreted with caution as they may differ from studies 
performed with high-affinity T-cell clones. At 12 days postinfection, lymphocytes isolated from 
the spleens of infected mice represent a polyclonal population of T cells that contains few, if any, 
T cells with high-affinity TCRs. Also, our data using antigen-specific T cells obtained from the 
spleen may vary from that obtained from T cells harvested from draining mediastinal lymph 
nodes. Finally, these experiments must be repeated using T cells (preferably from the lungs) of 
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HLA-B*0702-positive influenza virus-infected patients to confirm the patterns of NP418-426 T-cell 
cross-reactivity observed in mice. 
Molecular modeling of the NP418-426 peptide in context of the HLA-B*0702 binding 
groove provides a model for how immune receptors interact with this epitope. Amino acids 
located at P4, P5, and P8 are solvent exposed and available for direct interaction with the TCR. 
In contrast, residues at P6 are directed toward the alpha-1 helix of the peptide binding groove 
and are less accessible to the TCR. Nonconservative amino acid substitutions at P6 may slightly 
alter the conformation of the peptide in the HLA-B*0702 peptide binding cleft, but it is unlikely 
that P6 changes directly interact with the TCR. These data suggest that viruses modulate CTL 
recognition by accumulating one or two conservative amino acid substitutions at peptide 
positions in direct contact with the TCR. However, it should be noted that the majority of 
naturally occurring human H1N1 and H3N2 NP418-426 peptide sequences that influence CTL 
recognition exhibit variability at two or more peptide positions. Factors that influence viral 
mutagenesis must extend well beyond the selective pressures exerted by T-cell recognition. 
It is interesting that during 40 years of concurrent circulation in the human population, 
influenza A H1N1 and H3N2 virus strains have evolved a propensity for different amino acids at 
P4 of the NP418-426 epitope (for H1N1, Asp; for H3N2, Glu). Aspartic acid has not been reported 
at P4 of the NP418-426 sequence in influenza A H3N2 strains isolated in the United States since 
1978, 10 years after the introduction of the H3N2 subtype into the human population in 1968. 
Glutamic acid has not been absent at P4 in H1N1 isolates from the United States, its appearance 
in human circulation has been sporadic at best28. As demonstrated in this study, variability at P4 
eliminates IFN-γ CTL cross-reactivity. Based upon these observations, we hypothesize that viral 
strain specificity at P4 deters CTL cross-reactivity between the H1N1 and H3N2 influenza A 
	   273	  
virus subtypes and that amino acid variability at P5, P6, and P8 modulates CTL recognition 
within a subtype. 
We have so far focused upon viral substitutions within, and CTL recognition of, an 
influenza virus NP epitope. What can we learn from HLA molecules of the B7 supertype that 
interact with this epitope? HLA-B*0702 is found in roughly one-fourth of the population (26% 
and 16% of the Caucasian and African American populations of the United States, respectively), 
and presentation by other members of the B7 supertype family would extend presentation of 
NP418-426 to one-third or more of the population35,36. Indeed, we find that epitope NP418-426 is 
presented by HLA-B*3501, a member of the B7 supertype and an allele found at a phenotype 
frequency of 12% and 10% in Caucasian and African American populations of the United States, 
respectively35. Additional experiments will need to confirm presentation by all alleles within the 
B7 supertype, yet the extraordinary variability that influenza virus strains exhibit within this 
epitope (others have classified this region as hypervariable)24 certainly suggests that the cellular 
immune system has focused considerable pressure on this segment of the virus. It is important 
for vaccine architects to recognize that variable sequences bracketed by conserved anchors can 
indicate robust class I HLA-presented immune targets. 
In summary, observations including direct HLA-B*0702 epitope elution following 
infection by divergent viral strains justifies a detailed characterization of the consistently 
presented influenza A virus epitope NP418-426. This particular epitope cannot avoid class I HLA-
B7 presentation, and CTL cross-recognition experiments demonstrate that influenza virus utilizes 
substitutions at P4 to P6 and P8 within this epitope to diminish and/or abrogate immune 
targeting. The natural variants tested indicate that the virus is constrained in its ability to 
substitute amino acids, yet by accumulating one or two conservative intraepitope substitutions, 
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the influenza virus is able to thwart cross-targeting of NP418-426. These data additionally show 
that particular substitutions do not disrupt CTL recognition, which is useful information for the 
design of CTL-eliciting therapeutics. Finally, it is conceivable that other class I HLA-B alleles 
present immunodominant epitopes from regions of variability; the HLA-B locus plays a critical 
role in controlling several viruses33,37–39, and future testing is needed to determine the 
presentation of epitopes spanning more variable regions to CTL. 
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Figure 1. Mass spectrometric identification of NP418-426 during infection with three influenza A 
virus strains. Class I HLA peptides eluted from naïve and influenza virus-infected HeLa cells 
were separated by reverse-phase high-pressure liquid chromatography, and fractions were 
sprayed via nanospray into a Q-Star Elite mass spectrometer. Naïve (data not shown) and 
infected mass spectrometric (MS) ion maps were aligned and visually compared to identify ions 
unique to the infected MS spectra. Despite tremendous amino acid variability within the 
influenza virus NP418-426 epitope, the NP418-426 peptide was eluted from sHLA-B*0702-
transfected HeLa cells and identified during infection with three influenza virus A strains: PR8 
(H1N1) (A), A/Oklahoma/7485/01 (7485; H1N1) (B), and A/Oklahoma/309/06 (309; H3N2) 
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(C). In addition, the NP418-426 peptide was eluted from sHLA of 309-infected HeLa cells 
transfected with sHLA-B*3501, a HLA-B7 supertype allele25 (D). 
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Figure 2. IFN-? ELISPOT reactivity of 10 PR8-infected HLA-B*0702 transgenic mice to 20 
NP418-426 variant peptides. IFN-? ELISPOT responses are illustrated for each mouse in 
SFU/105 lymphocytes. (A) The parental PR8 NP418-426 peptide (LPFDRTTVM) generated an 
average of 103.6 SFU/105 lymphocytes. The T-cell cross-reactive IFN-? response elicited to 
each H1N1 (B), H1N1/H3N2 (C), and H3N2 (D) variant NP418-426 peptide was compared to 
the parental PR8 NP418-426 peptide (shaded in gray). Three H1N1 restricted NP418-426 
peptides (LPFDKTTIM, LPFDRPTIM, and LPFDKATIM) and three H1N1/H3N2 variants 
(LPFDRTTIM, and LPFDKSTIM, and LPFDKSTVM) elicited an average of at least 10 
SFU/105 lymphocytes (shown in red). 
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Figure 3. IFN-? ELISPOT reactivity of PR8 virus-infected HLA-B*0702 transgenic mice to 
the PR8 NP418-426 variant peptide containing single amino acid substitutions at P4 to P9. IFN-
? ELISPOT responses of splenocytes isolated from mice infected with 1,000 EID50s of PR8 
virus generated against the P4 to P9 single mutant influenza A virus NP418-426 peptides are 
illustrated for each mouse in SFU/105 lymphocytes. (A) Nine PR8 virus-infected mice generated 
an average of 161.4 SFU/105 lymphocytes to the parental PR8 NP418-426 peptide 
(LPFDRTTVM). The T-cell cross-reactive IFN-? response elicited to synthetic PR8 NP418-426 
peptides containing a single amino acid substitution at P4 to P6 (B) was compared to the parental 
PR8 NP418-426 peptide (shaded in gray). The IFN-? ELISPOT reactivity of lymphocytes 
isolated from the spleens of four PR8-infected mice to the PR8 NP418-426 (average, 137.9 
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SFU/105 lymphocytes) peptide (C) was compared to PR8 NP418-426 synthetic peptides 
containing a single amino acid substitution at P7 and P9 (D). NP418-426 single mutant peptides 
generating an average of greater than 10 SFU/105 lymphocytes are shown in red, and synthetic 
peptides that elicited less than 10 SFU/105 lymphocytes are shown in black. 
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Figure 4. Molecular modeling of the HLA-B*0702 PR8 NP418-426 peptide complex. The 
orientation of the PR8 NP418-426 peptide (LPFDRTTVM) in the HLA-B*0702 binding groove 
was determined by molecular modeling. The position of LPFDRTTVM amino acid residues in 
the peptide binding groove are designated as follows: ?, up from the peptide binding groove; ?
, down toward the peptide binding groove; ?, toward the alpha-1 helix; ?, toward the alpha-2 
helix;, anchor residue. Molecular modeling indicates that amino acid residues at P4, P5, and P8 
of the peptide point up from the peptide binding groove while residues at P6 point toward the 
alpha-1 helix. Single amino acid substitutions at P4 to P9 increase, decrease, or produce no 
change in IFN-? ELISPOT reactivity during PR8 murine infection. 
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A.IV.1 Doctoral candidate contribution to manuscript.  
The primary author of this manuscript (Klechevsky E ) observed inhibition of CTL priming by 
dermal CD14+ dendritic cells expressing ILT2 (LIR-1) and ILT4 (LIR-2) in a manner similar to 
the use of αCD8 MAb. I was enlisted to perform a computational investigation to determine if 
these molecules might prevent CD8 association by occupying the same or a nearby binding site.  
Available crystallographic models were aligned and analyzed for potential steric clashes using 
PyMOL1 and LIGPLOT2. These studies were assembled for publication (figures & methods) and 
returned to the primary author. 
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A.IV.2 Results 
 
Figure 1. LIR-2 (ILT4) & CD8αα cannot simultaneously engage MHCI. The MHCI α1/α2 
platform of the LIR-2/HLA-G (PDB: 2DYP)3 & CD8αα/HLA-A*0201 (PDB: 1AKJ)4 crystal 
structures were aligned to examine the potential steric/contact overlap between LIR-2 & CD8αα. 
Complexes are shown as ribbon diagrams: CD8αα (cyan/magenta), LIR-2 (light green), heavy 
chain (blue), β2m (grey), peptide (yellow, spheres). (a) Ribbon diagram of significant steric 
clashes (≤5 Å, red) between LIR-2 & CD8αα that would occur if both receptors engaged MHCI. 
HLA-G was omitted from this figure. (b-d) Contacts for each receptor/MHCI complex are 
shown as spheres: CD8αα (dark green), LIR-2 (blue), CD8αα & LIR-2 (red, D227). Receptors 
were omitted in (c) for clarity.  
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Figure 2. LIR-1 (ILT2) & CD8αα cannot simultaneously engage MHCI. The MHCI α1/α2 
platform of the LIR-1/HLA-A2 (PDB: 1P7Q)5 & CD8αα/HLA-A*0201 (PDB: 1AKJ)4 crystal 
structures were aligned to examine the potential steric/contact overlap between LIR-1 & CD8αα. 
Complexes are shown as ribbon diagrams: CD8αα (cyan/magenta), LIR-1 (light green), heavy 
chain (blue), β2m (grey), peptide (yellow, spheres). (a) Ribbon diagram of significant steric 
clashes (≤5 Å, red) between LIR-1 & CD8αα that would occur if both receptors engaged MHCI. 
(b-d) Contacts for each receptor/MHCI complex are shown as spheres: CD8αα (dark green), 
LIR-1 (blue). Receptors were omitted in (c) for clarity. LIGPLOT analysis did not identify 
contacts shared by CD8αα and LIR-1. 
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A.IV.3 Materials and Methods 
Structure Analysis 
Combinatorial extension6 was used to align the MHCI α1/α2 platform (aa 1-180) of the LIR-
2/HLA-G (PDB: 2DYP)3, LIR-1/HLA-A2 (PDB: 1P7Q)5, and CD8αα/HLA-A*0201 (PDB: 
1AKJ)4 crystal structures. Receptor/MHCI interfaces were analyzed using LIGPLOT2. PyMOL1 
was used to prepare all structural figures.  
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